

May 2004

May 2004

May 2004

# HIV/AIDS

## EPI Updates



Our mission is to help the people of Canada  
maintain and improve their health

*Health Canada*

This document is available:

- By mail**            Surveillance and Risk Assessment Division  
                         Centre for Infectious Disease Prevention and Control  
                         Population and Public Health Branch  
                         Health Canada  
                         Address locator: 0602B  
                         Tunney's Pasture, Ottawa (Ontario)  
                         Canada, K1A 0K9
- Or from**            HIV/AIDS Clearinghouse  
                         Canadian Public Health Association  
                         1565 Carling Avenue, Suite 400  
                         Ottawa, Ontario  
                         Canada, K1Z 8R1  
                         Tel.: (613) 725-3434, Fax: (613) 725-1205
- By Internet**        *HIV/AIDS Epi Updates* can be assessed electronically in either official  
                         language via the Internet at [www.hc-sc.gc.ca/pphb-dgsp/hast-vsmt/](http://www.hc-sc.gc.ca/pphb-dgsp/hast-vsmt/).

© Her Majesty the Queen in Right of Canada, represented by the Minister of Health (2004)  
Cat. H39-1/1-2004E  
ISBN 0-662-37133-X  
(On-line) Cat. H39-1/1-2004E-PDF  
ISBN 0-662-37134-8



# HIV/AIDS *EPI UPDATES* Centre for Infectious Disease Prevention and Control

## Acknowledgements

National level HIV and AIDS surveillance is possible as a result of all provinces and territories participating in, and setting directions for, HIV and AIDS surveillance. Accordingly, the Centre for Infectious Disease Prevention and Control acknowledges the provincial/territorial HIV/AIDS coordinators, public health units, laboratories, health care providers and reporting physicians for providing the non-nominal confidential data that enable this report to be published. Without their close collaboration and participation in HIV and AIDS surveillance, the publication of this report would not have been possible.

We also thank Scientific Publication and Multimedia Services, Population and Public Health Branch, for its contribution in editing and producing the report, both in print and on the Internet.

**N.B.** This document must be cited as the source of any information extracted and used from it.

**Suggested citation:** Health Canada. *HIV/AIDS EPI Updates, May 2004*, Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Health Canada, 2004.



# HIV/AIDS *EPI UPDATES* Centre for Infectious Disease Prevention and Control

Surveillance and Risk Assessment Division  
Centre for Infectious Disease Prevention and Control  
Health Canada  
Tunney's Pasture, Postal Locator 0602B  
Ottawa, ON K1A 0K9

Tel: (613) 954-5169  
Fax: (613) 957-2842  
[www.hc-sc.gc.ca/pphb-dgspssp/hast-vsmt/](http://www.hc-sc.gc.ca/pphb-dgspssp/hast-vsmt/)

## Information to the readers of *HIV/AIDS Epi Updates*

The Surveillance and Risk Assessment Division of the Centre for Infectious Disease Prevention and Control, Population and Public Health Branch, Health Canada, is pleased to provide you with the May 2004 publication of *HIV/AIDS Epi Updates*.

The Centre conducts national surveillance and research on the epidemiology and laboratory science related to HIV/AIDS and other sexually transmitted infections. As part of this mandate, *HIV/AIDS Epi Updates* are compiled on an annual basis to summarize recent trends and developments related to the HIV epidemic in Canada.

All *Epi Updates* are available at the address noted above and also at our website: [www.hc-sc.gc.ca/pphb-dgspssp/hast-vsmt/](http://www.hc-sc.gc.ca/pphb-dgspssp/hast-vsmt/). The *HIV/AIDS Epi Updates* are complementary to other Centre materials, which are also available at the website.

Sincerely,

Chris Archibald MDCM, MHSc, FRCPC  
Director

# Centre for Infectious Disease Prevention and Control

## Surveillance and Risk Assessment Division

Tel.: (613) 954-5169

Fax: (613) 957-2842

**Division personnel who contribute to the production of the Epi Updates are noted below:**

**Director** Chris Archibald, MDCM, MHSc, FRCPC  
Executive Assistant Moheene Soondrum

### HIV/AIDS Epidemiology Section

---

Contractor Yogesh Choudhri, MD, MPH  
Statistical Analyst Marene Gatali, MHSc, BSc  
Surveillance Officer Stephen Cule, BSc  
Surveillance Officer Kathleen Lydon-Hassen, DipSc  
Surveillance Officer Paul Alexander, MHSc, BA

### HIV/AIDS Surveillance Section

---

Manager Jennifer Geduld, MHSc, BSc  
Senior Research Analyst Dana Reid, MSc, BSc  
Research Analyst Chris Sheardown, BA  
Surveillance Officer Bruce Tudin, MA, BES  
Surveillance Analyst Caroline Chevalier, BSc  
Surveillance Analyst Micheline Miron

### Field Surveillance Officer Program

---

Manager Vacant  
Senior Field Surveillance Officer Tig Shafto, PhD  
Field Surveillance Officer Elsie Wong, MBA, BSN  
Field Surveillance Officer Michelyn Wood, MS, BS  
Field Surveillance Officer Sonia Harmen, MAppS, BSc  
Field Surveillance Officer Gayatri Jayaraman, PhD, MPH  
Field Surveillance Officer Jane Njihia, MHSc, BSc, RN  
Field Surveillance Officer Tracey MacDonald, BN, MN, CMHN

**HIV/AIDS**  
***EPI UPDATES***  
**Centre for Infectious Disease Prevention and Control**

## Table of Contents

<b>1</b>	National HIV Prevalence and Incidence Estimates for 2002 . . . . .	1
<b>2</b>	Prevalent HIV Infections in Canada: 30% May Not Be Diagnosed . . . . .	6
<b>3</b>	HIV Testing and Infection Reporting in Canada . . . . .	10
<b>4</b>	HIV and AIDS among Youth in Canada . . . . .	15
<b>5</b>	HIV and AIDS among Women in Canada . . . . .	22
<b>6</b>	HIV/AIDS among Older Canadians . . . . .	27
<b>7</b>	Perinatal Transmission of HIV . . . . .	33
<b>8</b>	Ethnicity Reporting for AIDS and HIV in Canada: Aboriginal and Black Communities Demand Attention . . . . .	40
<b>9</b>	HIV/AIDS among Aboriginal Peoples in Canada: A Continuing Concern . . . . .	46
<b>10</b>	HIV Infections among MSM in Canada . . . . .	57
<b>11</b>	HIV/AIDS among Injecting Drug Users in Canada . . . . .	65
<b>12</b>	Risk Behaviours among Injecting Drug Users in Canada . . . . .	73
<b>13</b>	Oral Sex and the Risk of HIV Transmission . . . . .	80
<b>14</b>	HIV-1 Strain Surveillance in Canada . . . . .	87
<b>15</b>	Primary HIV Anti-retroviral Drug Resistance in Canada. . . . .	93
<b>16</b>	Nonoxynol-9 and the Risk of HIV Transmission . . . . .	100
	Glossary . . . . .	106



# HIV/AIDS *EPI UPDATE*

Centre for Infectious Disease Prevention and Control

## National HIV Prevalence and Incidence Estimates for 2002

### *At a Glance*

- ◆ **Greater vigilance is required to successfully control the HIV epidemic in Canada.**
- ◆ **More Canadians are living with HIV infection, an estimated 56,000 at the end of 2002.**
- ◆ **The overall number of new infections in 2002 was 2,800 to 5,200, approximately the same as in 1999.**

### **Introduction**

This Epi Update outlines the estimates of the total number of Canadians who were living with HIV infection at the end of 2002 (prevalence) and the number of individuals who became newly infected in 2002 (incidence). It updates estimates produced in 1999. National estimates of HIV prevalence and incidence are an integral part of the work carried out by the Centre for Infectious Disease Prevention and Control. They are used as a tool to monitor the HIV epidemic and to help evaluate and guide prevention efforts, and they are part of ongoing risk assessment and management work conducted by the Centre.

### **Methods**

Methods to estimate prevalence and incidence at the national level are complex and uncertain. The methods used are described below and have been given in detail previously.<sup>1</sup> They are similar to methods that have been used in the USA<sup>2</sup> and internationally.<sup>3</sup>

The four provinces that account for over 85% of the population of Canada and over 95% of reported HIV and AIDS diagnoses are Ontario, Quebec, British Columbia and Alberta. Separate HIV prevalence and incidence estimates were produced for each of these four provinces for each exposure category: men who have had sex with men (MSM), injecting drug users (IDU), MSM-IDU, heterosexual (heterosexual contact with a person who is either HIV-infected or at risk of HIV, heterosexual as the only identified risk, or origin in a country where HIV is endemic) and other (recipients of blood transfusion or clotting factor, perinatal and occupational transmission). Methods to estimate prevalence and incidence are based on a combination of different methods and incorporate data from a wide variety of sources, such as AIDS

### ***CIDPC Website:***

[www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/](http://www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/)

case reports, provincial HIV testing databases, population-based surveys, targeted epidemiologic studies and census data. After the calculation of draft estimates by means of these methods, experts in each of the four provinces, including public health officials, researchers and community representatives, were consulted. On the basis of this valuable feedback, the provisional estimates were improved.

HIV prevalence was estimated by using the three methods for each of the four provinces by exposure category. Using Method 1 (direct method), the number of prevalent infections was calculated by multiplying the prevalence rate by the estimated population size (total population for that group). Methods 2 and 3 (indirect methods) were used together to estimate HIV prevalence; they were both based on the number of HIV diagnoses and on information about HIV testing behaviour. In Method 2, the cumulative number of HIV diagnoses less cumulative AIDS deaths was divided by the proportion of the population that had ever been tested for HIV. In Method 3, the number of HIV diagnoses in 2002 was divided by the proportion of the population that had been tested for HIV within the previous year. The result was then added to the cumulative number of HIV diagnoses to the end of 2001 less cumulative AIDS deaths, plus an estimate for 2002 HIV incidence.

The number of incident infections was derived by multiplying the incidence rate by the estimated population at risk (total

population for that group minus those already infected with HIV).

## Results

### Prevalence Estimates

More people are living with HIV infection (prevalent infections). At the end of 2002, there were an estimated 56,000 (46,000-66,000) people in Canada living with HIV infection (including AIDS), which represents an increase of about 12% from the point estimate of 49,800 at the end of 1999 (Table 1). In terms of exposure category, these prevalent infections in 2002 comprised 32,500 MSM (58% of total), 11,000 IDU (20% of total), 10,000 heterosexuals (18% of total), 2,200 MSM/IDU (4% of total), and 300 attributed to other exposures (< 1% of total) (Table 1).

### Incidence Estimates

The number of new infections (incident infections) continues at approximately the same rate as three years ago. In Canada, there were an estimated 2,800 to 5,200 new HIV infections in 2002 compared with the estimate of 3,310 to 5,150 in 1999 (Table 2). Examining the estimates for 2002 by exposure category, it is clear that MSM continue to account for the greatest number of new infections, 1,000 to 2,000. This represents about 40% of the national total of new infections, which is a slight increase from the 38% estimated in 1999 (Figure 1). The proportion of new infections attributable

**Table 1. Estimated number of prevalent HIV infections in Canada and associated ranges of uncertainty at the end of 2002 compared with 1999 (point estimates and ranges are rounded)**

	MSM	MSM-IDU	IDU	Heterosexual	Other	Total
2002	32,500 (26,000-39,000)	2,200 (1,500-3,000)	11,000 (8,500-13,500)	10,000 (7,000-13,000)	300 (200-400)	56,000 (46,000-66,000)
1999	29,600 (26,000-33,400)	2,100 (1,700-2,600)	9,700 (8,100-11,800)	8,000 (6,300-10,100)	400 (330-470)	49,800 (45,000-54,600)

MSM: men who have sex with men; IDU: injecting drug users; heterosexual: heterosexual contact with a person at risk of HIV, origin in a country where HIV is endemic or heterosexual as the only identified risk; Other: recipients of blood or blood products, perinatal and occupational transmission



**Table 2. Estimated ranges of uncertainty for number of incident HIV infections in Canada in 2002, compared with 1999 (ranges are rounded)**

	MSM	MSM-IDU	IDU	Heterosexual	Other*	Total
2002	1,000-2,000	150-350	800-1,600	600-1,300	< 20	2,800-5,200
1999	1,190-2,060	190-360	1,030-1,860	610-1,170	< 20	3,310-5,150

\*New infections in the Other category are very few and are primarily due to perinatal transmission.

to IDU has decreased slightly, from 34% of the total in 1999 to 30% in 2002 (800-1,600 new infections in 2002). The proportion attributed to the heterosexual exposure category increased slightly, from 21% in 1999 to 24% in 2002 (600-1,300 new infections in 2002).

Figure 1 shows how the exposure category distribution of new HIV infections has changed since the beginning of the HIV epidemic in Canada. Until 1996, there was a steady increase in the proportion of new infections attributed to IDU, and since then this proportion has decreased. Conversely, the proportion attributed to MSM steadily declined until 1996 and has increased since then. The proportion of new infections attributed to the heterosexual exposure category has increased steadily since the beginning of the epidemic.


### Trends among Women

At the end of 2002, there were an estimated 7,700 (6,500-9,000) women living with HIV in Canada, (including those living with AIDS), accounting for about 14% of the national total. This represents a 13% increase from the 6,800 estimated in 1999. There were 600 to 1,200 new HIV infections among women in 2002, representing 23% of all new infections, a finding similar to that in 1999. With respect to the exposure category distribution among newly infected women, a slightly higher proportion of new infections was attributed to the heterosexual category in 2002 compared with 1999 (53% versus 46% respectively). The remainder of new infections among women was attributable to IDU.

### Trends among Aboriginal Persons

In 2002, it was estimated that approximately 3,000 to 4,000 Aboriginal persons were living with HIV in Canada. This represents about

**Figure 1. Estimated exposure category distributions (%) among new HIV infections in Canada, by time period**



5% to 8% of all prevalent HIV infections, compared with the 1999 estimate of about 6% of the total, or 2,500 to 3,000 persons. Aboriginal persons accounted for approximately 250 to 450 of the new HIV infections in Canada in 2002, or 6% to 12% of the total, compared with 9% in 1999. The composition of exposure category among Aboriginal persons newly infected in 2002 was similar to that in 1999. The distribution in 2002 was 63% IDU, 18% heterosexual, 12% MSM and 7% MSM-IDU.

### **Persons from HIV-endemic Countries within the Heterosexual Exposure Category**

As already outlined, the heterosexual exposure category is a diverse group that includes those who have had sexual contact with a person at risk of HIV (such as an IDU or a bisexual male), those who were born in a country where HIV is endemic, and those who have not identified any risk apart from sexual contact with the opposite sex. On the basis of the proportions in positive HIV test reports and reported AIDS cases, it is estimated that in 2002 there were approximately 3,700 to 5,700 prevalent HIV infections and 250 to 450 incident infections among persons who were born in a country where HIV is endemic. These numbers represent approximately 7% to 10% of total prevalent infections and 6% to 12% of total incident infections in Canada. We are currently collaborating with provincial/territorial partners, researchers and community groups to explore ways to better understand the current status and trends of HIV infection in this group.

### **Undiagnosed HIV Infections: the Hidden Epidemic**

Using methods described elsewhere,<sup>1,2</sup> it was estimated that of the 56,000 prevalent infections in 2002, about 17,000 (13,000-21,000) or 30% were unaware of their HIV infection. The number of persons in this group is especially difficult to estimate because they are "hidden" to the health care and disease monitoring systems, since they

have not yet been tested for HIV infection and their condition diagnosed. This group is particularly important because until their infection has been diagnosed, they cannot take advantage of available treatment strategies or appropriate counselling to prevent the further spread of HIV.

### **Comments**

The methods that were used to estimate HIV prevalence and incidence make maximum use of a wide variety of data. Producing these national estimates is becoming increasingly difficult because of the existing limitations associated with HIV surveillance data and the limited availability of research data specific to HIV incidence, prevalence and the population size of risk groups. Limitations associated with HIV surveillance in Canada are currently being addressed in collaboration with our provincial/territorial partners and community groups. Epidemiological research in Canada needs to be strengthened to provide information that will help improve the estimates. To reflect the challenges associated with the data, the presentation of the 2002 estimates differs from previous years, in that more emphasis is placed on ranges rather than point estimates, especially in the case of incidence, for which data on recent trends are more limited. Given the information we have, however, we believe that this is an accurate picture of the state of the epidemic in Canada.

Available data show that more Canadians are living with HIV infection, and the overall rate of new infections in 2002 was approximately the same as in 1999. MSM continue to be the most affected group, and new infections among IDU continue to decline slightly. Infections attributed to the diverse heterosexual exposure category continue the gradual increase seen previously. The reasons for these trends need to be better understood. It is clear that the number of new infections in all exposure categories remains unacceptably high. Findings also indicate that there are a large number of people in Canada who are unaware of their HIV infection and that Aboriginal persons are

still overrepresented in terms of HIV infections in Canada.

Greater vigilance is needed if we are going to successfully control the HIV epidemic in Canada. This includes more effective strategies to prevent new infections in all risk groups and to provide services to the increasing number of Canadians living with HIV infection, particularly those who are vulnerable and disadvantaged. In addition, there is an increasing need to address the limited availability of data in order to better understand and monitor the full scope of the HIV epidemic in Canada.

## References

1. Geduld J, Gatali M, Remis RS, Archibald CP. *Estimates of HIV prevalence and incidence in Canada, 2002*. *CCDR* 2003;29:197-206.
2. Holmberg S. *The estimated prevalence of HIV in 96 large US metropolitan areas*. *Am J Public Health* 1996; 86:642-54.
3. Walker N, Stanecki KA, Brown T, Stover J, et al. *Methods and procedures for estimating HIV/AIDS and its impact: the UNAIDS/WHO estimates for the end of 2001*. *AIDS* 2003;17:1-11.

## Acknowledgements

National level HIV and AIDS surveillance is possible as a result of all provinces and territories participating in, and setting directions for, HIV and AIDS surveillance. CIDPC acknowledges the provincial/territorial HIV/AIDS coordinators, public health units, laboratories, health care providers, and reporting physicians for sharing non-nominal, confidential data for national surveillance.

### *For more information, please contact:*

**Surveillance and Risk Assessment Division  
Centre for Infectious Disease Prevention and Control  
Health Canada  
Tunney's Pasture  
Postal Locator 0602B  
Ottawa, ON K1A 0K9  
Tel: (613) 954-5169  
Fax: (613) 957-2842  
[www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/](http://www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/)**

Our mission is to help the people of Canada  
maintain and improve their health

*Health Canada*



# HIV/AIDS *EPI UPDATE*

Centre for Infectious Disease Prevention and Control

## Prevalent HIV Infections in Canada: 30% May Not Be Diagnosed

### *At a Glance*

- ◆ There were an estimated 56,000 people living with HIV infection (including AIDS) in Canada at the end of 2002.
- ◆ Of these, approximately 17,000 or 30% are not aware of their infection.
- ◆ Given the new treatments for HIV, it is more important than ever that all Canadians are able to access HIV testing.

### Introduction

This *Epi Update* presents the estimated number of Canadians who were HIV-infected but unaware of their infection at the end of 2002. It also summarizes available data on the characteristics of persons tested for HIV in Canada.

### HIV Testing in Canada

Knowledge of one's HIV status can be useful for several reasons. Counselling received at the time of HIV testing can provide critical information about how to reduce the risk of HIV infection. If an individual is found to be HIV-infected, consideration can be given to starting antiretroviral therapy. In the case of pregnant women, treatment can reduce the chances that the infant will be infected, from about 25% to 8% or less.<sup>1</sup>

Canadians have had the opportunity to be tested for HIV infection in Canada since the test became available in 1985. Individuals have accessed HIV testing services through either coded or confidential testing at a doctor's office or clinic, or through anonymous testing sites.

Positive HIV test report data are provided by all provinces and territories in Canada to the Centre for Infectious Disease Prevention and Control (CIDPC) and are presented in the most recent semi-annual report: *HIV and AIDS in Canada: surveillance report to June 30, 2003*.<sup>2</sup> They are based on non-nominal, confidential HIV testing information with duplicate tests for the same individual removed to the extent possible. The removal of duplicates is necessary to accurately reflect the annual number of new HIV diagnoses. Duplicate removal rates vary by year, province and type of data (nominal, non-nominal or anonymous). It is important to note that in most

### *CIDPC Website:*

[www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/](http://www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/)

provinces the ability to remove duplicates has improved significantly since 1995.

## HIV-infected but Unaware

There have been 52,680 positive HIV tests reported to CIDPC up to December 31, 2002.<sup>2</sup> After adjustment for under and delayed reporting, it is estimated that approximately 57,000 Canadians have tested positive for HIV from 1985 (when testing became available) to the end of 2002. Of this total, an estimated 18,000 individuals had died by the end of 2002 (also adjusted for under and delayed reporting). Therefore, of this 57,000 approximately 39,000 individuals were aware of their HIV infection and were still alive at the end of 2002.

It is important to note that data on positive HIV tests represent only those who have tested positive for HIV infection and do not represent all persons who have been infected with HIV as some who have been infected have not yet come forward for testing.

In December 2003, CIDPC published estimates of HIV prevalence in Canada to the end of 2002.<sup>3</sup> It was estimated that approximately 56,000 (46,000-66,000) Canadians were living with HIV infection (including those living with AIDS) at the end of 2002. This number includes those who are aware of their infection (had a positive HIV test) and those who are unaware of their infection.

The difference between the total number who were HIV-infected and alive at the end of 2002 (56,000) and the number who were aware of their HIV infection and alive at the end of 2002 (39,000) represents an estimate of the number of persons unaware of their infection (had not yet tested positive for HIV) and alive. This difference is approximately 17,000 (13,000-21,000) or about 30% of the estimated 56,000 Canadians living with HIV infection at the end of 2002.

## Characteristics of Persons Tested for HIV

A Canada-wide survey conducted in March 2003 of randomly selected individuals above 15 years of age revealed that just over one-quarter (27%) reported ever having been tested for HIV, excluding testing for the purposes of insurance, blood donation, and participation in research.<sup>4</sup> In this survey, women were more likely to have been tested than men (29% versus 24%), and among people who reported having been tested, 42% had not been tested in the previous two years, 38% had been tested once in the previous two years and 18% had been tested twice or more in the previous two years.

The figures from this 2003 survey show that a higher proportion of individuals reported having been tested as compared with the results of a Canada-wide survey conducted in January 1997, when it was found that 18.6% of men and 16.2% of women aged 15 years and older had been tested for HIV (excluding tests for blood donation and insurance purposes).<sup>5,6</sup> Of those tested, 39% had been tested in the year before the survey, 57% in the previous two years, and 43% had had their most recent test more than 2 years before the survey. A 1996 survey found that, taking into account ancillary testing such as donating blood or being tested for life-insurance purposes, 41% of men and 31% of women in Canada had ever been tested for HIV.<sup>7</sup>

National surveys of the general population suggest that those who report risk factors are more likely to be tested:

- ◆ Among heterosexuals, those with two or more partners in the previous year were more likely to be tested than those with one partner (50.5% versus 17.4%). Of those who reported having had a sexually transmitted infection (STI) in the previous five years, 58% had been tested compared with 17.4% of those who did not report an STI.<sup>5,6</sup> The percentage of Canadians being tested is higher among individuals who

reported casual partners (45%); this percentage increases with the number of partners, from 30% among individuals reporting one partner to 41% among those reporting two partners and 51% among those reporting three partners.<sup>4</sup>

- ◆ For men, testing was higher among those who had had sexual intercourse with men (71%), used injecting drugs (62%), received blood or clotting factor between 1978 and 1985 (27%), or had had a partner with a risk factor (injecting drug user [IDU], received blood or clotting factor between 1978 and 1985, origin in country endemic for HIV) (30%).<sup>5,6</sup> For women, testing was higher among those who had received blood or clotting factor between 1978 and 1985 (32%), had had a high-risk partner (38%), or had had sexual intercourse with a man since 1978 (17%).<sup>7</sup>
- ◆ Testing was highest among individuals aged 25 to 34 years. Even after all other risk factors are taken into account, those aged 45 years and over were still less likely to be tested than those younger than 45 years.<sup>5-7</sup> In the survey conducted in March 2003, Canadians aged 25-34 years and 35-44 years were more likely to be tested (46% and 35% respectively).<sup>4</sup>
- ◆ Targeted studies have shown that a large proportion of individuals in high-risk populations have been tested for HIV, though it is possible that some were tested for the purpose of participation in research. Among men who have sex with men (MSM) surveyed in B.C. in 2002, the proportion who reported ever having been tested was 89%.<sup>8</sup> In the I-TRACK survey of IDUs conducted at selected centres across Canada in 2002-03, 89.7% of IDU reported having been tested for HIV.<sup>9</sup>
- ◆ Although those reporting risk factors such as IDU, multiple partners, or MSM are more likely to be tested, a substantial proportion of those reporting risk factors have not been tested recently, or have not been tested at all. For example, in the 1997 survey, among those who reported

more than one partner in the previous year and not using condoms consistently, 53% of men and 38% of women had never been tested.<sup>5,6</sup>

## Comment

Canadians with risk factors for HIV infection are more likely to have been tested for HIV than those without such risk factors. However, there is still a significant proportion of persons with risk factors who have never been tested for HIV. It has been estimated that there are approximately 17,000 people or 30% of the HIV-infected population who are unaware that they are infected. More information is needed about individuals who are at risk of HIV but have not been tested. Given these data and the fact that new treatments are available for HIV infection, it is more important than ever that all Canadians be able to access HIV testing, particularly those at highest risk of infection.

## References

1. Mofenson LM, McIntyre JA. Advances and research directions in the prevention of mother-to-child HIV-1 transmission. *Lancet* 2000;355:2237-44.
2. Health Canada. *HIV and AIDS in Canada: Surveillance Report to June 30, 2003*. Division of HIV/AIDS Epidemiology and Surveillance, Centre for Infectious Disease Prevention and Control, Health Canada, November 2003.
3. Geduld J, Gatali M, Remis RS, Archibald CP. *Estimates of HIV prevalence and incidence in Canada, 2002*. *CCDR* 2003;29:197-206.
4. *HIV/AIDS - an attitudinal survey*. Summary of the findings available at URL: <[http://www.hc-sc.gc.ca/hppb/hiv\\_aids/pdf/execsum\\_e.pdf](http://www.hc-sc.gc.ca/hppb/hiv_aids/pdf/execsum_e.pdf)>.
5. Houston SM, Archibald CP, Sutherland D. *Sexual risk behaviours are associated with HIV testing in the Canadian general*

- population. *Can J Infect Dis* 1998; 9(Suppl A):39A, #239P.
6. Canada Health Monitor Survey. Division of HIV Epidemiology, Centre for Disease Prevention and Control, Health Canada, January 1997 (unpublished data).
  7. Houston SM, Archibald CP, Strike C, Sutherland D. *Factors associated with HIV testing among Canadians: results of a population-based survey*. *Int J STD AIDS* 1998;9:341-46.
  8. Trussler T, Marchand R, Barker A. *Sex NOW by the numbers: a statistical guide to health planning for gay men*. Vancouver, BC: Community-Based Research Centre, 2004: 44. URL: <[www.sexnowsurvey.com](http://www.sexnowsurvey.com)>.
  9. Health Canada. *I-Track: Enhanced surveillance of risk behaviours among injecting drug users in Canada. Pilot survey report. February 2004*. Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Health Canada, 2004.

## Acknowledgements

National level HIV and AIDS surveillance is possible as a result of all provinces and territories participating in, and setting directions for, HIV and AIDS surveillance. CIDPC acknowledges the provincial/territorial HIV/AIDS coordinators, public health units, laboratories, health care providers, and reporting physicians for sharing non-nominal, confidential data for national surveillance.

### ***For more information, please contact:***

**Surveillance and Risk Assessment Division  
Centre for Infectious Disease Prevention and Control  
Health Canada  
Tunney's Pasture  
Postal Locator 0602B  
Ottawa, ON K1A 0K9  
Tel: (613) 954-5169  
Fax: (613) 957-2842  
[www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/](http://www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/)**

Our mission is to help the people of Canada  
maintain and improve their health

*Health Canada*



# HIV/AIDS *EPI UPDATE*

Centre for Infectious Disease Prevention and Control

3

## HIV Testing and Infection Reporting in Canada

### *At a Glance*

- ◆ **Nominal, non-nominal and anonymous HIV testing is available in Canada.**
- ◆ **Although anonymous testing may encourage testing, it is not available in all provinces and territories.**
- ◆ **HIV infection is notifiable in all provinces and territories as of May 1, 2003.**

### Introduction

There have been 18,934 AIDS cases reported to the Centre for Infectious Disease Prevention and Control (CIDPC) between 1979 and June 30, 2003, and 53,887 positive HIV tests reported between 1985 and the end of June 2003.<sup>1</sup> The positive HIV test results reported to CIDPC are from people who test positive for HIV through nominal, non-nominal or anonymous testing in the provinces and territories and whose results are reported to CIDPC by their respective health authority or HIV testing laboratory.

This *Epi Update* summarizes the most current information on the reporting of HIV infection in Canada, including the types of HIV testing available and when HIV infection reporting became notifiable in each province and territory. A notifiable disease is one that is considered to be of such importance to public health that its occurrence is required to be reported to public health authorities. (The terms notifiable and reportable are used interchangeably when discussing HIV/AIDS reporting in Canada.)

### HIV Infection Becomes Notifiable Across Canada

- ◆ As of May 1, 2003, HIV infection became legally notifiable in all provinces and territories, therefore now both positive HIV test reports and AIDS diagnoses are notifiable in all jurisdictions across Canada.
- ◆ In most testing situations, laboratories and physicians are responsible for reporting HIV infection, but this varies by province or territory.
- ◆ When HIV infection is notifiable, “nominal/name-based” or “non-nominal/non-identifying” informa-

### *CIDPC Website:*

[www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/](http://www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/)



tion about an individual who tests positive for HIV infection is forwarded to provincial or territorial public health officials. This includes demographic data, such as the person's age and gender; risks associated with the transmission of HIV; and laboratory data, such as the date of the person's first positive HIV test.

- ◆ HIV infection is not legally notifiable at the national level, yet notification to CIDPC is voluntarily undertaken by all provinces and territories. Positive HIV test reports and reported AIDS cases are provided non-nominally to CIDPC.
- ◆ HIV testing patterns within the general population, along with the profile of people being tested, are important for designing and targeting intervention programs<sup>2</sup> and for developing a context for HIV/AIDS surveillance data.

### Three Types of HIV Testing Available in Canada

Canadians choosing to be tested for the presence of HIV infection may have three different testing options, depending on the province or territory in which testing takes place:

#### 1. Nominal/name-based HIV testing

- May be carried out at numerous locations, including clinics and the office of a health care provider.
- The person ordering the test knows the identity of the person being tested for HIV.
- The HIV test is ordered using the name of the person being tested.
- There is collection of patient information (such as age, gender, city of residence, name of diagnosing health care provider, country of birth); information detailing the HIV-related risk factors of the person being tested; and laboratory data. The amount of information collected is dependent upon the province/territory.

- If the HIV test result is positive, the person ordering the test is legally obligated to notify public health officials of the positive test result.
- The test result is recorded in the health care record of the person being tested.

#### 2. Non-nominal/non-identifying HIV testing

Similar to nominal/name-based testing on all points except

- The HIV test is ordered using a code or the initials of the person being tested (not the full or partial name).

#### 3. Anonymous testing

- Usually available at specialized clinics, organized and supported by public health departments, and by some health care providers.
- The person ordering the HIV test does not know the identity of the person being tested for HIV.
- The HIV test is carried out using a code. The person ordering the HIV test and the laboratory carrying out the testing on the blood sample do not know to whom the code belongs. Only the person being tested for HIV knows the unique, non-identifying code.
- Information such as age, gender, HIV-related risk factors and the ethnicity of the person being tested for HIV may be collected during anonymous testing, depending on the province or territory in which the test is ordered or on the test site.
- Test results are not recorded on the health care record of the person being tested. It is only the person being tested who may subsequently decide to give his or her name and include the HIV test result in the medical record.

The types of HIV testing services available and HIV infection reporting information across Canada are summarized in Table 1.

**Table 1. HIV testing and HIV reporting by province/territory**

Province/ territory	Type of HIV testing available	Year in which HIV infection became notifiable	Responsibility for reporting of HIV infection	Type of testing reported to the province/ territory
British Columbia	N, NN, A	2003	L, P	N, NN*
Yukon	N, NN	1995	P	N
Northwest Territories	N, NN	1988	L, P, RN	N
Nunavut	N, NN	1999	L, P, RN	N
Alberta	N, NN, A	1998	L, P	NN
Saskatchewan	N, NN, A	1988	L, P	NN
Manitoba	NN	1987	L, P	NN
Ontario	N, NN, A	1985	L, P	N, NN*
Quebec	N, NN, A	2002	L, P	NN
New Brunswick	N, NN, A	1985	L, P, RN	NN
Nova Scotia	N, NN, A	1985	L, P	N, NN
Prince Edward Island	N, NN	1988	L, P, RN	N, NN
Newfoundland and Labrador	N, NN, A**	1987	L, P	N

N = nominal/name-based  
A = anonymous  
P = physician

NN = non-nominal/non-identifying  
L = laboratory  
RN = nurse

\*In Ontario and British Columbia, data from positive HIV tests completed by means of anonymous HIV testing (AHT) are reported non-nominally at the provincial level.

\*\*If someone tests positive for HIV through AHT, that individual then becomes part of the nominal/name-based system, in which counselling, follow-up care and HIV data reporting are all done nominally.

### The availability of anonymous HIV testing (AHT) may increase testing

Information regarding the status of anonymous HIV testing in Canada is summarized in Table 2.

- ◆ An evaluation study of AHT in Ontario suggested that AHT provides testing to populations that are not otherwise accessing it.<sup>4</sup>
- ◆ Several studies in the USA have shown that AHT programs encourage people to be tested for HIV infection, especially those at high risk or those who would not volunteer for testing

under nominal/name-based or non-nominal/non-identifying circumstances.<sup>5-7</sup>

- ◆ Interviews of 835 patients with newly diagnosed AIDS in the USA revealed that the availability of anonymous testing was associated with testing closer to the time of HIV infection and, thus, earlier access to medical care.<sup>8</sup>
- ◆ In Ontario, the proportion of HIV testing done anonymously has remained steady since 1992, at approximately 4%.<sup>9</sup>
- ◆ In Quebec, between 1994 and 1998, over 45% of the anonymous test users declared that the anonymity of the test was one of their primary reasons for getting tested.<sup>10</sup>

**Table 2. Status of anonymous HIV testing (AHT) by province/territory**

Province/territory	Year in which AHT became available	Number of AHT sites	AHT data reported*	Counselling services available
British Columbia	1985	Any physician's office	Yes	Yes
Yukon	—	—	—	—
Northwest Territories	—	—	—	—
Nunavut	—	—	—	—
Alberta	1992	3	Yes	Yes
Saskatchewan	1993	3	No	Yes
Manitoba	—	—	—	—
Ontario	1992	33	Yes	Yes
Quebec	1987	60+	No	Yes
New Brunswick	1998	7	—	Yes
Nova Scotia	1994	1	No	Yes
Prince Edward Island	—	—	—	—
Newfoundland and Labrador	**	6	Yes†	Yes†

\*Refers to whether or not data from positive HIV tests from AHT are reported to the Centre for Infectious Disease Prevention and Control, Canada.

\*\*AHT is available upon request but is not part of the official guidelines for the province.

†If someone tests positive for HIV infection through AHT, that individual then becomes part of the nominal/name-based system, in which counselling, follow-up care and HIV data reporting are all done nominally.

## Comment

HIV infection is now legally notifiable in all provinces and territories; however, each has a different practice for reporting HIV infection. Legislation of HIV infection reporting in all Canadian provinces and territories may increase the number of tests received at CIDPC. A change to mandatory reporting of HIV infection in Alberta in 1998 resulted in a significant increase in HIV tests among both men and women.<sup>11</sup> As a result, having HIV notifiable across Canada should allow for the collection of more complete epidemiological data as well as enable more accurate and timely monitoring of the HIV epidemic.

All provinces and territories in Canada offer at least one of three forms of HIV testing: 1) nominal/name-based, 2) non-nominal/non-identifying, and/or 3) anonymous testing. At

present, nominal/name-based and non-nominal/non-identifying HIV testing is widely available in Canada; however, anonymous HIV testing is available in only eight provinces. Increased availability and accessibility to different types of HIV testing may allow individuals to choose the testing and counselling environment in which they feel most comfortable, thereby encouraging more people to be tested and facilitating the targeting of intervention and treatment programs.<sup>12</sup>

## References

1. Health Canada. *HIV and AIDS in Canada: surveillance report to June 30, 2003*. Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Health Canada, 2003.

2. Houston S, Archibald CP, Strike C, Sutherland D. *Factors associated with HIV testing among Canadians: results of a population-based survey*. Int J STD AIDS 1998;9:341-46.
3. Jürgens R, Palles M. *HIV testing and confidentiality: a discussion paper*. Canadian HIV/AIDS Legal Network and the Canadian AIDS Society, 1997: 52-69.
4. Ontario Ministry of Health. *Anonymous HIV testing evaluation: January 1992 to June 1993*. Toronto: AIDS Bureau, Ontario Ministry of Health, November 1994.
5. Keagles SM, Catania JA, Coates TJ et al. *Many people who seek anonymous HIV-antibody testing would avoid it under other circumstances*. AIDS 1990;4(6):585-88.
6. Hoxworth T, Hoffman R, Cohn D et al. *Anonymous HIV testing: does it attract clients who would not seek confidential testing?* AIDS Public Policy J 1994;9(4):182-88.
7. Hertz-Picciotto I, Lee LW, Hoyo C. *HIV test-seeking before and after the restriction of anonymous testing in North Carolina*. Am J Public Health 1996;86(10):1446-50.
8. Bindman AB et al. *Multistate evaluation of anonymous HIV testing and access to medical care*. JAMA 1998;280(16):1416-20.
9. Remis RS, Swantee C, Rottensten K et al. *Report on HIV/AIDS in Ontario 2002*. November 2003. URL: <[http://www.phs.utoronto.ca/ohemu/doc/technical%20reports/Phero2002v4\\_lorraine.pdf](http://www.phs.utoronto.ca/ohemu/doc/technical%20reports/Phero2002v4_lorraine.pdf)>.
10. Ministère de la santé et des services sociaux du Québec. *Le dépistage anonyme du VIH, 2001*. URL: <<http://ftp.msss.gouv.qc.ca/publications/acrobat/f/documentation/2001/01-327-01.pdf>>.
11. Jayaraman GC, Preiksaitis JK, Larke B. *Mandatory reporting of HIV infection and opt-out prenatal screening for HIV infection: effect on testing rate*. Can Med Assoc J 2003;168(6):679-82.
12. Hong BA, Berger SG. *Characteristics of individuals using different HIV/AIDS counseling and testing programs*. AIDS 1994;8:259-62.

## Acknowledgements

National level HIV and AIDS surveillance is possible as a result of all provinces and territories participating in, and setting directions for, HIV and AIDS surveillance. CIDPC acknowledges the provincial/territorial HIV/AIDS coordinators, public health units, laboratories, health care providers, and reporting physicians for sharing non-nominal, confidential data for national surveillance.

### *For more information, please contact:*

**Surveillance and Risk Assessment Division  
Centre for Infectious Disease Prevention and Control  
Health Canada  
Tunney's Pasture  
Postal Locator 0602B  
Ottawa, ON K1A 0K9  
Tel: (613) 954-5169  
Fax: (613) 957-2842  
[www.hc-sc.gc.ca/pphb-dgsp/hast-vsmt/](http://www.hc-sc.gc.ca/pphb-dgsp/hast-vsmt/)**

Our mission is to help the people of Canada  
maintain and improve their health

*Health Canada*



**HIV/AIDS**  
***EPI UPDATE***  
Centre for Infectious Disease Prevention and Control

## HIV and AIDS Among Youth in Canada

### *At a Glance*

- ◆ Risk behaviour data on young Canadians show the potential for HIV transmission.
- ◆ Street-involved youth, youth who inject drugs and young men who have sex with men are particularly vulnerable to HIV.
- ◆ A wide range of prevention activities needs to be implemented to help minimize the risk of HIV transmission among youth.

### **Introduction**

Although youth (defined here as those aged 10 to 24 years) currently constitute a small proportion of the total number of reported HIV and AIDS cases in Canada, they are a group that has been greatly affected by the HIV/AIDS epidemic at a global level. According to the most recent UNAIDS report, an estimated 11.8 million people aged 15 to 24 years are living with HIV/AIDS, and half of all new infections worldwide are occurring among young people.<sup>1</sup> Youth, in general, are vulnerable to HIV infection as a result of many factors, including risky sexual behaviour, substance use (including injecting drug use) and perceptions that HIV is not a threat to them. Young Canadians require the necessary information and skills to help them to adopt and maintain behaviours that are protective against HIV. This *Epi Update* provides the most current information on the status of HIV and AIDS among Canadian youth. HIV-related risk behaviours in this population are also highlighted.

### **AIDS Data<sup>2</sup>**

- ◆ As of June 30, 2003, there were 18,929 AIDS cases with information about age reported to the Centre for Infectious Disease Prevention and Control (CIDPC). Of these, 649 (3.4%) were among youth aged 10 to 24 years.
- ◆ As seen in Table 1, of the cumulative reported AIDS cases in youth aged 10 to 19 years, almost two-thirds of cases were attributed to recipients of blood and blood products. Among youth aged 20 to 24 years of age with AIDS, almost half were attributed to men who have sex with men (MSM), and 20% to heterosexual contact. Heterosexual

### ***CIDPC Website:***

[www.hc-sc.gc.ca/pphb-dgsp/hasst-vsmt/](http://www.hc-sc.gc.ca/pphb-dgsp/hasst-vsmt/)

**Table 1. Number of reported AIDS cases and exposure category distribution for individuals 10 to 24 years of age, in Canada, diagnosed up to June 30, 2003**

Category	10-19 years of age	20-24 years of age
Number of cases	93	556
Percentage of all reported AIDS cases	0.49%	2.9%
Exposure category*	61% Blood and blood products 9% MSM 13% Heterosexual contact/endemic 8% IDU 6% MSM/IDU 3% Other + perinatal	51% MSM 20% Heterosexual contact/endemic 11% IDU 11% MSM/IDU 7% Blood and blood products 0% Other**

IDU = Injecting drug users, MSM = Men who have sex with men

\*Percentages based on the total number of cases minus those reports for which exposure category was unknown or "not identified."

\*\*Mode of transmission is known but cannot be classified into any of the major exposure categories.

contact includes sexual contact with a person at risk of HIV, origin from a country where HIV is endemic, and heterosexual contact as the only identified risk.

## HIV Testing Data<sup>2</sup>

Data received from provincial and territorial HIV testing programs do not allow separation of the 10-14 and 20-24 year age groups before 1998, thus restricting the analysis of HIV test reports for youth.

- ◆ As of June 30, 2003, there were 50,332 positive HIV tests with information about age reported to CIDPC. Of these, 721 (1.4%) were among youth aged 15 to 19 years, and 13,083 (26.0%) were among individuals aged 20 to 29 years.
- ◆ Of all HIV positive test reports the proportion attributed to females varies considerably by age and is highest among adolescents and young adults. In 2002, females accounted for 38.6% of positive HIV test reports among those aged 15 to 29 years (196/508), a decrease from 44.4% in 2001 (194/437).
- ◆ In 2002, MSM, heterosexual contact and injecting drug use accounted for 41.9%, 35.0% and 17.5% respectively of reported

positive HIV tests with known exposure category among those aged 20 to 29 years. Heterosexual contact and injecting drug use accounted for 63% and 32% of reported HIV tests with known exposure category among those aged 15 to 19 years ( $n = 19$ ).

- ◆ A cumulative total of 675 positive HIV test reports had been received by June 30, 2003, for individuals less than 15 years of age. Of the 360 cases in this group with known exposure category information, perinatal transmission and exposure to infected blood or blood products accounted for over 90% of cases.

## HIV Incidence and Prevalence among Youth

HIV prevalence and incidence information, in conjunction with HIV/AIDS surveillance data, are more useful than surveillance data alone for depicting the current magnitude of the HIV epidemic in various population subgroups. To date, a small number of Canadian studies have examined HIV prevalence or incidence among youth, although most research has involved higher risk populations:

- ◆ In the Vancouver Injection Drug User Study (VIDUS), the prevalence of HIV among injecting drug users (IDU) aged 24 years and younger during the period 1996-2001 was 17%. HIV incidence among participants in this age category was reported as 2.96 for males and 5.69 for females per 100 person years (PY).<sup>3</sup>
- ◆ Young Aboriginal IDU in BC have been shown to have a high HIV prevalence rate. In the VIDUS study, a comparison of young Aboriginal versus non-Aboriginal IDU (age 24 or under) revealed an HIV prevalence rate of 39% for Aboriginal IDU and 11% for non-Aboriginal IDU.<sup>4</sup>
- ◆ Further information from the VIDUS study has shown there to be a high prevalence of HIV/hepatitis C (HCV) co-infection. In a recent study, a sample of IDU aged 29 and under had a co-infection rate of 16%, while a further 53% were solely HCV positive and 3% were solely HIV positive.<sup>5</sup>
- ◆ In the Montreal Street Youth Cohort study (MSYC), participants between 14 and 25 years old have been observed since January 1995. HIV prevalence at study entry in the cohort was 1.4% (14 of 1,013 subjects). HIV incidence up to September 2000 was 0.69 per 100 person years.<sup>5</sup> Among MSM participating in the Montreal Street Youth study in 2000 the prevalence of HIV was 4.9% and the incidence was 1.2 per 100 PY.<sup>6,7</sup>
- ◆ An HIV prevalence of 0.25% was observed in the mid-1990s among young offenders aged 12 to 19 years in British Columbia, many of whom reported a history of injecting drug use.<sup>8</sup>
- ◆ Sentinel hospital surveillance of HIV infection in Quebec (early 1990s),<sup>9</sup> a study of women seeking prenatal care in British Columbia (early 1990s)<sup>10</sup> and a survey of youth from across Canada involved in an international exchange program (early to mid 1990s)<sup>11</sup> reported prevalence rates of 0.04% to 0.08% among young people aged 14 to 25 years. In a study in the late 1990s of women seeking abortions in Montreal, the prevalence of HIV among those aged 20 to 24 years was 0.0015%, and there were no infections detected among women under 20 years of age.<sup>12</sup> It should be noted that these latter studies involved relatively small, non-representative samples of youth; thus, a zero to very low HIV prevalence rate is not necessarily reassuring.
- ◆ In a recent study focusing on MSM aged 16 to 30 (Omega cohort in Montreal), seroprevalence rates of 19.4% and 19.5% were found among MSM who were new Canadians and for established Canadians respectively.<sup>13</sup> Another study from the same cohort found that MSM under 30 years of age had a slightly higher incidence rate, of 0.72 per 100 PY, compared with 0.52 per 100 PY for MSM aged 30 years and older.<sup>14</sup>
- ◆ In Vancouver, the Vanguard study observes young MSM (under 30 years of age) for HIV infection and risk behaviours. In a recently published study, the incidence of HIV reported in the cohort was 1.9 per 100 PY.<sup>15</sup>
- ◆ The Enhanced Surveillance of Canadian Street Youth (ESCSY) is a national, multicentre, cross-sectional surveillance system of street youth aged 15 to 24 years in Canada. Of the youth tested in 2001, 1.0% were positive for HIV, 3.6% for hepatitis C virus, 11.5% for chlamydia and 14.2% for herpes simplex virus 2.<sup>16</sup>

## Risk Behaviour Data among Youth

Research shows that Canadian youth begin to have sexual intercourse at a relatively early age:

- ◆ In the 1996 National Population Health Survey (NPHS), 25.6% of female participants in the 15 to 19 age group reported that they had had intercourse by the age of 15 years. Almost 20% of young men in this age group also reported that

they had started having intercourse by this age.<sup>17</sup>

A substantial proportion of young people report having had multiple sexual partners in the past year:

- ◆ Among sexually experienced, single respondents (those never married and those divorced or widowed) in the 1996 NPHS, 29.4% of males aged 15 to 19 years had had more than one sex partner in the previous 12 months, and 27.5% of males aged 20 to 24 years had had more than one sex partner in this period. In comparison, 21.8% of females aged 15 to 19 years had had more than one sex partner in the previous 12 months, and the same percentage of females (21.9%) aged 20 to 24 years had had more than one sex partner in this time frame.<sup>17</sup>
- ◆ In a study of young gay and bisexual men aged 15 to 30 in Vancouver, 16% of the study subjects reported selling sex for money or drugs. HIV prevalence among those who had engaged in prostitution was significantly higher than those who had not (7.3% versus 1.1%), and incidence was higher as well (4.7 per 100 PY versus 0.9 per 100 PY).<sup>18</sup>

Research suggests that many Canadian youth are having unprotected sexual intercourse. Not using condoms appears to be more common among young women than it is among young men:

- ◆ Among sexually active youth aged 15 to 19 years in the 1994 NPHS (excluding subjects who had a single sex partner and who were married, common-law, divorced, or widowed), 51% of females and 29% of males reported never or only sometimes using a condom in the previous year.<sup>19</sup> The corresponding percentages among those aged 20 to 24 years were 53% and 44%.<sup>19</sup>

- ◆ In an ongoing study of Montreal street youth, only 13.2% of participants reported always using condoms during vaginal intercourse, and only 32.4% reported always using condoms during anal intercourse.<sup>20</sup> Further risk behaviour data also indicate some alarming sexual risk behaviours: 33% had engaged in survival sex (prostitution), 51.1% had had sex with an IDU, 26.6% with an MSM, 40.6% with a prostitute and 8.2% with someone who was HIV positive.<sup>21</sup>

The extent of unprotected intercourse among youth is further captured in rates of chlamydia and gonorrhoea among those aged 15 to 24 years:


- ◆ Figure 1 shows that in 2000, the reported incidence of chlamydia in Canada was highest among females aged 15 to 19 years (1,236.1/100,000 women). The reported incidence of gonorrhoea in Canada was also highest in this group of young women (96.4/100,000)<sup>22,23</sup> (Figure 2).

Research reveals that levels of injecting drug use and injecting risk behaviours among youth, particularly those who are street-involved, require ongoing assessment:


- ◆ In a study of IDU in Calgary in 1998, 46% of participants who were under age 25 years as compared with 24% of those aged 25 or older reported that they had borrowed injection equipment in the previous six months.<sup>24</sup>
- ◆ Recent results from the ongoing Montreal Street Youth Cohort Study showed that 42.8% of participants had a history of injecting drug use.<sup>25</sup> Also alarming was the incidence of the initiation of injecting drug use in street youth, estimated to be 7.9 per 100 person-years.<sup>26</sup>
- ◆ In 2001, 18.3% of youth recruited for the Enhanced Surveillance of Canadian Street



**Figure 1. Reported genital chlamydia rates in Canada by age group and sex, 2000**



**Figure 2. Reported gonorrhoea rates in Canada by age group and sex, 2000**



Youth reported that they had injected drugs in their lifetime.<sup>16</sup>

### Comment

HIV/AIDS is affecting many subgroups of the Canadian population, including youth. Although the limited data available suggest that HIV prevalence is currently low among youth, sexual risk behaviour and STI data clearly indicate that the potential for HIV remains significant among young Canadians. More incidence and prevalence information as well as trend data on HIV-related risk behaviours are needed in order to guide and evaluate prevention programs for young Canadians. Epidemiological and behavioural

data for high-risk youth, such as street youth, are also needed to assess fully the risk of HIV transmission in Canada's youth population.

### References

1. UNAIDS. *Report on the global HIV/AIDS epidemic*. Geneva, July 2002.
2. Health Canada. *HIV and AIDS in Canada. Surveillance report to June 30, 2003*. Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Health Canada, 2003

3. Miller CL, Tyndall M, Li K et al. *High rates of HIV positivity among young injection users*. Can J Infect Dis 2001;12(Suppl B):65B(Abstract 340P).
4. Miller CL, Li K, Laliberte N et al. *Higher prevalence and incidence of HIV and hepatitis C and associated risk factors among young Aboriginal injection drug users*. Can J Infect Dis 2003;14(Suppl A):48A-49A (Abstract 224P).
5. Miller CL, Li K, Braitstein P et al. *The future face of co-infection: prevalence and incidence of HIV and hepatitis C co-infection among young injection drug users*. Can J Infect Dis 2003;14(Suppl A):46A-47A (Abstract 217).
6. Roy E, Haley N, Leclerc P et al. *HIV incidence in the Montreal Street Youth Cohort (MSYC)*. Can J Infect Dis 2002;12(Suppl A):49A(Abstract 317).
7. Roy E, Hayley N, Boivin JF et al. *Étude de cohorte sur l'infection au VIH chez les jeunes de la rue de Montréal*. Final report to Health Canada, March 1998.
8. Rothon D, Strathdee SA, Cook D et al. *Determinants of HIV-related high risk behaviours among young offenders: a window of opportunity*. Can J Public Health 1997;88(1):14-7.
9. Alary M, Joly JR, Parent R et al. *Sentinel hospital surveillance of HIV infection in Quebec*. Can Med Assoc J 1994; 151(7):975-80.
10. Pi D, Ballem PJ, Schechter MT. *The B.C. prenatal study: 1989-94*. Final report to Health Canada, January 1995.
11. Morrisset R, Czyziw E, Lambert J. *HIV infection in young Canadian adults before and after an international exchange program: 1986-96*. 6<sup>th</sup> Conference of the International Society of Travel Medicine, Montreal, June 1999.
12. Remis RS, Leclerc P, Palmer RW et al. *HIV prevalence and incidence and reported risk factors among women undergoing abortion in Montreal*. Can J Infect Dis 1997;8(Suppl A):33A(Abstract 242).
13. George C, Alary M, Hogg RS et al. *High risk behaviours among men having sex with other men (MSM) who were born in Canada compared to those who immigrated to Canada – what should we measure?* Can J Infect Dis 2003;14(Suppl A):41A(Abstract 199).
14. Alary M, Remis RS, Otis J et al., the OMEGA Study Group. *Persistent increase in risky sexual behaviour but stable HIV incidence among men who have sex with men (MSM) in Montreal*. Can J Infect Dis 2003;14(Suppl A):42A(Abstract 202).
15. Weber AE, Craib KJ, Chan K et al. *Determinants of HIV seroconversion in an era of increasing HIV infection among young gay and bisexual men*. AIDS 2003;17(5):774-7.
16. Health Canada. *Enhanced surveillance of Canadian street youth*. Sexual Health and STI Section, Community Acquired Infections Division, Centre for Infectious Disease Prevention and Control, Health Canada.
17. Maticka-Tyndale E, Barrett M, McKay A. *Adolescent sexual and reproductive health in Canada: a review of national data sources and their limitations*. Can J Hum Sex 2000;9(1):41-65.
18. Weber AE, Craib KJP, Chan K et al. *Sex trade involvement and rates of human immunodeficiency virus positivity among young gay and bisexual men*. Int J Epidemiol 2001;30(6):1449-54.

19. Galambos NL, Tilton-Weaver LC. *Multiple-risk behaviour in adolescents and young adults*. Health Rep 1998; 10(2):9-20.
20. Roy E, Haley N, Leclerc P et al. *Prevalence of HIV infection and risk behaviours among Montreal street youth*. Int J STD AIDS 2000; 11(4):241-47.
21. Roy E, Haley N, Leclerc P et al. *HIV and HCV risk behaviours in the new Montreal Street Youth Cohort*. Can J Infect Dis 2003;14(Suppl A):46A(Abstract 216).
22. Health Canada. *STD data tables Appendix 1.1*. Division of Sexual Health Promotion and STD Prevention and Control, CIDPC, Health Canada. URL: <<http://www.hc-sc.gc.ca/pphb-dgspsp/std-mts/>>.
23. Health Canada. *STD data tables Appendix 2.2*. Division of Sexual Health Promotion and STD Prevention and Control, CIDPC, Health Canada. URL: <<http://www.hc-sc.gc.ca/pphb-dgspsp/std-mts/>>.
24. Guenter CD, Fonesca K, Nielsen DM et al. *HIV Prevalence remains low among Calgary's needle exchange program participants*. Can J Public Health 2000; 91(2);129-32.
25. Roy E, Haley N, Leclerc P et al. *Heroin or cocaine? How can we predict which drug Montreal street youth will first inject?* Can J Infect Dis 2003;14(Suppl A):49A (Abstract 226P).
26. Roy E, Haley N, Leclerc P et al. *Drug use behaviours of new injectors in the Montreal street youth cohort*. Can J Infect Dis 2000;11(Suppl B):54B (Abstract 301).

## Acknowledgements

National level HIV and AIDS surveillance is possible as a result of all provinces and territories participating in, and setting directions for, HIV and AIDS surveillance. CIDPC acknowledges the provincial/territorial HIV/AIDS coordinators, public health units, laboratories, health care providers, and reporting physicians for sharing non-nominal, confidential data for national surveillance.

### *For more information, please contact:*

**Surveillance and Risk Assessment Division  
Centre for Infectious Disease Prevention and Control  
Health Canada  
Tunney's Pasture  
Postal Locator 0602B  
Ottawa, ON K1A 0K9  
Tel: (613) 954-5169  
Fax: (613) 957-2842  
[www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/](http://www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/)**

Our mission is to help the people of Canada  
maintain and improve their health

*Health Canada*



# HIV/AIDS *EPI UPDATE*

**Centre for Infectious Disease Prevention and Control**

**5**

### *At a Glance*

- ✦ **In Canada, a total of 1,555 AIDS cases and 7,256 HIV cases have been reported in adult women up to June 30, 2003.**
- ✦ **Women represent an increasing proportion of those with positive HIV test reports in Canada and in 2002 accounted for 25% of all positive HIV test reports.**
- ✦ **Heterosexual contact and injecting drug use are the two major risk factors for HIV infection in women.**

### *CIDPC Website:*

[www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/](http://www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/)

### **Introduction**

The HIV/AIDS epidemic in Canada has changed from the early epidemic, which affected primarily men who have sex with men (MSM), to the current epidemic, which increasingly affects other groups such as injecting drug users (IDU) and heterosexuals. As a result, the number and percentage of women living with HIV/AIDS is increasing. The HIV/AIDS epidemic among women is of particular concern because of the potential for transmission to their infants. This report updates the status of HIV and AIDS among adult and adolescent women (15 years and older) in Canada up to June 30, 2003.

### **AIDS Surveillance Data**

In Canada, of the 18,713 cumulative AIDS cases in adults reported up to June 30, 2003, to the Centre for Infectious Disease Prevention and Control (CIDPC), 1,555 (8.3%) were women. The proportion of all reported adult AIDS cases (for which gender and age are known) occurring in women has increased over time, from 6.1% before 1994 to 15.8% in 1999; in 2002, the proportion was 16.5%.<sup>1</sup>

Of all cumulative reported AIDS cases in women up to June 30, 2003, 67.9% were attributed to heterosexual contact,\* 23.3% to injecting drug use and 8.5% to recipients of blood or blood products. The proportion of adult female AIDS cases attributed to IDU increased from 20.1% before 1998 to 46.2% in 1998 and has since dropped to 29.3% in 2002.<sup>1</sup>


\* Heterosexual category includes three subcategories: sexual contact with a person at risk, origin from a country where HIV is endemic and sex with the opposite gender as the only identified risk.

## HIV Surveillance Data

AIDS data can contribute to an understanding of trends in HIV infections but only on infections acquired approximately 10 years in the past. In contrast, positive HIV test reports provide a picture of more recent infections. Data from provincial and territorial HIV testing programs indicate that a total of 7,256 positive HIV test reports with known age and gender have been reported in adult women up to June 30, 2003.<sup>1</sup>

Among women, the primary exposure categories associated with newly diagnosed HIV infection are heterosexual contact and IDU (Table 1). The proportion of positive HIV test reports in women attributed to heterosexual contact has increased over time, from 46.2% for the period 1985-1997 to 62.5% in 2001. In 2002, this proportion decreased slightly to 58.3%. The proportion attributed to IDU varied between 33% and 48% during this period, with the suggestion of a slight decrease over time (Table1).

**Figure 1. Proportion of positive HIV test reports among women by age group and year of test (1985-2002)**



Women account for a growing proportion of positive HIV tests reports with known age and gender among adults in Canada. The proportion of females each year has risen, from 12% in the years between 1985 and 1997 to nearly 25% of adult positive HIV test reports between January 1999 and December 31, 2001. In 2002, this proportion increased slightly to 25.4%. The proportion of women among positive HIV test reports varies considerably by their age and is highest among adolescents and young adults. In 2001, women accounted for 44.4% of positive HIV test reports among those aged 15 to 29 years, an increase from 42% in 2000. In 2002, this proportion decreased slightly to 38.6% (Figure 1).<sup>1</sup>

Heterosexual contact still remains the main risk factor for HIV infection in women, although injecting drug use is also a significant risk factor and in some studies this risk is greater among female than male IDU.<sup>2</sup>

**Table 1. Proportion (%) of positive HIV tests among adult females by exposure category and year of test, Canada, 1985-2002**

Year	Exposure category (%)		
	Heterosexual contact*	IDU**	Blood and blood products
1985-97	46.2	40.0	8.1
1998	52.8	38.9	3.6
1999	47.3	48.5	1.2
2000	54.6	39.9	1.7
2001	62.5	32.7	1.4
2002	58.3	37.2	1.5
TOTAL	52.6	42.1	6.0

\*Heterosexual category includes three subcategories: sexual contact with a person at risk, origin from a country where HIV is endemic and sex with the opposite gender as the only identified risk.

\*\*IDU: Injecting drug users

### HIV Prevalence and Incidence Estimates Show More Women Are Living with HIV/AIDS

The national HIV prevalence (total number living with HIV) estimates indicate that the number of women in Canada living with HIV, including those with AIDS, continues to grow. By the end of 2002, an estimated 7,700 (6,500-9,000) women were living with HIV, accounting for about 14% of the national total. This represents an increase of 13% from the 6,800 estimated at the end of 1999.<sup>3</sup>

Data from positive HIV test reports do not provide the complete picture of the annual number of new HIV infections, since only a proportion of those newly infected are tested in the same year. Furthermore, not all HIV tests reported in a given year are from cases infected in that year. The estimated number of new infections (incidence) among women continues at approximately the same rate as three years ago. In 2002, women represented 23% of all new HIV infections or an estimated 600 to 1,200 out of the total of 2,800 to 5,200 new infections in Canada. With respect to exposure category distribution among newly infected women, a slightly higher proportion was attributed to the heterosexual category in 2002 compared

with 1999 (53% versus 46% respectively). The remainder of new infections among women was attributed to IDU (Figure 2).<sup>3</sup>


### HIV among Pregnant Women and Women of Childbearing Age

HIV testing during pregnancy is an option available to women across Canada. However, physician guidelines and/or recommendations encouraging informed decisions regarding HIV testing during pregnancy vary by province and territory. These are discussed in detail in the *Epi Update* entitled "Perinatal Transmission of HIV," May 2004.

HIV prevalence studies among pregnant women can provide an important source of information on the prevalence rate of HIV in the general heterosexual population. Prenatal seroprevalence studies in Canada report an estimated national rate of HIV infection among pregnant women of 3-4/10,000 population.

Anonymous, unlinked seroprevalence studies across the country show that large metropolitan areas report higher rates of HIV infection among pregnant women (4.7 for Vancouver versus 3.4 for the rest of B.C. in 1994<sup>4</sup>; 15.3 for Montreal versus 5.2 for the province of Quebec in 1990<sup>5</sup>). Even provinces

**Figure 2. Estimated exposure category distribution (%) of new HIV infections among women by time period.**



without large metropolitan areas have indicated significant rates (for example, 4.1/10,000 in New Brunswick for 1994-96<sup>6</sup>). Data from Manitoba suggest an increasing trend of HIV infection among women of childbearing age, from 0.7/10,000 in 1991 to 3.2/10,000 in 1994-95.<sup>7</sup> An ongoing study among pregnant Aboriginal women in B.C. reported an HIV prevalence rate of 31.3 per 10,000 pregnancies in 2000-2002 (JD Martin, Programs Medical Officer, Pacific Region, First Nations and Inuit Health Branch, Health Canada, and A Jin, consultant for the BC First Nations Chiefs' Health Committee: personal communication).

The Alberta universal prenatal HIV screening program (in which all pregnant women are tested unless they opt out) reported an HIV infection rate of 3.3/10,000 pregnancies in 2000.<sup>8</sup> An ongoing HIV seroprevalence study of pregnant women in Ontario reported a rate of 3.7/10,000.<sup>9</sup> This rate is based on pregnant women who volunteered for testing (approximately 70%) whereas the rates in the other provinces (except Alberta) are based on complete samples from unlinked anonymous studies.

Risky behaviours among women, such as unsafe sex and injecting drug use, continue to put women at an increased risk of HIV. An ongoing study involving IDU in different areas across Canada found that, in 2003,

about 40% of female IDU reported engaging in commercial sex work. It also showed that about 92% always used condoms with their male client partners, but almost a third never used condoms with their casual partners and condom use was infrequent with their regular partners.<sup>10</sup>

### Comment

Women in Canada, especially IDU and women with high-risk sexual partners, are increasingly becoming infected with HIV. Even though the rate of new HIV infections among women is similar to three years ago, this number is still unacceptably high. The prevalence estimates indicate that more women are living with HIV in 2002 compared with 1999, and this has implications for prevention and care programs. Efforts to reduce transmission of HIV among women will need to focus not only on promoting safer sexual behaviours and reducing substance abuse but also on the intersection between the two and the underlying factors that put women at an increased risk of HIV infection.

All women, and especially women of childbearing age, should have access to HIV testing, counselling and care. More enhanced data on the trends, risk factors and geographic differences of HIV among Canadian women are needed to help target prevention and care programs.

## References

1. Health Canada. *HIV and AIDS in Canada. Surveillance report to June 30, 2003*. Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Health Canada, 2003.
2. Spittal PM, Craib KJP, Wood E et al. *Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver*. *Can Med Assoc J* 2002; 166(7):894-99.
3. Geduld J, Gatali M, Remis R, Archibald CP. *Estimates of HIV prevalence and incidence in Canada, 2002*. *CCDR* 2003; 29:197-206.
4. Pi D, Ballem PJ, Schechter MT. *The B.C. Prenatal Study: 1989-94*. Final report to Health Canada, January 1995.
5. Hankins C, Hum L, Tran T et al. *HIV seroprevalence in women giving birth to live infants in Northern Quebec (1989-93)*. *Can J Infect Dis* 1995; 6(Suppl):B:39 (Abstract 314).
6. Getty G, Leighton P, Mureika R et al. *NB antenatal seroprevalence study*. *Can J Infect Dis* 1997;8:24A(Abstract 205).
7. Blanchard J, Hammond G, Fast M et al. *HIV seroalence among antenatal women in Manitoba: August, 1994 through August, 1995*. Final report to Health Canada, 1996.
8. Jayaraman GC, Preiksaitis JK, Larke B. *Mandatory reporting of HIV infection and opt-out prenatal screening for HIV infection: effect on testing rates*. *Can Med Assoc J* 2003;168(6).
9. Remis SR, Swantee C, Major CI et al. *Increasing HIV testing of pregnant women in Ontario: results from the HIV seroprevalence study to September 2002*. *Can J Infect Dis* 2003;14(Suppl A):79 (Abstract 322).
10. Health Canada. *I-Track: enhanced surveillance of risk behaviours among injecting drug users in Canada. Pilot survey report, February 2004*. Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Health Canada, 2004.

## Acknowledgements

National level HIV and AIDS surveillance is possible as a result of all provinces and territories participating in, and setting directions for, HIV and AIDS surveillance. CIDPC acknowledges the provincial/territorial HIV/AIDS coordinators, public health units, laboratories, health care providers, and reporting physicians for sharing non-nominal, confidential data for national surveillance.

### ***For more information, please contact:***

**Surveillance and Risk Assessment Division  
Centre for Infectious Disease Prevention and Control  
Health Canada  
Tunney's Pasture  
Postal Locator 0602B  
Ottawa, ON K1A 0K9  
Tel: (613) 954-5169  
Fax: (613) 957-2842  
[www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/](http://www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/)**

Our mission is to help the people of Canada  
maintain and improve their health

*Health Canada*





# HIV/AIDS *EPI UPDATE* Centre for Infectious Disease Prevention and Control

## HIV/AIDS among Older Canadians

6

### *At a Glance*

- ✦ **As of June 30, 2003, 11.7% (2,222) of all reported AIDS cases have been among persons aged 50 years or older.**
- ✦ **Approximately 10% of the positive HIV test reports in Canada each year since the beginning of the epidemic have been among those aged 50 years or older.**
- ✦ **Sexual contact is the major risk factor for HIV infection in older Canadians.**

### Introduction

HIV/AIDS is generally believed to be a young person's disease and, therefore, little focus has been given to the issue of HIV/AIDS among older Canadians. It should be noted that the age range for "older" is subjective, and the lower age limit in the literature varies between 40 years and 55 years of age. For the purpose of this *Epi Update*, older individuals will be defined as those aged 50 years or older.


### AIDS Case Report Data<sup>1</sup>

- ✦ As of June 30, 2003, 18,929 AIDS cases with age information have been reported to the Centre for Infectious Disease Prevention and Control (CIDPC). Of these reports, 2,222 (11.7%) have been among persons 50 years of age or older.
- ✦ Figure 1 shows that the annual number of reported AIDS cases among older adults has decreased from the mid-1990s, following a trend similar to the decrease in the number of overall AIDS cases. This is due, in part, to the introduction of new, effective anti-HIV drugs in the mid-1990s. However, the proportion of AIDS cases attributable to those aged 50 years or more has increased over time, from 11.3% in 1994 to over 20% in 2002. This increase may be influenced by the use of the new anti-HIV drugs, which have likely delayed the onset of AIDS to an older age.

### *CIDPC Website:*

[www.hc-sc.gc.ca/pphb-dgsp/hast-vsmt/](http://www.hc-sc.gc.ca/pphb-dgsp/hast-vsmt/)

**Figure 1. Number of reported AIDS cases among persons 50 years and older and percentage of all reported AIDS cases by year (1994-2002)**



6

**Table 1. Distribution of exposure categories among reported AIDS cases for individuals 50 years of age and older in Canada, diagnosed up to June 30, 2003**

Exposure category	Percentage in each exposure category*	
	50-59 years (n = 1632)	≥ 60 years (n = 590)
MSM	70.1	52.1
MSM/IDU	2.4	0.7
IDU	3.9	1.5
Recipient of Blood/Blood Products	5.4	16.4
Heterosexual contact**	17.9	28.0
Occupational & Other†	0.4	1.1

IDU = Injecting drug users, MSM = Men who have sex with men

\*Percentages based on the total number of cases minus those reports for which exposure category was unknown or "not identified."

\*\*Heterosexual contact: sexual contact with a person at risk of HIV, origin from a country where HIV is endemic, and heterosexual contact as the only identified risk.

†Mode of transmission is known but cannot be classified into any of the major exposure categories.


Table 1 shows the distribution of exposure categories for all reported AIDS cases among older Canadians up to June 30, 2003. Men who have sex with men (MSM) made up the majority of reported cases among those aged 50-59 and those aged 60 years and older. Other exposure categories included exposure to blood and blood products (before 1985) and heterosexual contact.

### Positive HIV Test Reports<sup>1</sup>

While AIDS data provide information on HIV infection that occurred about 10 years in the past, HIV data provide a picture of more recent infections.

Data from provincial and territorial HIV testing programs indicate that 4,124 positive HIV tests with information on age have been reported among persons 50 years and older

**Figure 2. Comparison of the age distribution of positive HIV test reports between 1985-97 and 1998-2002**



up to June 30, 2003. As seen in Figure 2, the proportion of annual positive HIV test reports among those aged 50 years or older has risen from 7.2% between 1985 and 1997 to 11.3% during the period 1998-2002. Men have accounted for 87.8% of the cumulative 3,873 positive HIV test reports with known gender information among those aged 50 years or older (data not shown).

**Table 2. Distribution of exposure categories among positive HIV test reports for individuals 50 years of age and older in Canada, reported between January 1, 2002 and December 31, 2002**

Exposure category	Percentage 50 years and older* (n = 289)
MSM	47.1
MSM/IDU	0.7
IDU	20.7
Recipients of blood/blood products	0.7
Heterosexual contact**	27.1
Occupational and other†	3.6

In 2002, 47.1% of positive HIV test reports among those aged 50 years and older with known exposure category information were attributable to MSM. Heterosexual contact accounted for 27.1% of positive HIV test reports among those aged 50 years or older (Table 2).

IDU = Injecting drug users, MSM = Men who have sex with men

\*Percentages based on the total number of cases minus those reports for which exposure category was unknown or "not identified."

\*\*Heterosexual contact: origin in a pattern II country, sexual contact with a person at risk, or no identified risk other than heterosexual contact.

†Mode of transmission is known but cannot be classified into any of the major exposure categories.

## More Information Needed: Older Adults and Risk Behaviours, HIV Testing Patterns, and Knowledge of HIV/AIDS

Healthy sexual relationships continue to be an important part of life for the majority of older adults. The availability of sexual partners and health status may be more important factors than age in determining sexual activity.<sup>2</sup>

- ◆ In one international study of adults aged 45 years and older ( $n = 1,384$ ), 51.7% of men and 55.1% of women who reported having a sexual partner ( $n = 949$ ) reported having sexual intercourse once a week or more during the previous six months.<sup>2</sup>

Although surveillance data for Canada suggest that sexual contact is the major risk factor for HIV infection among older adults, very little research has been conducted on risky sexual behaviour in this group. However, some information has been captured by national population surveys:

- ◆ Table 3 shows selected sexual risk behaviours among respondents aged 50 to 59 compared with all respondents in the 1996 National Population Health Survey.<sup>3</sup> While sexual risk behaviours were reportedly lower among older participants, they were not insubstantial.

In Canada, between 1996 and 2002, over 60% of reported AIDS diagnoses in those aged over 50 years old were made within 12 months after the first HIV positive test.<sup>4</sup>

**Table 3. High risk sexual behaviours among Canadians aged 15-59 compared with those aged 50 to 59 years, 1996 National Population Health Survey<sup>3</sup>**

Age category	Never used condoms*††	Did not use Condom during last sexual encounter*††	3+ sexual partners in previous year†
15-59 yrs	8%	16%	3%
50-59 yrs	7%	8%	1%

\*Use of a condom with a sexual partner of less than 12 months' duration.

†As a percentage of those in a relationship with a partner of less than 12 months' duration.

‡As a percentage of those who had had sexual intercourse in the previous year.

Table 4 suggests that older Canadians are less likely to have had an HIV test during their lifetime than the general adult population. Additionally, the percentage of older adults who have been tested for HIV declines with age.

**Table 4. Lifetime testing for HIV/AIDS, 1996 National Population Health Survey<sup>3</sup>**

Age category	Percentage of lifetime HIV testing
All ages 18+	15
45-54 yrs	11
55-64 yrs	7
65-74 yrs	4
75+ yrs	2

International studies suggest that some older adults may not be aware of HIV prevention methods or behaviours that put them at risk of HIV:

- ◆ In a 1996 US-based study, 14.7% of the respondents age 50 to 64 did not know whether condoms were effective in preventing HIV infection compared with 6.3% of the respondents aged 18-49.<sup>5</sup>

Older people may also face greater barriers to wellness, as some research has shown that older people living with HIV/AIDS experience higher rates of isolation and a lack of support from family and friends. In

one study, researchers reported that 42% of the subjects in the study needed more emotional support and 27% needed more practical support from family and friends.<sup>6</sup>

## Comment

Older adults account for a substantial minority of reported HIV and AIDS cases in Canada. The distribution of age among positive HIV tests reported to Health Canada shows that there is a shift towards an older age group, most marked in males. More epidemiological and behavioural data are needed to better understand the HIV/AIDS situation among older adults and to inform them of prevention and care programs. Population-based surveys should include questions regarding condom use and number of sexual partners, as well as HIV testing behaviours, for all age groups. Attitudes and knowledge about HIV/AIDS should be studied among those aged 50 years and older in order to assess the potential misconceptions or knowledge gaps that older adults may have with regard to HIV transmission and prevention. Given that one of the main exposure categories among older adults with reported positive HIV tests is MSM, research into the risk behaviours of older MSM needs to be supported, and qualitative studies examining the reasons why some older MSM engage in higher-risk practices need to be undertaken.

As our society ages and persons with HIV/AIDS live longer as a result of improved medical treatment, it is likely that HIV/AIDS among older adults will become a broader issue. While older adults have historically been excluded from many aspects of HIV/AIDS policy and programming, the available data show that this should not be the case. The data presented here should help to overcome the ageist assumption that persons aged 50 years and older are not at risk of HIV infection.

## References

1. Health Canada. *HIV and AIDS in Canada. Surveillance report to June 30, 2003*. Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Health Canada, 2003.
2. AARP/Modern Maturity Sexuality Survey. August 1999. URL: [http://research.aarp.org/health/mmsexsurvey\\_1.html](http://research.aarp.org/health/mmsexsurvey_1.html).
3. *Statistical report on the health of Canadians*. Prepared by the Federal, Provincial and Territorial Advisory Committee on Population Health for the Meeting of Ministers of Health Charlottetown, P.E.I. September 16-17, 1999.
4. Geduld J, Archibald CP. *Late HIV diagnosis among reported AIDS cases in Canada: a lesson for prevention*. 15th Annual Conference of the Australasian Society for HIV Medicine, October 22-25, October.
5. Mack KA, Bland SD. *HIV testing behaviours and attitudes regarding HIV/AIDS of adults aged 50-64*. *Gerontologist* 1999;39(6):687-94.
6. Schrimshaw EW, Siegel K. Perceived barriers to social support from family and friends among older adults with HIV/AIDS. *J Health Psychol* 2003; 8(6):738-52.

## Acknowledgements

National level HIV and AIDS surveillance is possible as a result of all provinces and territories participating in, and setting directions for, HIV and AIDS surveillance. CIDPC acknowledges the provincial/territorial HIV/AIDS coordinators, public health units, laboratories, health care providers, and reporting physicians for sharing non-nominal, confidential data for national surveillance.

***For more information, please contact:***

**Surveillance and Risk Assessment Division  
Centre for Infectious Disease Prevention and Control  
Health Canada  
Tunney's Pasture  
Postal Locator 0602B  
Ottawa, ON K1A 0K9  
Tel: (613) 954-5169  
Fax: (613) 957-2842  
[www.hc-sc.gc.ca/pphb-dgsp/hast-vsmt/](http://www.hc-sc.gc.ca/pphb-dgsp/hast-vsmt/)**

Our mission is to help the people of Canada  
maintain and improve their health

*Health Canada*



# HIV/AIDS *EPI UPDATE*

**Centre for Infectious Disease Prevention and Control**

## Perinatal Transmission of HIV

### *At a Glance*

- ◆ **HIV testing and antiretroviral treatment can dramatically reduce perinatal HIV transmission.**
- ◆ **The HIV prevalence rate among pregnant women is approximately 3-4/10,000 in Canada.**
- ◆ **The use of antiretroviral therapy by HIV-positive pregnant women is increasing.**
- ◆ **All pregnant women, and women considering pregnancy, now have access to prenatal care that includes an offer of HIV testing.**

### **Introduction**

Transmission of HIV from an HIV-infected pregnant woman to her newborn child is known as either mother-to-child, perinatal or vertical HIV transmission. HIV infection of the child can occur during gestation (in utero), during delivery (when the fetus makes contact with maternal blood and mucosa in the birth canal) or after delivery, through breast milk. In this *Epi Update*, the status of perinatal HIV transmission in Canada and HIV testing recommendations for pregnant women are discussed.

### **Positive HIV Test Reports**

Between 1985 and the end of June 2003, 49,657 positive HIV tests among adults have been reported to the Centre for Infectious Disease Prevention and Control (CIDPC), Health Canada, including 7,256 (15.0%) among women. Of the positive HIV test reports among adult women, 78.4% were in their prime child bearing years (15 to 39 years).<sup>1</sup>

### **HIV Infection among Pregnant Women**

HIV prevalence studies involving pregnant women indicate a rate for Canada of about 3-4/10,000, although rates are not available for all provinces, and data for some provinces have not been updated for 10 years. Rates for selected provinces are given in Table 1.

### ***CIDPC Website:***

[www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/](http://www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/)

**Table 1. HIV prevalence among pregnant women in Canada**

Province	HIV prevalence/ 10,000 pregnant women	Year
British Columbia	3.4	1994 <sup>2</sup>
Alberta	3.3	2003 <sup>3</sup>
Manitoba	3.2	1994-1995 <sup>4</sup>
Ontario	3.1*	2002 <sup>5</sup>
Quebec	5.2	1990 <sup>6</sup>
New Brunswick	4.1	1994-1996 <sup>7</sup>
Newfoundland and Labrador	1.5	1995-1996 <sup>8</sup>

\*Among the 78% of pregnant women tested for HIV

7


In Ontario, a total of 105 infants (< 2 years) born between 1984 and 2001 were confirmed to be HIV- infected. Almost 56% of the HIV-positive mothers reported that their risk factor for HIV infection was being from an HIV endemic country (a country in which the predominant means of HIV transmission is heterosexual contact). Another 32% reported non-endemic heterosexual contact, and 9% reported injecting drug use.<sup>9</sup>

In Quebec, between July 1997 and June 2001, nearly 60% of the 209 HIV-infected pregnant women were born in an endemic country. Of these women, 73 (34.9%) were African and 52 (24.9%) were Haitian.<sup>10</sup>

### Transmission of HIV from Mother to Infant

According to the Canadian Pediatric AIDS Research Group (CPARG), the annual number of perinatally HIV-exposed infants increased from about 50-70 per year in the early 1990s to 158 in 2002, as seen in Figure 1. Of the reported 1,584 infants who were exposed to HIV from their mothers between 1984 and 2002, 420 have been confirmed as infected. An additional 120 have an infection status that has not been confirmed (this includes indeterminate serostatus, died or lost to follow-up).<sup>11</sup> The remaining 1,044 infants have been confirmed as not infected with HIV.

**Figure 1. Reported number of infants exposed to HIV in utero and the number with confirmed HIV infection**





## Provincial/Territorial Prenatal HIV Screening Recommendations

In all Canadian provinces and territories, HIV testing of pregnant women remains the choice of the woman. Guidelines and/or recommendations for HIV testing of pregnant women have been developed in each province and territory to encourage informed decision-making; a summary of the various

prenatal HIV testing approaches in Canada is given in Table 2.

A two-year chart review of pregnant women, which began eight months after universal prenatal counselling and vertical transmission guidelines were put into place in Ontario, indicated that perinatal transmission was continuing. As a result, the study authors concluded that existing guidelines

**Table 2. Prenatal HIV testing approaches across Canada and year of implementation/recommendation\***

Province/territory	Testing approach	Year
British Columbia	HIV testing is offered as part of routine prenatal care with informed consent and pre- and post-test counselling.	1994
Yukon	HIV testing of pregnant women is strongly recommended and testing of sex partner is also encouraged.	1994
Northwest Territories	Prenatal HIV testing was introduced in 1993 as an opt-in program, and in 1998 became integrated with routine prenatal care, although women have the opportunity to opt out and decline testing.	1993, revised 1998
Nunavut**	Same policy as Northwest Territories	1999
Alberta	HIV screening is part of routine prenatal blood tests for all women in Alberta, and HIV testing is done unless the woman declines to be tested (opt-out policy).	1998
Saskatchewan	Consent is obtained before any testing is done and appropriate pre- and post-test counselling are provided.	1999
Manitoba	HIV testing is offered to all pregnant women as part of routine prenatal care; the decision to be tested is voluntary and based on informed choice.	2002
Ontario	All pregnant women are offered an HIV test as part of prenatal care, with informed consent and appropriate pre- and post-test counselling.	1998
Quebec	All pregnant women and women contemplating pregnancy are offered an HIV test.	1997
New Brunswick	Physicians are to routinely encourage all pregnant women to be tested for HIV with appropriate pre- and post-test counselling and informed consent.	1999
Nova Scotia	HIV testing is offered to all pregnant women with the other prenatal tests in the first trimester. Women who decline testing in the first trimester or who are known to engage in high-risk activities are to be offered testing again during the latter stages of pregnancy.	1998
Prince Edward Island	HIV testing is recommended for all pregnant women and is offered at the first prenatal visit.	1999
Newfoundland and Labrador	HIV testing is part of routine prenatal screening and is done unless the woman declines.	1997

\*As supplied by provincial/territorial HIV/AIDS data coordinators, January 2003.

\*\*Nunavut became a new territory in April 1999 after separating from the Northwest Territories.

were not being fully adopted and suggested that, to further decrease perinatal transmission, Ontario should include HIV testing as a routine prenatal test, ensuring that women are advised that they may refuse testing.<sup>12</sup>

## Canadian Women Can Access Prenatal HIV Screening Programs

Data from prenatal HIV screening programs can provide important information on the effectiveness of prenatal HIV screening recommendations. Data from several provinces are provided below:

- ◆ **British Columbia:** About 55% of pregnant women in British Columbia were tested for HIV in 1995. This percentage was estimated to be up to 80% in 1999, 60% through routine prenatal testing and 20% through groups identified as at high risk (Dr. M. Rekart: personal communication, March 2002).
- ◆ **Alberta:** In the first four months (September to December 1998) of their opt-out policy, 4.7% of the pregnant women who were eligible for prenatal HIV testing declined this option. In 1999, 3.3% declined, and in 2000 1.7% declined. Therefore, there has been a steady decrease in the number of pregnant women who declined HIV testing.<sup>3</sup>
- ◆ **Ontario:** HIV testing of pregnant women gradually increased from 40% in 1999 to 83% during the first three-quarters of 2003 (77% during the pregnancy and 6% previously).<sup>13</sup>
- ◆ **Quebec:** A recent study examined changes in medical practice regarding prenatal HIV testing in Ste-Justine Hospital, the referral centre for the province of Quebec, after the 1997 implementation of the HIV-screening strategy during pregnancy. The program consists of universal counselling and offers HIV testing to all pregnant women. The study found that the percentage of HIV tests offered to pregnant women was 61.8% in 2001.<sup>10</sup> Of the 58 HIV-positive

pregnant women seen at this hospital in 2002, 33 were given a diagnosis of HIV before pregnancy and 20 during pregnancy.<sup>14</sup>

- ◆ **Newfoundland and Labrador:** Since the 1997 implementation of Newfoundland and Labrador's policy of testing pregnant women unless the woman declines, 94% of all pregnant women have been tested. There have been no cases of perinatal transmission since 1994.<sup>15</sup>

## Antiretroviral Treatment Can Reduce the Likelihood of Transmission of HIV from Mother to Infant during Pregnancy

HIV testing during pregnancy can provide the opportunity to offer antiretroviral treatment to the mother and infant as, for example, in the following:

- ◆ A full AZT (zidovudine) protocol, which includes administering AZT to the mother during the second or third trimester, during labour and delivery, and after delivery to the infant for 6 weeks, can reduce the likelihood of transmission of HIV from mother to newborn by about 65%.<sup>16</sup>
- ◆ Clinical trials in developing countries have shown that short course AZT regimens (given to pregnant women starting at 36 weeks' gestation and during labour) can reduce vertical transmission rates by about 50%.<sup>17</sup>
- ◆ Studies indicate that even greater reductions can be achieved using single-dose nevirapine.<sup>18</sup>

Data from the national surveillance program of pediatric centres and HIV clinics in Canada (where 95% of infants exposed to mothers with diagnosed HIV are followed) indicate that the proportion of pregnant women receiving antiretroviral therapy has increased steadily in the last 10 years, from 19% in 1992 to 56% in 1996, 84% in 2000 and 90% in 2002.<sup>11</sup> The HIV infection rate of

perinatally HIV-exposed infants has decreased significantly over time in Canada because of antiretroviral therapy, from 33% during 1994-95 to 2.6% in 2000.<sup>11</sup>

In Quebec, at Sainte-Justine Pediatric Hospital, the use of AZT reduced the likelihood of mother-to-infant HIV transmission from 28.3% transmission among mother-infant pairs who had not received any AZT to 3.8% among mother-infant pairs who had received partial or full AZT therapy.<sup>19</sup>

A study done from 1993 to 1999 on AZT use in British Columbia found a reduction in the HIV vertical transmission rate, from 28% in untreated women-infant pairs to 13% in partially treated pairs and 0% in completely treated pairs.<sup>20</sup>

In Alberta, a study examining the prevention of perinatal HIV transmission from 1998 to 1999 found that when HIV-positive mothers were treated with antiretrovirals during pregnancy and the intrapartum period, 31 of 36 babies (86%) were not HIV-infected.<sup>21</sup>

## Canadian Prenatal HIV Screening Programs Are Valuable

Screening pregnant women for HIV clearly represents an important opportunity to prevent the transmission of HIV to infants through perinatal transmission. It is estimated that if such programs screened 90% of pregnant women across Canada, there would be a 65% reduction in the number of HIV-infected infants (compared with no prenatal testing and assuming 24% of untreated pregnancies and 6% of treated pregnancies result in HIV-infected infants).<sup>22</sup>

## Comment

CIDPC has estimated that about 17,000 Canadians are HIV-infected but unaware of their infection.<sup>23</sup> The proportion of positive HIV test reports in Canada attributed to women is on the rise. As a result, as more women become infected with HIV, the risk of perinatal transmission will increase. Given

this and the fact that perinatal infections are preventable, it is important that all pregnant women, and women considering pregnancy, should have access to prenatal care that includes the offer of HIV testing as well as appropriate counselling and care.

## References

1. Health Canada. *HIV and AIDS in Canada: Surveillance Report to June 30, 2003*. Surveillance and Risk Assessment Division, Epidemiology and Surveillance, Centre for Infectious Disease Prevention and Control, Population and Public Health Branch, November 2003.
2. Pi D, PJ Ballem and MT Schechter. *Final Report: the BC prenatal study: 1989-94*. Report submitted to Laboratory Centre for Disease Control, Jan 1995, and Rekart M. *HIV in pregnancy*. BC AIDS Update Quarterly Report: 4th Quarter 1995.
3. Jayaraman GC et al. *Mandatory reporting of HIV infection and opt-out prenatal screening for HIV infection: effect on testing rates*. Canadian Medical Association Journal 2003; 168(6); 679-682,
4. Blanchard J et al. *Manitoba antenatal study*. Report submitted to Laboratory Centre for Disease Control, June 1996.
5. Remis RS et al. *Seroprevalence study among pregnant women in Ontario: preliminary report of the serologic component*. Unpublished progress report submitted to Centre for Infectious Disease Prevention and Control.
6. *Seroprevalence of HIV-1 antibodies in women giving birth to live infants: a five-year trend analysis for selected regions outside Montreal, 1989-93*. Reported submitted to Laboratory Centre for Disease Control, Nov 1994 and Hankins D, Laberge C, Lapointe N et al. HIV infections among Quebec women giving birth to live infants. Canadian

- Medical Association Journal 1991; 144(3):277-80.
7. Getty G et al. *Seroprevalence of HIV infection in pregnant women in New Brunswick*. Canadian Journal of Infectious Disease 1997; 8:24A.
  8. Ratnam S, Sutherland D. *A follow-up to prenatal HIV seroprevalence study in Newfoundland*. Final report to Laboratory Centre for Disease Control, March 1997.
  9. Remis RS et al. *Epidemiologic modeling to evaluate prevention of mother-infant HIV transmission in Ontario* J AIDS, 2003;34 (2);221-230.
  10. Boucher M, J Samson and N Lapointe *HIV Screening Among Pregnant Women in the Province of Quebec: Success and Failure*. Can J Infect Dis 2002; 13 (suppl A): 30A (abstract 223).
  11. Health Canada. *HIV and AIDS in Canada: Surveillance Report to December 31, 2002*. Division of HIV/AIDS Epidemiology and Surveillance, Centre for Infectious Disease Prevention and Control, population and Public Health Branch, April 2003.
  12. Bitnun A et al. *Failure to prevent perinatal HIV Infection*. Canadian Medical Association Journal 2002; 166(7); 904-905.
  13. Remis RS. Tables of prenatal HIV testing in Ontario: Summary. [http://www.phs.utoronto.ca/ohemu/doc/Summary2003\\_Q3.pdf](http://www.phs.utoronto.ca/ohemu/doc/Summary2003_Q3.pdf)
  14. Santé et Services sociaux Québec *Portrait des infections transmissibles sexuellement et par le sang (ITSS), de l'hépatite C, de l'infection par le VIH et du sida au Québec décembre 2003* <http://ftp.msss.gouv.qc.ca/publications/acrobats/f/documentation/2003/03-329-01.pdf>
  15. Mossman, CL and S Ratnam *Opt-out prenatal HIV testing in Newfoundland and Labrador* Canadian Medical Association Journal 2002; 167 (6);630.
  16. Connor EM et al. *Reduction of maternal infant transmission of human immunodeficiency virus type 1 with zidovudine treatment*. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. New England Journal of Medicine 1994; 331:1173-80.
  17. Shaffer N et al. *Short course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomized clinical trial*. Lancet 1998; 353(9155):773.
  18. Marseille E et al. *Cost effectiveness of single dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa*. Lancet 1999; 354(9181): 803-9.
  19. Antiretroviral Therapy in Pregnant Women (CPARG): *Access and Outcome (1995-1997) and the Experience of Transmission of HIV in Treated Pregnant Women at Ste. Justine's Clinic, Quebec*. Presentation by Lapointe N. in the Proceedings of a Scientific Meeting to Review the Vertical transmission of HIV in Canada, June 1998.
  20. Forbes JC et al. *Effect of antiretroviral use on HIV vertical transmission rate and injection drug use on adherence in British Columbia, Canada*. Can J Infect Dis 2000; 11:46B {Abstract 246P}.
  21. Robinson JL and EL Bonita. *Prevention of perinatal transmission of HIV infection*. Canadian Medical Association Journal 2000; 163(7):831-832.

22. Archibald CP et al. *Estimating the impact of antenatal HIV testing in Canada: a lesson on the difference between efficacy and effectiveness*. Canadian Journal of Infectious Disease 1999; 10:43B {Abstract C304}.
23. Geduld J, Gatali M, Remis RS, Archibald CP. *Estimates of HIV prevalence and incidence in Canada, 2002*. Canada Communicable Disease Report 2003; 29:197-206.

## Acknowledgements

National level HIV and AIDS surveillance is possible as a result of all provinces and territories participating in, and setting directions for, HIV and AIDS surveillance. CIDPC acknowledges the provincial/territorial HIV/AIDS coordinators, public health units, laboratories, health care providers, and reporting physicians for sharing non-nominal, confidential data for national surveillance.

***For more information, please contact:***

**Surveillance and Risk Assessment Division  
Centre for Infectious Disease Prevention and Control  
Health Canada  
Tunney's Pasture  
Postal Locator 0602B  
Ottawa, ON K1A 0K9  
Tel: (613) 954-5169  
Fax: (613) 957-2842  
[www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/](http://www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/)**

7

Our mission is to help the people of Canada  
maintain and improve their health

*Health Canada*



# HIV/AIDS *EPI UPDATE*

Centre for Infectious Disease Prevention and Control

## Ethnicity Reporting for AIDS and HIV in Canada: Aboriginal and Black Communities Demand Attention

8

### *At a Glance*

- ✦ **Aboriginal peoples and Blacks are overrepresented among reported AIDS cases in Canada.**
- ✦ **Nearly half of all positive HIV test reports among Aboriginal peoples and Blacks are attributable to females, yet females account for only 16.4% of reports among Whites.**
- ✦ **Positive HIV test reports indicate that injecting drug use and heterosexual exposure are key factors for Aboriginal peoples and Blacks respectively.**

### Introduction

Documentation of ethnicity for reported AIDS cases and positive HIV test reports has become an important component of AIDS and HIV surveillance because of the unique perspective it offers on the epidemic. As with other demographic identifiers, ethnic information can contribute to the creation and evaluation of targeted prevention and treatment programs as well as to the development of health policy.

This *Epi Update* presents a summary of ethnic information from the national AIDS and HIV surveillance system. Additional information is available in *HIV and AIDS in Canada: Surveillance Report to June 30, 2003*.<sup>1</sup>

### AIDS

#### Improved Ethnicity Reporting Among AIDS Cases

Since 1982, when the first AIDS case was reported in Canada, a total of 85.8% (16,244/18,934) of AIDS cases reported up to June 30, 2003, have included ethnic information. During this time, the proportion of cases with this information has increased. Between 1982 and 1991, 80.6% of reported AIDS cases included information about ethnicity, increasing to 89.6% in the period between 1992 and 2001. In 2002, reporting of ethnicity was achieved in 85.2% (241/283) of cases.

#### Reported AIDS Cases and Ethnicity: A Balance of Changing Proportions

The total annual number of reported AIDS cases has declined over the last 10 years, from 1,750 cases in 1992 to 283 in 2002. In the first six months of 2003, 71

### *CIDPC Website:*

[www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/](http://www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/)

AIDS cases were reported. The number of cases in some ethnic groups, however, has not declined at the same rate as in others. In order to better understand trends by ethnic status, it is helpful to examine the proportion of all reported AIDS cases attributed to a particular ethnic group.

Whites have historically represented the largest proportion of reported AIDS cases, yet this proportion has declined over the last 10 years. The proportion of reported AIDS cases with known ethnicity attributed to Whites was highest in 1988, at 91.1%, but declined steadily to 68.0% in 1999. Since that time, the proportion increased to 74.5% in 2000 and dropped to 68.1% in 2001. In 2002, 58.9% of reported AIDS cases with known ethnicity occurred in Whites.

With a decrease among Whites, there has been a corresponding increase in the proportion of reported AIDS cases in other ethnic groups. The increase in the proportion has been most notable among Aboriginal peoples and Blacks since 1994 (Figure 1). In 2001, Aboriginal peoples and Blacks accounted for 3.3% and 2.2% of Canada's population respectively.<sup>2</sup> In the same year, they respectively accounted for 5.5% and 15.3% of reported AIDS cases with known ethnicity. In 2002, these proportions were 12.9% and 18.3% respectively. This indicates that both Aboriginal peoples and Blacks are overrepresented in reported AIDS

cases. Blacks account for the highest proportion of reported AIDS cases among non-White groups. This is notable considering the population of this community in Canada.


## HIV

### Missing Pieces: Positive HIV Tests Often Reported Without Ethnicity Information

Ethnicity reporting for positive HIV test reports is not as complete as that for reported AIDS cases because ethnicity data are available only for some provinces and territories. Reporting of HIV is more recent than AIDS, and there is still some concern regarding documentation of confidential information. As a result, the analysis of ethnicity information for HIV test reports presents a challenge.

Ethnicity data for positive HIV test reports have only been available since 1998, and therefore comparisons are possible only for this limited period of time. Between January 1998 and June 30, 2003, a total of 29.4% of positive HIV test reports have included ethnic information (3,706/12,602). The proportion of positive HIV test reports with ethnicity information was 27.1% in 1998, and peaked at 32.8% in 2000 before dropping to 28.5% in 2002.

**Figure 1. Proportion of Reported AIDS Cases for Selected Ethnic Groups by Year**



When examining HIV data, it is important to consider that HIV ethnicity data are not available for all provinces and territories. Provinces and territories that report ethnic information include British Columbia, Yukon Territory, Alberta, Northwest Territories, Nunavut, Saskatchewan, Manitoba, New Brunswick, Nova Scotia, Prince Edward Island, and Newfoundland and Labrador. As a result, only data from these provinces and territories are used when examining data by ethnic category, including reports for Aboriginal peoples or Blacks. Of those provinces and territories that report information on ethnicity, a total of 90.8% of positive HIV test reports have included ethnic information between January 1998 and June 30, 2003 (3,706/4,080). Therefore, please note that reports on ethnicity should not be viewed as representative of all of Canada. It must also be considered that the sources of HIV reports that include ethnicity are some areas where the Aboriginal population is large in comparison with other parts of Canada.

### Aboriginal Peoples Constitute a Notable Proportion of Positive HIV Tests with Known Ethnicity


The majority of positive HIV test reports with ethnicity information are among Whites, as is the case with reported AIDS cases. Whites represented 67.8% of positive HIV test

reports with known ethnicity in 1998. This figure dropped to 60.6% between 1999 and 2001 and decreased again, to 56.1%, in 2002 (399/711).

In 1998, 18.8% of positive HIV tests with known ethnicity were from Aboriginal peoples, as compared with a high of 26.2% in 2001 (Figure 2). The proportion of positive HIV test reports attributed to Aboriginal peoples in 2002 was 23.8%. These proportions are higher than the proportions attributed to Aboriginal peoples for reported AIDS cases. For example, in 2001, Aboriginal peoples accounted for 5.5% of reported AIDS cases with known ethnicity. This difference is likely due in part to HIV ethnicity information being primarily from western provinces where the Aboriginal population is greater. In addition, positive HIV test reports better reflect the current HIV epidemic than do reported AIDS cases. For additional information on HIV/AIDS among Aboriginal peoples, refer to the *Epi Update* entitled "HIV/AIDS Among Aboriginal Peoples in Canada: A Continuing Concern", May 2004.<sup>3</sup>

Compared with other non-White groups, Aboriginal peoples account for a higher proportion of positive HIV test reports where ethnicity has been recorded (Figure 2). However, one must remember that the two largest provinces, Ontario and Quebec, are not represented in HIV ethnicity data.

**Figure 2. Proportion of Positive HIV Test Reports with Known Ethnicity Attributed to Non-White Ethnic Groups, 1998-2002**





### The Proportion of Positive HIV Test Reports Attributed to Blacks on the Rise

As data for ethnicity are incomplete for positive HIV tests at the national level, caution must be taken when making interpretations. It is important to note, however, that the proportion of reports among Blacks has steadily increased over the last five years. In 1998, Blacks represented 5.5% of positive HIV test reports with known ethnicity. This figure rose to 10.7% in 2002.

### Positive HIV Tests Reflect Differences among Ethnic Groups

Of the 3,706 positive HIV test reports with ethnic information reported between January 1998 and June 30, 2003, 851 were among Aboriginal peoples, 306 among Blacks and 2,254 among Whites. The remaining 295 reports were attributed to other ethnic categories. Table 1 shows the distribution of gender, age and exposure category of positive HIV test reports for the three named ethnic groups. Such information may be of assistance in the design and targeting of prevention and care programs.

As shown in Table 1, reports for Aboriginal peoples and Blacks are equally distributed between males and females, and there is a higher proportion at a younger age as compared with Whites. Injecting drug use has been a key mode of transmission among Aboriginal peoples. As shown in Table 1, injecting drug users (IDU) accounted for 61.1% of positive HIV test reports among Aboriginal peoples between 1998 and June 30, 2003. Among Whites, the highest proportion of positive HIV test reports was attributed to men who have sex with men (MSM) (40.0%) and IDU (34.2%). People whose HIV infection was attributed to heterosexual exposure\* represented the largest proportion of positive HIV test reports among Blacks (75.3%). The majority (68.1%) of those in the heterosexual exposure category are categorized to the subgroup indicating origin in an endemic country (a country where heterosexual transmission of HIV predominates).

**Table 1. Comparison of positive HIV test reports between selected ethnic groups, 1998 to June 30, 2003**

	White	Aboriginal	Black
<b>Gender</b>	<b>n = 2,241</b>	<b>n = 847</b>	<b>n = 304</b>
Female	16.4%	45.1%	43.8%
<b>Age</b>	<b>n = 2,251</b>	<b>n = 848</b>	<b>n = 305</b>
20-29 yrs	16.1%	26.5%	33.1%
30-39 yrs	38.2%	40.9%	41.3%
40-49 yrs	29.7%	22.3%	14.1%
<b>Exposure category</b>	<b>n = 2,161</b>	<b>n = 828</b>	<b>n = 300</b>
MSM	40.0%	7.9%	13.3%
IDU	34.2%	61.1%	8.0%
Heterosexual*	21.2%	26.4%	75.3%

MSM = men who have sex with men, IDU = injecting drug users

\* The heterosexual exposure category includes people born in a country where HIV is endemic, people who report heterosexual contact someone who is either HIV-infected or is at increased risk of HIV infection, and people who report heterosexual contact as the only risk factor.

## Limitations of Ethnicity Data from Reported HIV and AIDS Cases

There are several significant limitations regarding the accuracy of ethnicity data obtained from AIDS and HIV surveillance information. The following should be kept in mind when examining such data:

- ◆ Misclassifications of ethnic status may occur at the time of HIV or AIDS diagnosis.
- ◆ People in certain communities may not wish to identify their ethnicity, resulting in underrepresentation.
- ◆ For AIDS reporting, patients and health care providers are constrained by the list of ethnic categories available on the AIDS Case Report Form, which may compromise the accuracy of ethnicity reporting.
- ◆ Not all provinces and territories routinely collect and/or report ethnicity.
- ◆ Variations in the completeness of ethnicity reporting among and within provinces may result in a systematic over or underrepresentation of specific communities.
- ◆ Reporting delay may vary by ethnicity and may therefore affect how representative ethnicity data are for recently reported HIV and AIDS cases.

Given these limitations, caution should be exercised in interpreting the AIDS and HIV ethnicity data presented. This is particularly true of positive HIV test reports, for which there is less complete ethnicity information.

## Comment

Community health groups and public health officials may use information about ethnicity in HIV/AIDS surveillance data to more effectively plan prevention and care programs for the different ethnic communities. When combined with other epidemiological descriptors of the HIV/AIDS epidemic, such as gender, age group and exposure category, such information becomes a powerful tool for directing programs to where they will have the most impact. To increase our ability to do this, it is essential that the completeness and accuracy of ethnicity reporting in surveillance data be improved.

## References

1. Health Canada. *HIV and AIDS in Canada: surveillance report to June 30, 2003*. Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Health Canada, 2003.
2. Statistics Canada. URL:  
 <<http://www12.statcan.ca/english/census01/products/highlight/Ethnicity/Page.cfm?Lang=E&Geo=PR&View=1&Table=1&StartRec=1&Sort=2&B1=Counts>>  
 . January 30, 2003.
3. Health Canada. *HIV/AIDS among Aboriginal peoples in Canada: a continuing concern, HIV/AIDS Epi Update*. Centre for Infectious Disease Prevention and Control, Health Canada, 2004.

## Acknowledgements

National level HIV and AIDS surveillance is possible as a result of all provinces and territories participating in, and setting directions for, HIV and AIDS surveillance. CIDPC acknowledges the provincial/territorial HIV/AIDS coordinators, public health units, laboratories, health care providers, and reporting physicians for sharing non-nominal, confidential data for national surveillance.

***For more information, please contact:***

**Surveillance and Risk Assessment Division  
Centre for Infectious Disease Prevention and Control  
Health Canada  
Tunney's Pasture  
Postal Locator 0602B  
Ottawa, ON K1A 0K9  
Tel: (613) 954-5169  
Fax: (613) 957-2842  
[www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/](http://www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/)**

Our mission is to help the people of Canada  
maintain and improve their health

*Health Canada*



# HIV/AIDS *EPI UPDATE*

**Centre for Infectious Disease Prevention and Control**

## **HIV/AIDS Among Aboriginal Peoples in Canada: A Continuing Concern**

### *At a Glance*

- ◆ **Aboriginal peoples are overrepresented in the HIV epidemic in Canada.**
- ◆ **Aboriginal peoples make up a growing percentage of positive HIV test reports and reported AIDS cases.**
- ◆ **Injecting drug use continues to be a key mode of transmission in the Aboriginal community.**
- ◆ **HIV/AIDS has a significant impact on Aboriginal women.**
- ◆ **Aboriginal peoples are being infected with HIV at a younger age than non-Aboriginal peoples.**

### *CIDPC Website:*

[www.hc-sc.gc.ca/pphb-dgsp/hasst-vsmt/](http://www.hc-sc.gc.ca/pphb-dgsp/hasst-vsmt/)

### **Introduction**

In Canada, Aboriginal populations are very diverse, with communities (First Nations, Inuit and Métis) that reflect variations in historical backgrounds, language and cultural traditions. Yet, unfortunately, these communities are disproportionately affected by many social, economic and behavioural factors such as high rates of poverty, substance abuse, sexually transmitted infections and limited access to or use of health care services, all of which increase their vulnerability to HIV infection.

This report updates current information on the status of the HIV/AIDS epidemic among Aboriginal peoples in Canada. To summarize Canadian HIV and AIDS surveillance data, Aboriginal peoples are identified as First Nations, Inuit and Métis. The category Aboriginal Unspecified is also used if no further details are known.

National HIV and AIDS surveillance data that appear in this document are from both a) *HIV and AIDS in Canada. Surveillance report to June 30, 2003*<sup>1</sup> and b) unpublished data, from the Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control (CIDPC), Health Canada.

### **Aboriginal Peoples are Overrepresented in the HIV/AIDS Epidemic in Canada**

#### **AIDS Surveillance Data**

- ◆ Between 1979 and June 30, 2003, there have been 18,934 AIDS cases reported to CIDPC, of which 16,244 (85.8%) included information on ethnicity. Of these 16,244 cases, 509 were reported to be Aboriginal peoples (3.1%).

- ◆ According to the 2001 Census, Aboriginal communities make up 3.3 % of the Canadian population.<sup>2</sup>

### HIV Surveillance Data

- ◆ Between 1998 and the end of June 2003, there have been 12,602 positive HIV tests reported to CIDPC, 3,706 of which contained information on ethnicity (29.4%).<sup>3\*</sup> Of these 3,706 reports, 851 were for Aboriginal peoples (23.0%). As ethnicity data for positive HIV test reports have only been available since 1998, comparisons are only possible for this limited period of time.
- ◆ In the provinces and territories that report ethnic information with positive HIV tests, Aboriginal communities make up 6.0% of the population.<sup>2</sup>

### Data from Targeted Studies

- ◆ Prenatal seroprevalence studies in Canada report an estimated national rate of HIV infection among pregnant women of 3 to 4 per 10,000 population. An ongoing study of pregnant Aboriginal women in British Columbia reported an HIV prevalence rate of 31.3 per 10,000 pregnancies in 2002 (JD Martin, Programs Medical Officer, Pacific Region, First Nations and Inuit Health Branch, Health Canada, and A. Jin,

consultant for the BC First Nations Chiefs' Health Committee: personal communication).

## Aboriginal Peoples Make Up a Growing Percentage of HIV Reports and AIDS Cases

A steady rise has been seen in the proportion of reported AIDS cases and positive HIV test reports among Aboriginal peoples in Canada over the last number of years.


### AIDS Surveillance Data

- ◆ Before 1992, out of the 6,203 reported AIDS cases with information on ethnicity, 80 cases or 1.3% were Aboriginal. This proportion steadily increased until it reached a high of 9.7% in 1999. In 2000 and 2001, the proportion decreased to 7.2% and 5.5% respectively. However, an increase was seen in 2002, when Aboriginal peoples accounted for 12.9% of the total reported AIDS cases for which ethnicity was known.

### HIV Surveillance Data


- ◆ From provinces and territories with ethnicity reporting, there were 119 positive HIV tests among Aboriginal peoples out of the 634 reported in 1998, representing 18.8% of positive HIV tests

**Figure 1. Reported AIDS Cases in the Aboriginal Community in Canada**



\* The provinces and territories that report ethnicity with positive HIV test reports are British Columbia, Yukon Territory, Alberta, Northwest Territories, Nunavut, Saskatchewan, Manitoba, New Brunswick, Nova Scotia, Prince Edward Island, and Newfoundland and Labrador.

**Figure 2. Positive HIV Test Reports in the Aboriginal Community in Canada for Provinces and Territories that Report Ethnicity for HIV\***



\* Provinces/territories with reported ethnicity include BC, YT, AB, NT, NU, SK, MB, NB, NS, PEI, NL.

reported in that period. This proportion increased to 23.8% (169/711) of positive HIV test reports with information on ethnicity in 2002.

with respect to exposure category. Although the proportion attributed to heterosexual exposure\* is similar, Aboriginal peoples have a higher proportion of reports attributed to IDU and a smaller proportion to MSM.

## Injecting Drug Use Continues To Be a Key Mode of Transmission in the Aboriginal Community

9

Injecting drug users (IDU) continue to be an important risk group in the Canadian HIV epidemic. Recent evidence supports the trends seen in surveillance data suggesting that injecting drug use is a particularly important risk factor for HIV and AIDS among Aboriginal peoples.

As Table 1 indicates, there are notable differences between Aboriginal and non-Aboriginal reported AIDS cases and positive HIV test reports

**Table 1. Comparison of selected exposure categories for reported AIDS cases and positive HIV test reports among Aboriginal and non-Aboriginal peoples†**

	Aboriginal	non-Aboriginal
	<i>n</i> = number of cases with available information on exposure category	
<b>AIDS</b>	<b><i>n</i> = 495</b>	<b><i>n</i> = 15,354</b>
IDU	38.0%	6.5%
MSM	34.7%	70.7%
Heterosexual	16.0%	14.3%
<b>HIV</b>	<b><i>n</i> = 828</b>	<b><i>n</i> = 2,727</b>
IDU	61.1%	29.7%
MSM	7.9%	36.6%
Heterosexual*	26.4%	29.2%

IDU = Injecting drug users, MSM = Men who have sex with men

†For reported AIDS cases, includes data up to June 30, 2003. For positive HIV test reports, includes data from 1998 to June 30, 2003, and from provinces/territories with reported ethnicity (BC, YT, AB, NT, NU, SK, MB, NB, NS, PEI, NL).

\* The heterosexual exposure category includes people born in a country where HIV is endemic, people who report heterosexual contact someone who is either HIV-infected or is at increased risk of HIV infection, and people who report heterosexual contact as the only risk factor.

## AIDS Surveillance Data

- ◆ Of reported AIDS cases with known exposure, the proportion of Aboriginal cases attributed to injecting drug use has dramatically increased over time, from 8.8% before 1992 to 30.1% during 1992-1996 and 54.1% during 1997-2001. In 2002, 53.3% of reported AIDS cases among Aboriginal peoples were attributed to IDU.
- ◆ Of the 509 reported AIDS cases among Aboriginal peoples between 1979 and June 30, 2003, there were 383 male cases, 125 were female, and 1 was a transgender person. Figures 3a and 3b display how these cases are distributed by exposure category. As there is only one transgender case, it is not shown.

## HIV Surveillance Data


- ◆ The monitoring of positive HIV test reports between 1998 and June 2003 also shows that injecting drug use is the most common route of transmission among Aboriginal peoples. Of the Aboriginal reports with exposure category information, 61.1% were attributed to injecting drug use.
- ◆ There have been 454 males, 372 females and two cases for which gender was not reported in positive HIV test reports among Aboriginal peoples between 1998

and June 30, 2003. Figure 3c displays how reports among males are distributed by exposure category. Of female reports, 66.9% were attributed to IDU and 31.5% to heterosexual exposure, proportions similar to those for reported AIDS cases.


## Data from Targeted Studies

- ◆ In the recently initiated, enhanced risk behaviour surveillance system among IDU in Regina, Sudbury, Toronto and Victoria (I-Track), 339 of the 794 participants identified themselves as Aboriginal (38.6%). Of these, 67.6% were from Regina (229/339).<sup>3</sup>
- ◆ A 2000 study of IDU in Regina indicated that of the 255 participants, 90% self-identified as an Aboriginal person.<sup>4</sup>
- ◆ In a study of Calgary's Needle Exchange Program, most participants were White (75%), but Aboriginal persons were the second highest ethnic group, representing 20% of total participants.<sup>5</sup>
- ◆ The Vancouver Injection Drug Users Study (VIDUS) is an open cohort of IDU. Of the 1,400 recruited between May 1996 and May 2000, 25% of participants were Aboriginal persons, more than half of whom were female (54% female, 46% male). In contrast, females accounted for 29% of non-Aboriginal participants.<sup>6</sup>


**Figure 3a. Distribution of Exposure Categories among Reported AIDS Cases of Aboriginal Males, November 1979-June 30, 2003**



**Figure 3b. Distribution of Exposure Categories among Reported AIDS Cases of Aboriginal Females, November 1979-June 30, 2003**



**Figure 3c. Distribution of Exposure Categories among Positive HIV Test Reports of Aboriginal Males, January 1998-June 30, 2003**



- ◆ In a further analysis of the VIDUS study, investigators found that Aboriginal status was significantly associated with new HIV infection both in men and in women<sup>7</sup> and also in study participants 24 years of age or younger.<sup>8</sup>
- ◆ VIDUS has reported that, as of December 2001, 19.1% of Aboriginal participants had seroconverted compared with 9.6% of persons who identified as non-Aboriginal.<sup>9</sup> In a 2003 publication, investigators concluded that in Vancouver, Aboriginal IDU are becoming HIV positive at twice the rate of non-Aboriginal IDU.<sup>10</sup>

### **HIV/AIDS Has a Significant Impact on Aboriginal Women**

In contrast to HIV and AIDS cases in the non-Aboriginal population, females make up a comparatively larger part of the Aboriginal HIV epidemic. Table 2 shows the distribution of gender among positive HIV test reports and reported AIDS cases for Aboriginal and non-Aboriginal peoples. Females represent nearly half (45.1%) of all positive HIV test reports among Aboriginal peoples, compared with 19.5% of reports among non-Aboriginal peoples.



**Table 2. Comparison of gender of reported AIDS cases and positive HIV test reports among Aboriginal and non-Aboriginal Peoples\***

	<b>Aboriginal</b>	<b>non-Aboriginal</b>
	<i>n</i> = number of cases with available information on gender	
<b>AIDS</b>	<b><i>n</i> = 509</b>	<b><i>n</i> = 15,717</b>
Female	24.6%	8.5%
<b>HIV</b>	<b><i>n</i> = 847</b>	<b><i>n</i> = 2,839</b>
Female	45.1%	19.5%

\*For reported AIDS cases, includes data up to June 30, 2003; for positive HIV test reports, includes data from 1998 to June 30, 2003, from provinces/territories with reported ethnicity (BC, YT, AB, NT, NU, SK, MB, NB, NS, PEI, NL).

### AIDS Surveillance Data

- ◆ Before 1992, females represented 13.8% of reported AIDS cases among Aboriginal peoples (11/80), yet by 2002, the proportion had increased to 25.8% (8/31).

### HIV Surveillance Data

- ◆ Among Aboriginal peoples, the proportion of positive HIV test reports attributed to females peaked in 1999 at 52.1% (87/167). In 2002, females represented 39.6% of reports (67/169).

### Data from Targeted Studies

- ◆ Pregnant women infected with HIV are at risk of transmitting the virus to their unborn child. Data from some sites in western Canada have shown that a high proportion of HIV-infected pregnant women who deliver are Aboriginal. Of all pediatric centres across Canada where children and HIV-infected mothers were followed between 1995 and 1997, 19% (49/259) of the women seen were Aboriginal women.<sup>11</sup> Of 32 HIV-infected women who delivered in northern Alberta or the Northwest Territories in 1996-98, 29 (91%) were Aboriginal.<sup>12</sup>
- ◆ Despite high numbers of Aboriginal women seen at HIV clinics and pediatric centres,

there was encouraging news that during the period 1995 to 1997, pregnant Aboriginal women were as likely to be taking antiretroviral therapy (62%) as pregnant White women (66%) and pregnant Black women (63%).<sup>13</sup>

- ◆ In a 2001 study of anti-retroviral therapy in a cohort of HIV-positive pregnant women recruited at seven sites in Ontario, Manitoba and Saskatchewan, the

results show that 20% of women were Aboriginal. Late use of antiretroviral therapy (in third trimester or intrapartum) was unequally distributed by ethnic status, occurring in 38% of Aboriginal, 27% of Black and 9% of White women.<sup>14</sup>

- ◆ Of the infants known to have contracted HIV through perinatal transmission in British Columbia between 1994 and 1999, 50% were Aboriginal.<sup>15</sup>

### Aboriginal Peoples Are Being Infected with HIV at a Younger Age than Non-Aboriginal Peoples

HIV and AIDS among young people in Aboriginal communities is an increasing concern. Understanding the epidemic in this group will help to appropriately target early intervention strategies. It is important, however, that caution be used when reviewing proportions by age group, as they can change considerably with the addition of one case, particularly when total numbers are small, such as with youth (less than 30 years).

As indicated in Table 3, a higher proportion of Aboriginal peoples test positive for HIV and also receive an AIDS diagnosis at a younger age than do non-Aboriginal peoples.

**Table 3. Comparison of age at time of diagnosis for reported AIDS cases and at time of test for positive HIV test reports among Aboriginal and non-Aboriginal peoples\***

	<b>Aboriginal</b>	<b>non-Aboriginal</b>
	<i>n</i> = number of cases with available information on age	
<b>AIDS</b>	<b><i>n</i> = 509</b>	<b><i>n</i> = 15,733</b>
< 20 years	1.8%	1.5%
20-29 years	21.8%	14.9%
30-39 years	47.7%	44.0%
40-49 years	22.6%	27.9%
50+ years	6.1%	11.7%
<b>HIV</b>	<b><i>n</i> = 848</b>	<b><i>n</i> = 2,849</b>
< 20 years	4.1%	1.5 %
20-29 years	26.5 %	19.1 %
30-39 years	40.9%	38.9%
40-49 years	22.3%	26.6%
50+ years	6.1%	13.8%

\*For reported AIDS cases, includes data up to June 30, 2003; for positive HIV test reports, includes data from 1998 to June 30, 2003, from provinces/territories that report ethnicity (BC, YT, AB, NT, NU, SK, MB, NB, NS, PEI, NL).

accounted for 37.8% (45/119) of positive HIV test reports among Aboriginal peoples in 1998, which contrasts with 19.5% (33/169) of positive test reports in 2002.

- ◆ It is essential to note, however, that IDU make up nearly 60.0% (149/253) of positive HIV test reports among youth, followed by the heterosexual exposure category at 25.7% (65/253) and MSM at 10.7% (27/253).

#### **Data from Targeted Studies**

- ◆ A study of risk factors among 232 young (less than 25 years) IDU in Vancouver found that 9 of 16 (56%) of the incident cases were Aboriginal.<sup>9</sup>

9

#### **AIDS Surveillance Data**

- ◆ Before 1992, 9.7% (3/31) of Aboriginal AIDS cases were among youth (less than 30 years), whereas in 2002 youth represented 41.3% (33/80) of cases.
- ◆ MSM and IDU each accounts for approximately a third of reported AIDS cases among Aboriginal youth. MSM makes up the largest proportion, at 31.5% (38/120), followed closely by IDU at 30.0% (36/120).

#### **HIV Surveillance Data**

- ◆ Although reported AIDS cases show a growing number attributed to youth, there has been a decrease in the proportion of positive HIV tests in this age group. Youth

#### **HIV/AIDS Surveillance Data in Canada's Three Aboriginal Communities**

When compared with a non-Aboriginal community, the number of positive HIV test reports and reported AIDS cases in Aboriginal communities may appear small. However, it is important to understand that these are individuals, and every new diagnosis has a significant impact on the Aboriginal community. Caution should be used when reviewing community proportions, as they can change considerably with the addition of one case, particularly when total numbers are small.

## AIDS Surveillance Data

According to the 2001 Census, 62% of Aboriginal Canadians are First Nations, 30% are Métis, 5% are Inuit and another 3% are from multiple communities.<sup>2</sup> Of 509 Aboriginal AIDS cases reported to June 30, 2003, 72.3% or 368 were First Nations, 8.3% or 42 were Métis, 4.1% or 21 were Inuit, and 15.3% or 78 were in the category Aboriginal Unspecified.

The data on reported AIDS cases in terms of IDU, females and youth in specific Aboriginal communities and in the Aboriginal Unspecified category are summarized below. Further details regarding gender and selected age and exposure category distribution are shown in Table 4.

**First Nations:** Reported AIDS cases among First Nations people show that 43.0% of cases can be attributed to injecting drug use (153/356). Females represent 26.6% (98/368) of cases, and youth (< 30 years)

account for 22.0% (81/368) of all First Nations cases.

**Métis:** In the Métis community, 26.8% (11/41) of all reported AIDS cases are attributable to IDU, and few cases are female (3/42 or 7.1%). It is important to note that nearly 40% (16/42) of reported AIDS cases among the Métis occur in those under 30 years of age.

**Inuit:** The IDU exposure category represents about a third of reported AIDS cases among Inuit people, at 33.3% (7/21). A notable proportion of cases occur in females (8/21 or 38.1%), and youth (less than 30 years) represent 33.3% (7/21) of cases.

**Aboriginal Unspecified:** IDU account for 22.1% (17/77) of cases for which the specific Aboriginal community is unspecified. Females make up just over 20% of cases (16/78) and youth (less than 30 years) 20.5% of cases in this group (16/78).

**Table 4. Gender, and selected age and exposure categories of reported AIDS cases in Aboriginal groups in Canada between 1979 and June 30, 2003**

	First Nations	Inuit	Métis	Aboriginal unspecified
	<i>n</i> = number of cases with available information			
<b>Gender</b>	<b><i>n</i> = 368</b>	<b><i>n</i> = 21</b>	<b><i>n</i> = 42</b>	<b><i>n</i> = 78</b>
Female	26.6%	38.1%	7.1%	20.5%
<b>Age (years)</b>	<b><i>n</i> = 368</b>	<b><i>n</i> = 21</b>	<b><i>n</i> = 42</b>	<b><i>n</i> = 78</b>
20-29 years	20.4%	33.3%	35.7%	17.9%
30-39 years	48.4%	52.4%	35.7%	50.0%
40-49 years	22.6%	9.5%	23.8%	25.6%
<b>Exposure category</b>	<b><i>n</i> = 356</b>	<b><i>n</i> = 21</b>	<b><i>n</i> = 41</b>	<b><i>n</i> = 77</b>
MSM	31.2%	28.6%	46.3%	46.8%
IDU	43.0%	33.3%	26.8%	22.1%
Heterosexual	14.3%	28.6%	14.6%	20.8%

## Increasing Proportion of Aboriginal Peoples among Estimated HIV Prevalent and Incident Infections at the National Level

National HIV surveillance data capture only those who are tested, whose HIV infection is diagnosed and whose positive test results are reported to Health Canada. As a result, surveillance data do not describe the full scope of the epidemic. However, calculations using these data along with other sources of data are carried out to estimate the number of people living with HIV (prevalence) and the number newly infected with HIV (incidence).

- ◆ It has been estimated that 250 to 450 Aboriginal peoples were newly infected with HIV during 2002, compared with 370 in 1999. These figures correspond to 6% to 12% of the total number of new infections in Canada in 2002, compared with 9% in 1999.<sup>16</sup>
- ◆ It is also estimated that 3,000 to 4,000 Aboriginal peoples were living with HIV (including AIDS) in Canada in 2002, representing 5% to 8% of HIV prevalent infections. This is higher than the 1999 estimate of 2,500 to 3,000, or about 6% of the total.<sup>16</sup> These proportions are noteworthy because of the distinct contrast with the proportion of the population in Canada represented by Aboriginal peoples (3.3%).<sup>2</sup>

- ◆ Injecting drug use is the predominant risk factor for HIV infections in Aboriginal populations. The estimated exposure category distribution of prevalent and incident infections among Aboriginal peoples in 2002 is shown in Table 5. Findings for 2002 are similar to those of 1999.<sup>16</sup>
- ◆ It is important to note that the *estimated* proportion of new HIV infections due to injecting drug use among Aboriginal peoples (63%) is much higher than among all Canadians (30%),<sup>16</sup> reinforcing the finding given earlier that injecting drug use is a key mode of HIV transmission in the Aboriginal community.

### Comment

Aboriginal HIV and AIDS surveillance data are incomplete for several reasons. The primary one is the incomplete information on ethnicity in current surveillance data. Since 1982, 14% of all reported AIDS cases have had no information on ethnicity. Ethnicity data for positive HIV test reports have only been available since 1998. Furthermore, 69.8% of positive HIV test reports between 1998 and June 30, 2003, lack ethnicity. Other reasons include interprovincial variations in reporting ethnicity, misclassification of ethnic status and delays in reporting. Positive HIV test reports and reported AIDS cases represent only those infected individuals who came forward for testing or who received an AIDS diagnosis and are subsequently reported to Health Canada. As a result, the numbers in this report do not represent the total number of Aboriginal peoples who are infected with HIV or whose AIDS has been diagnosed.

**Table 5. Exposure category distribution for estimated prevalent and incident HIV infections among Aboriginal peoples in Canada, 2002**

Exposure category	Prevalent infections (N = 3,000-4,000)	Incident infections (N = 250-450)
IDU	57%	63%
Heterosexual contact	17%	18%
MSM	20%	12%
MSM/IDU	5%	7%

Despite these limitations, evidence suggests that the HIV epidemic in the Aboriginal community shows no sign of abating. Injecting drug use is the most common mode of HIV transmission among Aboriginal peoples, Aboriginal women make up a large part of the HIV epidemic in their community, and Aboriginal peoples are infected at a younger age than non-Aboriginals. This indicates the different characteristics of the HIV epidemic among Aboriginal peoples and emphasizes the complexity of Canada's HIV epidemic. Better data on HIV/AIDS epidemiology and HIV testing among Aboriginal peoples in Canada are needed to guide prevention and control strategies. In addition, it is vital to conduct further research to increase our understanding of the specific impact HIV has on Aboriginal peoples.

## References

1. Health Canada. *HIV and AIDS in Canada. Surveillance report to June 30, 2003*. Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Health Canada, 2003.
2. Statistics Canada. *Population by Aboriginal group. 2001 Census, Canada, provinces and territories*. URL: <<http://www.statcan.ca/english/Pgdb/popula.htm#ori>>.
3. Health Canada. *I-Track: enhanced surveillance of risk behaviours among injecting drug users in Canada. Pilot survey report, February 2004*. Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Health Canada, 2004.
4. Findlater R, Young , Bangura H et al. *The Regina Seroprevalence Study: a profile of injection drug use in a prairie city, 2000*. Unpublished report. Available through the Surveillance and Risk Assessment Division, Health Canada.
5. Guenter CD, Fonseca K, Nielsen DM et al. *HIV prevalence remains low among Calgary's needle exchange program participants* Can J Public Health 2000;(91)2:129-32.
6. Tyndall MW, Craib KJP, Currie S et al. *Impact of HIV infection on mortality in a cohort of injection drug users*. J Acquire Immune Defic Syndr 2001; (28)4:351-57.
7. Spittal PM, Craib KJP, Wood E et al. *Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver*. Can Med Assoc J 2002;166:894-99.
8. Miller CL, Tyndall M, Spittal P et al. *HIV incidence and associated risk factors among young injection drug users*. AIDS 2002;(16)3:491-93.
9. Craib KJP, Spittal PM, Li K et al. *Comparison of HIV incidence rates among aboriginal and non-aboriginal participants in a cohort of injection drug users in Vancouver*. Can J Infect Dis 2002;13(Suppl A):48A(Abstract 315).
10. Craib KJP, Spittal PM, Wood E et al. *Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver*. Can Med Assoc J 2003;168:19-24.
11. Forbes JC, Burdge DR, Money D. *Pregnancy outcome in HIV infected women in British Columbia: the impact of antiretroviral therapy on maternal-infant HIV transmission*. Can J Infect Dis 1997;8:31A(Abstract 235).
12. Birse E, Shokoples S, Houston S. *Demographic and clinical features of Aboriginal and non-Aboriginal patients with HIV infection in Northern Alberta*. Can J Infect Dis 1999;10(Suppl B):66B(Abstract C387P).

13. Lapointe N, Forbes J, Singer J et al. *Antiretroviral therapy in pregnant women in Canada: access and outcome 1995-97*. Can J Infect Dis 1998;9(Suppl A):70A(Abstract 449P).
14. King SM and the Motherisk-HIV Network Members. *Antiretroviral therapy (ART) in a cohort of HIV-positive pregnant women in Canada*. Can J Infect Dis 2001;12(Suppl B):26B(Abstract 203).
15. Ogilvie G, Money D, Forbes J et al. *Perinatal infection in Aboriginal maternal infant pairs (MIP) in British Columbia*. Can J Infect Dis 2002; 13(Suppl A):50A(Abstract 321).
16. Geduld J, Gatali M, Remis RS, Archibald CP. *Estimates of HIV prevalence and incidence in Canada, 2002*. CCDR 2003;29:197-206.

## Acknowledgements

National level HIV and AIDS surveillance is possible as a result of all provinces and territories participating in, and setting directions for, HIV and AIDS surveillance. CIDPC acknowledges the provincial/territorial HIV/AIDS coordinators, public health units, laboratories, health care providers, and reporting physicians for sharing non-nominal, confidential data for national surveillance.

### ***For more information, please contact:***

**Surveillance and Risk Assessment Division  
Centre for Infectious Disease Prevention and Control  
Health Canada  
Tunney's Pasture  
Postal Locator 0602B  
Ottawa, ON K1A 0K9  
Tel: (613) 954-5169  
Fax: (613) 957-2842  
[www.hc-sc.gc.ca/pphb-dgsp/hast-vsmt/](http://www.hc-sc.gc.ca/pphb-dgsp/hast-vsmt/)**

Our mission is to help the people of Canada  
maintain and improve their health

*Health Canada*



# HIV/AIDS *EPI UPDATE* Centre for Infectious Disease Prevention and Control

## HIV Infections among MSM in Canada

### *At a Glance*

- ◆ In Canada, MSM account for 77.1% of cumulative AIDS cases among adult males.
- ◆ MSM account for 70.2% of positive HIV test reports among adult males since testing began in 1985.
- ◆ MSM were estimated to account for 40% of all new HIV infections in Canada in 2002.

### Introduction

In Canada, the HIV/AIDS epidemic has had a tremendous impact on men who have sex with men (MSM). Even though the toll of the epidemic no longer affects MSM to the same extent that it did in the early to mid-1980s, this group still accounts for the largest number of reported HIV and AIDS diagnoses. Recent data on HIV incidence and risk behaviours suggest that MSM continue to be at risk for HIV infection and other sexually transmitted infections (STIs). This report updates the current information on the status of HIV and AIDS among MSM in Canada.

### AIDS Surveillance Data

- ◆ As of June 30, 2003, the Centre for Infectious Disease Prevention and Control (CIDPC) reported a cumulative total of 18,934 AIDS cases. Of the 17,136 adult male AIDS cases, 77.1% were attributed to MSM and an additional 5.0% were attributed to the MSM who also reported injecting drugs (MSM/IDU).<sup>1</sup>
- ◆ There has been a steady decrease in the proportion of adult male AIDS cases attributed to MSM that were reported to CIDPC from 1986 to 1999, from about 80% before 1996 to 54.4% in 1999. In 2000, this proportion increased to 57.4% and since then has remained fairly steady. The proportion was 53.2% in 2002.<sup>1</sup>
- ◆ The proportion of adult AIDS cases attributed to MSM/IDU has remained relatively steady, varying between 2.7% and 6% during the last five years.<sup>1</sup>

### *CIDPC Website:*

[www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/](http://www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/)

## HIV Surveillance Data

While AIDS data provide information on HIV infection that occurred about 10 years in the past, HIV data provide a picture of more recent infections.

- ◆ Positive HIV test reports sent from each province and territory are collated and synthesized at the national level by CIDPC. These reports show that before 1998, 75.5% of positive HIV test reports among adult males were attributed to MSM. This proportion then decreased to around 48% during 1998-1999. It increased to 53.7% in 2000 and has been in the range of 48% to 52% during 2001-02.<sup>1</sup> A similar trend is observed in the absolute number of positive HIV test reports attributed to MSM among adult males. The increase in the number and proportion of MSM among adult male positive HIV test reports noted in 2000 was the first increase seen since the 1980s.

### MSM Continue to Account for the Greatest Number of Prevalent and Incident HIV Infections

The 2002 estimates of prevalence (number living with HIV) and incidence (number newly infected in a year) show that MSM continue to be the most affected group. At the end of 2002, an estimated

56,000 (46,000-66,000) people in Canada were living with HIV infection (including AIDS) and, of these, 58% or 32,500 infections occurred among MSM. The largest absolute increase in prevalent infections in 2002 was in the MSM exposure category, which had 2,900 more prevalent infections than in 1999 (10% relative increase). The combined exposure category of MSM and IDU (MSM-IDU) made up 4% of total prevalent infections in 2002.<sup>2</sup>


In 2002, MSM accounted for 40% of the estimated total of 2,800 to 5,200 new infections in Canada or approximately 1,000 to 2,000 new HIV infections. This represents a slight increase from the 38% estimated in 1999 (Figure 1).<sup>2</sup>

### High Rates of New HIV Infections in Some Parts of Canada

- ◆ In the late 1990s, data from Ontario showed an increase in the rate of new HIV infections among MSM who were repeat testers for HIV, from 0.79 infections per 100 person years in 1996 to 1.39 per 100 person years in 1999. Incidence was significantly higher in Toronto and Ottawa compared with the rest of Ontario.<sup>3</sup> In 2000, incidence appeared to have stabilized in Ontario.<sup>3</sup> With the use of a new laboratory technique to identify recent infections among those with newly

10

**Figure 1. Distribution (%) of new HIV infections among MSM, by time period**





diagnosed HIV (STARHS assay) during 1999-2002, HIV incidence decreased among MSM in Toronto, from 4.3 per 100 person years (PY) in 1999 to 2.8 per 100 person years in 2001 and has remained fairly steady to 2002. In contrast, HIV incidence among MSM in Ottawa appeared to increase, from less than 0.1 per 100 PY in 1999 to 3.5 per 100 PY in the first half of 2001 and decreased to around 1.8 per 100 PY in 2002.<sup>4</sup>

- ◆ In Quebec, the Omega Cohort provides information on the incidence and psychosocial determinants of HIV infection among MSM living in Montreal. From October 1997 to August 2001, overall HIV incidence remained relatively stable, varying from 0.44 to 0.71 per 100 PY without any clear increasing or decreasing trend. However, trends in HIV incidence varied by age. The relative rates in 2001 were 2.7 among younger MSM and 1.3 among older MSM.<sup>5</sup> From October 1996 to October 2002, the overall incidence was 0.59 per 100 PY. It increased non-significantly from 0.56 to 0.88 per 100 PY between 1997 and 2002.<sup>6</sup>
- ◆ In British Columbia, results from the Vanguard study, a prospective cohort of young gay and bisexual men in Vancouver, show that the annual rate of new HIV infections among those men who had never injected drugs increased from a range of 0.2-1.0 per 100 PY during 1996 to 1999 to 2.0 per 100 PY in 2000 and to 2.5 per 100 PY in the first nine months of 2001.<sup>7</sup>
- ◆ With respect to HIV prevalence, data (self-reported or test data) from surveys done directly among MSM showed a very high rate before 1990: 23% to 32% in Vancouver,<sup>8,9</sup> 27% to 57% in Toronto,<sup>8,10</sup> 20% to 25% in Montreal<sup>8,11</sup> and between 10% and 20% in other regions of Canada.<sup>7</sup> By 1998/2000, it appeared that there was some decline in the HIV prevalence rate among MSM surveyed by similar methods: 16% in Vancouver<sup>12,13</sup> and 10%-16% in Montreal.<sup>14,15</sup> A 2002 survey in British

Columbia reported an overall prevalence of 12.9% with a higher proportion of HIV-positive men being residents of Vancouver.<sup>16</sup> However, a high prevalence rate is still seen among MSM who are also IDU, for example, 14% to 22% among MSM/IDU attending needle exchange programs in Quebec (1995-2000).<sup>17,18</sup>

- ◆ The Omega Cohort results showed that HIV prevalence increased with age from a rate of 0.0% in MSM under 20 years to 3.1% in those aged 40-44 years, and then decreased to 0.4% among those 45 years of age or over. However, this trend was not statistically significant.<sup>5</sup>

## Continuing Risk Behaviour among MSM

Recent data on risk behaviours suggest that MSM continue to be at considerable risk of HIV infection and other STIs through engaging in unprotected receptive or insertive anal intercourse (UAI) with casual or regular partners, or practising unsafe sex (oral or anal) with a known HIV-positive partner:

- ◆ It is estimated that around 15% of Montreal's MSM are currently HIV-infected. Results from the Montreal Omega Cohort Study indicate that 12% of MSM practise UAI with casual partners. This could result in a significant increase in the risk of new HIV infections.<sup>19</sup> From 1997 to 2002, risky anal sex (RAS) increased slightly from 16% to 19%, and UAI increased slightly from 34% to 39%. The increases in risky behaviour, though slight, need to be closely monitored and better understood in order to ascertain their possible impact on HIV incidence.<sup>6</sup>
- ◆ In another survey in Montreal, the prevalence of reported UAI was 12% among MSM recruited in bars or saunas but was up to 21% to 24% among MSM who were HIV-positive.<sup>14</sup> A study on sexual risk behaviours of HIV-positive MSM in Montreal found that 15% had had unprotected insertive anal sex with an

HIV-negative partner or a partner whose serostatus was unknown.<sup>15</sup>

- ◆ With respect to relapse to risky behaviours, available data indicate that 10% of the Montreal cohort and 26% to 30% of the Vancouver cohort who reported safe sex at baseline disclosed relapse to unprotected anal sex at follow-up six to 12 months later.<sup>20,21</sup>
- ◆ A 2002 survey of MSM in BC found that the majority of participants generally reported practising safe sex (73.4%). However, those with multiple partners reported a 25% increase in UAI, from 18.8% in 2000 to 23.5% in 2002. It also showed that at least 27% of participants had had unprotected sex with a partner of unknown serostatus in the previous year.<sup>16</sup>
- ◆ Between May 1995 and September 2001, participants aged 15 to 35 years in a cohort study of MSM in the Greater Vancouver region reported increasing unprotected insertive (relative risk: 3.5) and receptive (relative risk: 5.1) anal sex with an HIV-positive partner; this increase in UAI was associated with seroconversion.<sup>22</sup>
- ◆ Data from the Vancouver cohort and the Montreal cohort were combined and analyzed, comparing the sexual behaviours of HIV-positive and HIV-negative gay and bisexual men aged 16 to 30 years. Results show that 56% of HIV-positive men and 40% of HIV-negative men reported having engaged in receptive UAI during the previous six months or year.<sup>23</sup> More recently, high-risk behaviour among MSM in both cities was associated with nitrite inhalant use and sex in public and commercial sex venues. Independent determinants of risk-taking for men in both cities were the use of poppers (Vancouver: odds ratio [OR] 2.1, Montreal: OR 2.9) and having sex in a bathhouse (Vancouver: OR 1.9, Montreal OR 1.8). In Vancouver, having sex in a bar (OR: 1.8) and having at least 20 casual partners in the previous year (OR: 1.7) were associated with high-risk sex. For men in Montreal, having a casual partner (OR: 3.0) and having at least two regular partners in the previous year (OR: 3.0) were independently associated with high-risk sexual behaviour.<sup>24</sup>
- ◆ The results of a cohort study of MSM aged 15 to 35 enrolled in the Vanguard Project in Vancouver showed that the proportion of MSM reporting insertive UAI with casual partners increased significantly, from 17% in 1997-98 to 22% in 2001-02, and the proportion of MSM who reported receptive UAI increased from 11% to 16% during the same period.<sup>25</sup> There was an increase in both receptive and insertive UAI with a regular partner, although it was not statistically significant. There was, however, no significant change in HIV seroconversion rate during this period (1997-2002). This study also reported that most of the MSM who engaged in UAI reportedly did so with sero-concordant partners, although sero-concordant receptive UAI was reported by 12%.<sup>25</sup> In the same cohort study in Vancouver, a significant increase was observed in the proportion of MSM reporting recent use of crystal meth, ecstasy, and marijuana; the use of poppers, marijuana, hallucinogens, crystal meth, and ecstasy was found to be associated with receptive UAI with casual partners.<sup>26</sup>
- ◆ STI data may be used as a marker for unsafe sexual behaviour. A review of the gonorrhoea surveillance data in Canada reveals that reported cases of gonorrhoea among men increased by 53% between 1997 and 2001, the most dramatic increase (68%) being seen among those aged 30 to 39 years.<sup>27</sup> Despite the limitations of the data in assessing the sexual orientation of the reported cases, it is estimated that less than 4% of male cases from 1994 to 2001 are MSM-associated.<sup>28</sup> In an analysis of a syphilis outbreak among MSM in Calgary, Alberta, in 2000-2001, it was reported that 35.7% of the MSM cases were co-infected with HIV.<sup>28</sup> The reported high rate of HIV

co-infection, the syphilis outbreak itself and the increase in gonorrhoea cases further support the suggestion of an increase in unprotected sexual encounters among MSM.

## Comment

A number of biases must be taken into account when interpreting the results noted here. HIV diagnostic data are limited to persons who present themselves for testing, and so trends in these numbers may be influenced by testing patterns or improved ability to remove duplicate tests. In addition, identifying information that accompanies HIV testing data is sometimes incomplete or inaccurate, and this may limit the usefulness of HIV incidence estimates. Results of cohort studies are limited by selection biases, loss to follow-up and problems with generalizability.

Despite these limitations, available data suggest that there was an increase nationally in new HIV infections among MSM in the late 1990s, and although this increase may not have continued, overall incidence does not appear to have decreased since then. There is also a continued presence of high-risk behaviours among MSM across the country. This high-risk behaviour among MSM is also noted elsewhere. For example, increases have been seen for HIV-associated risk behaviours and/or STDs among MSM in the USA,<sup>29-31</sup> Amsterdam<sup>32</sup> and Sydney, Australia.<sup>33</sup>

Several hypotheses might explain these increases in HIV-associated risk behaviours, including feelings of complacency or optimism related to the success of antiretroviral therapy,<sup>27</sup> false reassurance upon learning an HIV-negative result, a lack of direct experience of the AIDS epidemic in the younger generation of gay men, a desire to escape the rigorous norms and standards required for a lifetime of safe sex,<sup>34-36</sup> alcohol/drug use<sup>24,36-38</sup> and the impact of Internet chat rooms as a risky environment.<sup>39</sup>

The increase in new infections among MSM and the number of MSM living with HIV underscore the need for innovative prevention programs to reduce the spread of HIV and STIs among the gay community. These programs should not only focus on those who are not yet infected but also those who are HIV positive. National risk behaviour measured over time and in different settings that reflect urban as well as rural areas would be useful to better characterize the epidemic among MSM and to support effective prevention and care programs.

## References

1. Health Canada. *HIV and AIDS in Canada: Surveillance Report to June 30, 2003*. Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Health Canada, 2003.
2. Geduld J, Gatali M, Remis R, Archibald CP. *Estimates of HIV prevalence and incidence in Canada, 2002*. *CCDR* 2003;29:197-206.
3. Calzavara L, Burchell A, Major C et al. and the Polaris Study Team. *Increases in HIV incidence among men who have sex with men undergoing repeat diagnostic HIV testing in Ontario, Canada*. *AIDS* 2002;16:1655-61.
4. Remis RS, Major C, Swantee C et al. *Trends in HIV incidence in Ontario based on the STARHSD assay: update to December 2002*. Presented at the Ontario HIV Treatment Network, 5<sup>th</sup> Annual Research Day, November 2003.
5. Remis RS, Alary M, Otis J et al. and the OMEGA Study Group. *Trends in HIV infection in the Omega cohort of men who have sex with men (MSM) in Montreal, 1996-2001*. *Can J Infect Dis* 2002;13(Suppl A):50A(Abstract 320).
6. Alary M, Remis RS, Otis J et al. and the OMEGA Study Group. *Persistent increase in risky sexual behaviour but*

- stable HIV incidence among men who have sex with men (MSM) in Montréal. *Can J Infect Dis* 2003;14(Suppl) A:43A, 202.
7. Martindale SL, Cook D, Weber AE et al. *The impact of STARHS "Detuned Assay" results on HIV incidence calculations in an ongoing cohort of men who have sex with men (MSM) in Vancouver.* *Can J Infect Dis* 2002;13 Supplement A:65A (Abstract 369P).
  8. Myers T, Godin G, Calzavara L et al and the Canadian AIDS Society Team. *The Canadian Survey of Gay and Bisexual Men and HIV Infection: men's survey.* Ottawa: National AIDS Clearing House (Catalogue ISBN 0-921906-14-5).
  9. Craib KJP, Strathdee SA, Hogg RS et al. *Incidence rates of HIV-1 infection, AIDS progression and mortality in the Vancouver Lymphadenopathy-AIDS Study: results at 14 years.* *Can J Infect Dis* 1998;9:31A(Abstract 213).
  10. Coates R, Calzavara LM, Read SE et al. *A prospective study of male sexual contacts of individuals with ARC or AIDS.* Final report to National Health Research and Development Program, 1992.
  11. Remis RS, Najjar M, Pass C, Paradis G. *Seroepidemiological study of HIV infection and sexual behaviour among men attending a medical clinic in Montreal.* Vth International Conference on AIDS (Abstract WAP42), Montreal, Canada, June 1989.
  12. Low-Beer S, Bartholomew K, Weber AE et al. *A demographic and health profile of gay and bisexual men in a large Canadian urban setting.* *AIDS Care* 2002;14(1):111-15.
  13. Low-Beer S, Weber AE, Bartholomew K et al. *A demographic and health profile of HIV-positive gay and bisexual men in the west end of Vancouver.* *Can J Infect Dis* 1999;10:62B.
  14. Dumas J, Lavoie R, Desjardins Y. *Project national Three Cities, Volet Montréalais: Étude de besoins en matière de santé des hommes gais de Montréal.* Action Séro Zéro. Report to the HIV/AIDS Policy, Coordination and Program Division, Health Canada, July 2000; presentation by Lavoie R in *Proceedings of the MSM/IDU Consultation Meeting (March 8-9, 2001, Ottawa, Canada)*, Centre for Infectious Disease Prevention and Control, Health Canada.
  15. Beauchemin J, Cox J. *Sexual risk behaviours of HIV-positive MSM in Montreal.* *Can J Infect Dis* 2003; 14(Suppl A):41.
  16. Trussler T, Marchand R, Barker A. *Sex now by the numbers: a statistical guide to health planning for gay men.* Vancouver, BC: Community-based research centres, 2003.
  17. Poulin C, Alary M, Noel L et al. *Prevalence and incidence of HIV among injecting drug users (IDU) attending a needle exchange program NEP in Quebec City.* *Can J Infect Dis* 1997;8(Suppl A):27(Abstract 218).
  18. Hankins C, Alary M, Parent R et al. and the SurvUDI Working Group. *Knowledge of HIV status among MSM and heterosexual men who inject drugs.* Paper presented at the 10th Annual Canadian Conference on HIV/AIDS Research, May 2001, Toronto.
  19. Dufour A, Alary M, Otis J et al. and the Omega Study Group. *Risk behaviours and HIV infection among men having sexual relations with men: baseline characteristics of participants in the Omega Cohort Study, Quebec, Canada.* *Can J Public Health* 2000;91(5):345-49.

20. Remis RS, Alary M, Otis J. *HIV infection and risk behaviours in young gay and bisexual men* (Letter to editor and response [Hogg RS, Strathdee SA, Chan K et al.]). *Can Med Assoc J* 2000; 163(1):14-15.
21. Strathdee SA, Martindale SL, Cornelisse PGA et al. *HIV infection and risk behaviours among young gay and bisexual men in Vancouver*. *Can Med Assoc J* 2000;162(1):21-25.
22. Weber AE, Craib KJP, Chan K et al. *Predictors of HIV sero conversion among young men who have sex with men*. *Can J Infect Dis* 2002;13(Suppl A):49A, 319.
23. Weber AE *Risk factors associated with HIV infection among young gay and bisexual men in Canada*. *J Acquir Immune Defic Syndr* 2001;28(1):81-8.
24. Weber AE, Otis J, Chan K et al. *Factors associated with high-risk sexual behaviour among men who have sex with men (MSM) in two Canadian cohorts*. *Can J Infect Dis* 2002;13(Suppl A):45A, 355.
25. Lampinen TM, Chan K, Craib KJP et al. *Trends in condom use and HIV-1 seroincidence in a cohort of young men who have sex with men (MSM) in Vancouver, 1997-2002*. *Can J Infect Dis* 2003;14(Suppl A): 41A, 200.
26. Lampinen TM, Chan K, Miller ML et al. *Substance use trends among young men who have sex with men (MSM) in Vancouver and relation to high-risk anal intercourse, 1997-2002*. *Can J Infect Dis* 2003;14(Suppl A):48A, 221P.
27. Hansen L, Wong T, Perrin M. *Gonorrhoea resurgence in Canada*. *Int J STD & AIDS* 2003;14:727-31.
28. Jayaraman GC, Read RR, Singh A. *Characteristics of individuals with male-to-male and heterosexually acquired infectious syphilis during an outbreak in Calgary, Alberta, Canada*. *Sex Transm Dis* 2003;30(4):315-19.
29. Denning P, Nakashima AK, Wortley P. *Increasing rates of unprotected anal intercourse among HIV-infected men who have sex with men in the United States*. 13<sup>th</sup> International AIDS Conference, July 9-14, 2000, Durban, South Africa (Abstract no. ThOrC714).
30. Page-Shafer KA, McFarland W, Kohn R et al. *Increases in unsafe sex and rectal gonorrhoea among men who have sex with men - San Francisco, California, 1994-97*. *MMWR* 1999;48:45-8.
31. Handsfield HH, Whittington WLH, Desmon S et al. *Resurgent bacterial sexually transmitted disease among men who have sex with men - King County, Washington, 1997-99*. *MMWR* 1999;48:773-7.
32. Dukers N, de Wit J, Goudsmit J, Coutinho R. *Recent increase in sexual risk behaviour and sexually transmitted diseases in a cohort of homosexual men: the price of highly active antiretroviral therapy?* 13<sup>th</sup> International AIDS Conference on AIDS, Durban, South Africa, July 9-14, 2000 (Abstract ThOrC715).
33. Van De Ven P, Prestage G, French J et al. *Increase in unprotected anal intercourse with casual partners among Sydney gay men in 1996-98*. *Aust N Z Public Health* 1998;22:814-8.
34. Ostrow DG, Fox K, Chmiel JS. *Attitudes toward highly active antiretroviral therapy predict sexual risk-taking among HIV infected and uninfected gay men in the Multicenter AIDS Cohort Study (MACS)*. 13<sup>th</sup> International AIDS Conference on AIDS, Durban, South

Africa, July 9-14, 2000 (Abstract ThOrC719).

35. Katz MH. *AIDS epidemic in San Francisco among men who report sex with men: successes and challenges of HIV prevention*. J Acquir Immune Defic Syndr 1997;14 Suppl 2:838-46.
36. Dufour A, Alary M, Otis J et al. and the Omega Study Group. *Correlates of risky behaviours among young and older men having sexual relations with men in Montréal, Québec, Canada*. J Acquir Immune Defic Syndr 2000;23:272-8.
37. Mansergh G, Colfax GN, Marks G et al. *The Circuit Party Men's Health Survey: findings and implications for gay and bisexual men*. Am J Public Health 2001;91:953-8.
38. Dolezal C, Meyer-Bahlburg HF, Remien RH, Petkova E. *Substance use during sex and sensation seeking as predictors of sexual risk behaviour among HIV+ and HIV- gay men*. AIDS and Behavior 1997;1:19-28.

39. McFarlane M, Bull S, Reitmeijer S. *The Internet as a newly emerging risk environment for sexually transmitted disease*. JAMA 2000;284(4):443-6.

## Acknowledgements

National level HIV and AIDS surveillance is possible as a result of all provinces and territories participating in, and setting directions for, HIV and AIDS surveillance. CIDPC acknowledges the provincial/territorial HIV/AIDS coordinators, public health units, laboratories, health care providers, and reporting physicians for sharing non-nominal, confidential data for national surveillance.

### *For more information, please contact:*

**Surveillance and Risk Assessment Division  
Centre for Infectious Disease Prevention and Control  
Health Canada  
Tunney's Pasture  
Postal Locator 0602B  
Ottawa, ON K1A 0K9  
Tel: (613) 954-5169  
Fax: (613) 957-2842  
[www.hc-sc.gc.ca/pphb-dgsp/hast-vsmt/](http://www.hc-sc.gc.ca/pphb-dgsp/hast-vsmt/)**

Our mission is to help the people of Canada  
maintain and improve their health

*Health Canada*



# HIV/AIDS *EPI UPDATE* Centre for Infectious Disease Prevention and Control

## HIV/AIDS Among Injecting Drug Users in Canada

### *At a Glance*

- ◆ **Injecting drug use accounts for 7.2% of cumulative adult AIDS cases and 16.7% of cumulative adult positive HIV test reports up to June 30, 2003.**
- ◆ **The 2002 national HIV estimates of prevalence and incidence indicate that the proportion of new HIV infections among IDU has decreased slightly from 34% of the total in 1999 to 30% or 800-1600 new infections in 2002.**
- ◆ **The estimated number of new HIV infections among IDU in 2002 remains unacceptably high.**
- ◆ **An enhanced surveillance system (I-Track) has been initiated at selected centres across Canada to monitor HIV-associated risk behaviours, and HIV and HCV prevalence among IDU.**

### *CIDPC Website:*

[www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/](http://www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/)

### Introduction

In the early 1980s, the Canadian HIV epidemic was concentrated among men who have sex with men (MSM). By the early to mid-1990s, there was a change toward increasing transmission among injecting drug users (IDU), and by 1999 approximately 34% of the total number of the estimated 4,190 new HIV infections that occurred in Canada that year were among IDU.<sup>1</sup> The Centre for Infectious Disease Prevention and Control (CIDPC) has recently published national HIV prevalence and incidence estimates for 2002.<sup>2</sup> The 2002 estimates indicate that the proportion of new infections among IDU has decreased slightly to 30% in 2002 (800-1,600 of a total 2,800-5,200 new infections). A similar trend has occurred in the number of adult positive HIV tests reported to CIDPC. Surveillance data as of June 30, 2003, indicate that in 2002, 24.0% of adult positive HIV tests reported to CIDPC were attributed to IDU, down from a peak of just over 33% in 1996 and 1997.<sup>3</sup> This *Epi Update* presents information on the status of HIV/AIDS among IDU in Canada.

### AIDS Surveillance Data<sup>3</sup>

#### Injecting Drug Use Remains a Significant Exposure Category among AIDS Cases

- ◆ As of June 30, 2003, there have been 18,934 AIDS cases reported to CIDPC since the early 1980s. Of the 18,041 cumulative adult AIDS cases with known exposure category, 7.2% (1,307) were attributed to injecting drug use and, of these, 73.4% were males. An additional 4.6% (834) were attributed to men who have sex with men and who also inject drugs (MSM/IDU).

- ◆ There was a rise in the proportion of IDU among reported adult AIDS cases from 3.3% between 1979 and 1993 to a peak of 21.5% in 1998. The proportion decreased to 14.8% in 2001 but increased to 19.1% in 2002 (Figure 1).
- ◆ The proportion of adult male AIDS cases attributed to IDU steadily increased from 3.8% in 1992 to a peak of 19.3% in 2000. This proportion was in the range of 15% to 17% in 2001-02.
- ◆ Females represent 26.5% of the total cumulative adult AIDS cases attributed to IDU for which exposure category and gender are reported. The proportion of adult female AIDS cases attributed to injecting drug use increased steadily from 18.0% in 1992 to a peak of 46.2% in 1998. This proportion dropped to 37% in 2000, and trends since then are difficult to interpret because of the small number of reported cases.

### HIV Surveillance Data<sup>3</sup>


#### Proportion of Adult HIV Positive Test Reports among IDU Continues Gradual Decline

While AIDS data provide information on HIV infections that occurred about 10 years in the

past, HIV data provide a picture of more recent infections.


- ◆ Of the 26,673 cumulative positive HIV tests in adults reported to CIDPC with exposure category information since reporting began in 1985 to June 30, 2003, 16.7% were attributable to injecting drug use (69% males). An additional 2.3% were attributed to MSM/IDU.
- ◆ Figure 2 shows the proportion of adult positive HIV tests attributed to injecting drug use by year of test, to the end of 2002. This proportion has gradually decreased from 28.8% in 1999 to 24.0% in 2002.
- ◆ The proportion of positive HIV test reports in adult females that could be attributed to IDU peaked at 48.5% in 1999, declining to about 35% in 2001-02. The proportion in adult males attributable to IDU remained stable at approximately 23% in 1999-2001 and decreased slightly to 20.3% in 2002.
- ◆ Of positive HIV test reports attributed to IDU during 2001-02 that provided age information, the highest proportion was among those aged 40-49 years (27.1%), followed by those aged 30-39 years (25.8%).

**Figure 1. Proportion of adult AIDS cases attributed to IDU, by year of diagnosis 1992-2002**





**Figure 2. Proportion of adult positive HIV test reports attributed to IDU, by year of test 1985-2002**



**Studies Confirm HIV Prevalence Remains Unacceptably High at Sentinel Centres across Canada**

In response to a need for ongoing monitoring of HIV prevalence and incidence rates as well as risk behaviours in IDU populations from across the country, an HIV and hepatitis C (HCV)-associated risk behaviour enhanced surveillance system (I-Track) is being established by Health Canada at sentinel centres across Canada through collaboration with provincial, regional and local health authorities, community-based organizations and researchers. A pilot study of the I-Track surveillance system was undertaken between October 2002 and March 2003 in which a total of 794 IDU were surveyed in Victoria, Regina, Sudbury and Toronto; linkages are also being made with the SurvUDI study in Quebec. Selected findings of the I-Track pilot phase<sup>4</sup> are reported below, as well as those reported by other studies among IDU in Canada.

- ◆ Results from the I-Track pilot phase show that the HIV prevalence among the IDU study participants in Victoria was 16.0%,<sup>4</sup> lower than the 21% prevalence rate observed in a 1999 Victoria study.<sup>5</sup>
- ◆ In Regina, the HIV prevalence among I-Track participants was 1.2%, slightly lower than the 2.0% reported by the

Regina Seroprevalence Study<sup>6</sup> involving a similar sample size of IDU in 2000.

- ◆ In Sudbury, an HIV prevalence of 10.1% was observed, and in Toronto the HIV prevalence of 5.1% was lower than the rate of 8.2% previously reported in a 1998 study in that city.<sup>7</sup>
- ◆ HCV prevalence rates were high at all I-Track sentinel centres and ranged from 54.3% in Toronto to 79.3% in Victoria.<sup>4</sup>
- ◆ The co-infection rate, in which participants are infected with both HIV and HCV, was found to be 7.8% overall in the I-Track pilot phase.<sup>4</sup>
- ◆ The SurvUDI study has been ongoing since 1995 and consists of centres providing needle exchange services and other prevention programs to IDU in the province of Quebec and in Ottawa, Ontario. HIV prevalence for the overall network has increased significantly from 12.2% in 1995 to 18.6% in 2002 (R Parent, Institut national de santé publique du Québec, Québec: personal communication, February 2004). Results show that HIV prevalence among study participants for the whole network from 1995 to June 30, 2003, was 14.7% and was higher in urban centres (15.7%) than semi-urban centres (6.0%). In 2002, HIV

prevalence in Montreal, Ottawa and Quebec were found to be 23.3%, 19.7% and 15.9% respectively.<sup>8</sup>

- ◆ Results from the Winnipeg Injection Drug Epidemiology (WIDE) study suggest that the prevalence of HIV infection among IDU in that city increased from 2.3% in 1986-90 to 12.6% in 1998.<sup>9</sup>
- ◆ Research conducted by Calgary's Needle Exchange Program showed that the prevalence of HIV among IDU attending that city's NEP increased from 2.2% in 1992 to 3.3% in 1998.<sup>10</sup>
- ◆ Results indicate that HIV incidence among repeat service attendees in the SurvUDI network decreased significantly from 5.3 per 100 person years (PY) in 1995 to 2.6 per 100 PY in 2002. Overall incidence from 1995 to June 30, 2003, was 2.9 per 100 PY in Quebec City, 4.4 per 100 PY in Montreal, 4.8 per 100 PY in Ottawa/Hull, 1.9 per 100 PY in semi-urban sites and 3.7 for the overall SurvUDI network.<sup>8</sup>
- ◆ The POLARIS study investigated HIV incidence according to risk category among repeat testers in Ontario's diagnostic HIV-testing database during the period 1992-2000. HIV incidence among IDU decreased from 0.64 per 100 PY in 1992 to 0.14 per 100 PY in 2000.<sup>11</sup>
- ◆ A study examining trends in HIV incidence in Ontario based on identifying recent infections among new HIV diagnoses (using the serological testing algorithm for recent HIV seroconvertors or STARHS assay) found that HIV incidence among IDU was 0.25 per 100 PY in Toronto, 0.70 per 100 PY in Ottawa and 0.15 per 100 PY elsewhere in Ontario.<sup>12</sup>
- ◆ Results from the Vancouver Injection Drug User Study (VIDUS) showed that HIV incidence was 1.5 per 100 PY in 2000, down from 10.3 in 1997 and 3.2 in 1999.<sup>13</sup>

## **Women, Youth and Aboriginal IDU Are Particularly at Risk of HIV Infection**

### **Women**

- ◆ Since 1996, approximately one-third to one-half of new HIV test reports among women have been attributed to injecting drug use. The latest national HIV estimates published by CIDPC for 2002 indicate that a slightly lower proportion of new HIV infections among women in 2002 were attributed to IDU than in 1999 (47% versus 54% respectively).<sup>2</sup>
- ◆ Findings from the VIDUS study in Vancouver show that during the period May 1996 and December 2000, HIV incidence rates among female IDU in Vancouver were about 40% higher than those of male IDU.<sup>14</sup>

### **Youth**

- ◆ Results from the I-Track pilot phase indicate that 30% of participants reported initiation of injecting at the age of 16 years or younger.<sup>4</sup>
- ◆ High HIV incidence rates were found among young IDU when the VIDUS study in Vancouver examined rates of HIV positivity among IDU participants who were 24 years of age and younger. HIV incidence rates in this age group were 2.96 among males and 5.69 among females per 100 PY,<sup>15</sup> compared with an overall incidence rate of 1.5 per 100 PY in 2000.<sup>13</sup> This study also found that among young IDU (age 13-24 years), HIV prevalence was associated with female gender, history of sexual abuse, engaging in survival sex, injecting heroin daily, injecting speedballs daily, and having numerous lifetime sexual partners.<sup>16</sup>
- ◆ The HIV incidence among street youth in the Montreal Street Youth Cohort Study was 0.69 per 100 PY as of September 2000. Injecting drug use was the strongest predictor of HIV seroconversion (becoming HIV positive).<sup>17</sup>

- ◆ The Enhanced Surveillance of Canadian Street Youth (ESCSY) is a national, multi-centre, cross-sectional surveillance system of Canadian street youth, aged 15-24, which examines sexually transmitted infections, blood-borne pathogens and risk behaviours among street youth. Results of phases II and III of ESCSY show that approximately one-fifth of street youth surveyed had injected drugs in their lifetime.<sup>18</sup>


### **Aboriginal**

- ◆ Aboriginal persons are overrepresented in IDU populations, and a larger proportion of Aboriginal HIV and AIDS cases are attributed to IDU than non-Aboriginal cases.<sup>19</sup> The 2002 national HIV estimates indicate that 63% of all new HIV infections among Aboriginal people in 2002 were attributable to injecting drug use, a proportion higher than the 30% attributed to IDU among new infections overall.<sup>2</sup>
- ◆ Results of the I-Track pilot phase showed that, overall, 38.6% of the study participants self-identified as being of Aboriginal ethnic background. Most of these were from Regina, where 90.2% of the study population was Aboriginal. The proportion of Aboriginal IDU among the remaining study population ranged from 11.3% in Toronto to 20.7% in Victoria.<sup>4</sup>
- ◆ An analysis comparing the seroconversion rates of Aboriginal IDU with those of non-Aboriginal IDU recruited between 1996 and 2000 for the VIDUS study in Vancouver found that Aboriginal IDU are seroconverting at twice the rate of non-Aboriginal IDU.<sup>20</sup>

### **International trends**

A report published by UNAIDS and the World Health Organization (WHO) in December 2003 indicates that an estimated 40 million people in the world are living with HIV/AIDS, of whom 2.5 million are children under 15 years of age. IDU is cited as one of the main modes of transmission for those living with HIV/AIDS in seven of the 10 regions of the world and include North America, North Africa and the Middle East, Western Europe, and East Asia and Pacific. In Eastern Europe and Central Asia, where the epidemic began relatively later than in other regions (early 1990s), injecting drug use is listed as the single main mode of transmission.<sup>21</sup> Figure 3 shows the proportion of AIDS cases attributed to IDU in selected countries since 1995. While caution should be taken when comparing and interpreting data from surveillance systems that may differ, it is interesting to note that although Canada is in the lower half of the graph, countries like Australia, Netherlands and the UK have even lower proportions of reported AIDS cases attributed to IDU. While such ecological comparisons have their limitations, this difference may be related to the availability and acceptability of programs and services that advocate harm reduction for IDU populations in these countries. More research is needed to study the effectiveness of these programs and whether similar approaches could be applicable in the Canadian setting.

**Figure 3. Proportion of reported AIDS cases attributed to IDU in selected countries by year of diagnosis**



**Sources (accessed January 2004)**

- Health Canada. Centre for Infectious Disease Prevention and Control  
<http://www.hc-sc.gc.ca/pphb-dgspsp/publicat/aids-sida/haic-vsac0603/index.html>
- Centers for Disease Control and Prevention (United States)  
<http://www.cdc.gov/hiv/stats/hasrlink/htm>
- National Center in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, NSW  
[www.med.unsw.edu.au/nchecr](http://www.med.unsw.edu.au/nchecr)
- European Center for the Epidemiological Monitoring of AIDS  
[www.eurohiv.org/AidsSurv/pdf/rap61.pdf](http://www.eurohiv.org/AidsSurv/pdf/rap61.pdf)
- UNAIDS/WHO. Epidemiological Fact Sheets on HIV/AIDS and Sexually Transmitted Infections  
[www.unaids.org/hivaidsinfo/statistics/fact\\_sheets/index\\_en.htm](http://www.unaids.org/hivaidsinfo/statistics/fact_sheets/index_en.htm)

**Comment**

11

A number of biases must be taken into account when interpreting the results given here.. HIV diagnostic data are limited to persons who present themselves for testing, and so trends in these numbers may be influenced by testing patterns and/or improved ability to remove duplicate tests. In addition, identifying information that accompanies HIV testing data is sometimes incomplete or inaccurate, and this may limit the usefulness of HIV data. Results of cohort studies are limited by selection biases, loss to follow-up, and problems with generalizability. Studies that have a cross-sectional design have their own respective limitations.

Despite these issues, available data show that the HIV epidemic among IDU in Canada continues to be a serious problem. Although the problem is best documented in larger cities, increasingly it is now being seen out-

side major urban areas. The establishment of the I-Track enhanced surveillance system represents a milestone in the objective of describing changing patterns in drug injecting and sexual behaviours, HIV testing behaviours, and HIV and HCV prevalence among IDU in Canada. Results from the I-Track pilot phase suggest that the pattern of drug use and HIV prevalence differs markedly across Canada and within provinces. These findings highlight the importance of expanding the geographic coverage of the surveillance system and the need to include semi-urban centres in the future. Policy and programs to address drug use and HIV will need to be tailored according to local issues and IDU migration patterns.

The high levels of risky injecting and sexual behaviours reported by IDU in sentinel sites across Canada suggest that the potential for the transmission of HIV in these populations continues to be significant. Given the

geographic mobility of IDU and their social and sexual interaction with non-users, the dual problem of injecting drug use and HIV infection is one that ultimately affects all of Canadian society.

## References

1. Health Canada. Archibald CP, Remis RS, Farley J, Sutherland D. *Estimating HIV prevalence and incidence at the national level: combining direct and indirect methods with Monte-Carlo simulation*. XII International Conference on AIDS, Geneva, June-July 1998 (Abstract 43475).
2. Geduld J, Gatali M, Remis RS, Archibald CP. *Estimates of HIV prevalence and incidence in Canada, 2002*. *CCDR* 2003;29(23):197-206.
3. Health Canada. *HIV and AIDS in Canada: surveillance report to June 30, 2003*. Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Health Canada, November 2003.
4. Health Canada. *I-Track: enhanced surveillance of risk behaviours among injecting drug users in Canada. Pilot survey report*. Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Health Canada, 2004.
5. Poffenroth L. *RARE Project in Victoria*. Proceedings of the Division of HIV/AIDS Epidemiology and Surveillance Annual Meeting, Halifax, November 16-18, 2000. Centre for Infectious Disease Prevention and Control, Health Canada.
6. Regina Health District, Saskatchewan Health, Division of HIV/AIDS Epidemiology and Surveillance, CIDPC, Health Canada. *The Regina Sero-prevalence Study: a profile of injection drug use in a Prairie city*. 2000.
7. Millson P, Myers T, Calzavara L et al. *Regional variation in HIV prevalence and risk behaviours in Ontario injection drug users (IDU)*. *Can J Public Health* 2003;94(6):431-35.
8. Parent R, Alary M, Morrisette C et al. and the SurvUDI working group. *Rapport SurvUDI 2003*. Dec 2003.
9. Elliot LJ, Blanchard JF, Dinner KI et al. *The Winnipeg Injection Drug Epidemiology (WIDE) Study*. Eighth Annual Canadian Conference on AIDS, Vancouver BC May 1-4 1999. *Can J Infect Dis* 1999;10(suppl B):C314.
10. Guenter DC, Fonseca K, Nielsen DM et al. *HIV prevalence remains low among Calgary's Needle Exchange Program participants*. *Can. J Public Health*. 2000;91(2):129-132.
11. Burchell A, Calzavara LM, Major C et al. and the Polaris Study Team. *HIV incidence among persons undergoing repeat diagnostic HIV testing in Ontario, 1992-2000*. *Can J Infect Dis* 2002;13(Suppl A):48A (Abstract 315).
12. Remis RS, Major C, Swantee C et al. *Trends in HIV incidence in Ontario based on the detuned assay: update to December 2002*. Presentation at Ontario HIV Treatment Network, 5th Annual Research Day, Toronto, Ontario, November 3-4, 2003.
13. Tyndall M, Johnston C, Craib K et al. *HIV incidence and mortality among injection drug users in Vancouver - 1996-2000*. *Can J Infect* 2001;11(Suppl B):69B 354P.
14. Spittal PM, Craib KJP, Wood E et al. *Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver*. *Can Med Assoc J* 2002;166(7):894-99.

15. Miller C, Tyndall M, Li K et al.. *High rates of HIV positivity among young injection users*. *Can J Infect Dis* 2001;12(Suppl B): 340P.
16. Miller CL, Spittal PM, LaLiberte N et al. *Females experiencing sexual and drug vulnerabilities are at elevated risk for HIV infection among youth who use injecting drugs*. *J Acquir Immune Defic Syndr* 2002;30(3):335-41.
17. Roy E, Haley N, Leclerc P et al. *HIV incidence among street youth in Montreal, Canada*. *AIDS* 2003; 17(7):1071-5.
18. *Enhanced surveillance of Canadian street youth*. Sexual Health and STI Section, Community Acquired Infections Division, Centre for Infectious Disease Prevention and Control, Health Canada, 2004.
19. Health Canada. *HIV/AIDS among Aboriginal peoples in Canada: a continuing concern.*, HIV/AIDS Epi Updates, May 2004. Surveillance and Risk Assessment Division, CIDPC, Health Canada, 2004.
20. Craib KJP, Spittal PM, Wood E et al. *Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver*. *Can Med Assoc J* 2003; 168(1)19-24.
21. *AIDS epidemic update*, December 2002. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO), 2002.

## Acknowledgements

National level HIV and AIDS surveillance is possible as a result of all provinces and territories participating in, and setting directions for, HIV and AIDS surveillance. CIDPC acknowledges the provincial/territorial HIV/AIDS coordinators, public health units, laboratories, health care providers, and reporting physicians for sharing non-nominal, confidential data for national surveillance.

### *For more information, please contact:*

**Surveillance and Risk Assessment Division  
Centre for Infectious Disease Prevention and Control  
Health Canada  
Tunney's Pasture  
Postal Locator 0602B  
Ottawa, ON K1A 0K9  
Tel: (613) 954-5169  
Fax: (613) 957-2842  
[www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/](http://www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/)**



# HIV/AIDS *EPI UPDATE*

Centre for Infectious Disease Prevention and Control

## Risk Behaviours Among Injecting Drug Users in Canada

### *At a Glance*

- ✦ Available data indicate high levels of risky injecting and sexual behaviours among IDU, suggesting that the potential for the transmission of HIV in these populations continues to be significant.
- ✦ Behavioural trend data are needed to reliably interpret changes in HIV incidence and prevalence among IDU, and to help evaluate prevention programs targeting this population.
- ✦ Marked differences in the injecting drug use and HIV prevalence across different cities in Canada reflect the need to increase the geographic coverage of surveillance of risky behaviours among IDU.

### *CIDPC Website:*

[www.hc-sc.gc.ca/pphb-dgsp/hasst-vsmt/](http://www.hc-sc.gc.ca/pphb-dgsp/hasst-vsmt/)

### Introduction

The recently published national HIV prevalence and incidence estimates indicate that 30% or 800-1,600 of the estimated 2,800-5,200 new HIV infections that occurred in Canada in 2002 were among injecting drug users (IDU).<sup>1</sup> Similarly, 34% of the estimated HIV infections that occurred in 1999 were among IDU.<sup>1</sup> A similar trend has been observed in the number of positive HIV test reports attributed to injecting drug use reported to the Centre for Infectious Disease Prevention and Control (CIDPC). The proportion of adult positive HIV tests attributed to injecting drug use, after peaking at just over 33% in 1996 and 1997, has gradually decreased to 24.0% in 2002.<sup>2</sup>

Although these declining trends are encouraging, HIV among IDU remains a major concern. In the absence of a vaccine for HIV, behaviour change is the main tool for preventing HIV infection among drug injectors. Behaviour change concerns both IDU who are HIV-infected and those who are uninfected, and relates mainly to their injecting-related and sexual behaviour.

In response to a need for ongoing monitoring of HIV-associated risk behaviours in IDU populations, Health Canada, through collaboration with provincial, regional and local health authorities, community-based organizations and researchers, is establishing an HIV and hepatitis C (HCV)-associated risk behaviour enhanced surveillance system (I-Track) at sentinel centres across Canada. A pilot study of the I-Track surveillance system was undertaken between October 2002 and March 2003, when a total of 794 IDU were surveyed in Victoria, Regina, Sudbury and Toronto.<sup>3</sup> In addition, linkages are also being made with the SurvUDI study in Quebec and Ottawa.

This *Epi Update* describes the drug injecting and sexual risk behaviours that have been reported by the I-Track pilot survey as well as by other studies of IDU in Canada.

## Neither a Borrower Nor a Lender Be: The Sharing of Needles and Syringes

The sharing (borrowing and lending) of needles and syringes is well established as a means of transmitting HIV infection and is a common behaviour among IDU:

- ◆ Results of the I-Track pilot survey indicate that, overall, 24.5% of study participants reported injecting with used needles in the six months before the survey. Proportions ranged from 16.5% in Regina to 30.7% in Victoria. IDU borrow mostly from people with whom they inject, most often close friends/family or regular sex partners. Overall, a similar proportion reported passing on or lending needles/syringes (20.5%) to other IDU for injecting purposes in the preceding six month period. The range by site was 15.7% in Regina to 30.0% in Victoria.<sup>3</sup>
- ◆ A cohort study of IDU in Vancouver showed that 27.6% of the participants reported sharing needles in the previous six month period (administered during January 1999 to October 2000). Furthermore, 19.1% of the participants reported that they had shared even though they did not report having difficulty obtaining new, sterile needles.<sup>4</sup>
- ◆ Results from the SurvUDI study show that the prevalence of needle/syringe borrowing in the previous six months among first time needle exchange program (NEP) attendees in Montreal decreased from 45.1% in 1995 to 35.3% in 2002. In Quebec City, needle/syringe borrowing declined from 41.2% to 23.3% over the same period (although a slight increase was observed between 2001 and 2002). A decline in needle/syringe borrowing, from 31.8% in 1996 to 14.1%

in 2002, was observed in Ottawa. While these results suggest that positive trends in the reduction of sharing behaviour among IDU may be occurring in these jurisdictions, the proportion of participants who report sharing needles is still relatively high.<sup>5</sup>

The borrowing and lending of other injecting equipment (e.g. spoons, filters and water), often referred to as "indirect sharing," have also been found to be associated with HIV infection. Research indicates that indirect sharing also occurs frequently among IDU:

- ◆ Of study participants in the I-Track pilot survey, 43.2% (range: 31.7% in Toronto to 53.5% in Regina) reported borrowing previously used other injecting equipment (filters, cookers, water) for injecting purposes in the preceding six months; 32.9% reported lending or passing on other injecting equipment in the six months prior to the survey.<sup>3</sup>
- ◆ In a 1998 study conducted in Calgary's needle exchange program (NEP), 25% of the participants reported that they had shared injecting equipment in the six months preceding the study.<sup>6</sup>
- ◆ In the VIDUS cohort study of IDU in Vancouver during 1996 to 2000, 38% of men and 37% of women reported borrowing injecting equipment, and it was found to be one of the risk factors for seroconversion among men.<sup>7</sup>
- ◆ International studies<sup>8-10</sup> of IDU have identified other aspects of drug injecting, such as "front-loading" or "back-loading", which may also increase the risk of HIV transmission. These practices involve two or more IDU who use only one syringe to prepare a drug solution. The solution is then squirted into one or more additional syringes either via the front of the recipient syringe after removing its needle (front-loading) or via the back after removing the plunger (back-loading). However, the full extent of such risk



behaviours among Canadian IDU is still under investigation.

## **Risky Business: Trading Unprotected Sex for Money and Drugs**

Many IDU in Canada are involved in the commercial sex trade, and studies report inconsistent condom use with clients:

- ◆ Among IDU in the I-Track pilot survey, 39.5% of females reported engaging in commercial sex work in the six months before the survey. Condom use among female IDU during penetrative sex with client partners was generally high but was less so during oral sex: 5.7% reported never using a condom during oral sex and an additional 17.6% reported inconsistent condom use during oral sex.<sup>3</sup>
- ◆ Results from the SurvUDI study indicate that, between 1995 and 2003, 49.3% of females and 9.2% of males among repeat visit participants reported engaging in prostitution.<sup>5</sup>
- ◆ Among IDU recruited between 1988 and 1999 in a cohort study in Montreal, 18.1% of males reported that they had ever been a prostitute.<sup>11</sup>
- ◆ In a 1998 study in Winnipeg, 71.5% of female IDU and 30.2% of male IDU reported that they had ever been paid for sex. Among females, 25.0% used condoms inconsistently with their sex trade clients. Among men with male clients, 52.0% reported inconsistent condom use.<sup>12</sup>
- ◆ In a 1998 study in Saskatoon, half of the female IDU population reported having been paid for sex and 19% having exchanged sex for drugs or a place to sleep in the preceding six months.<sup>13</sup> In the same study, condom use with casual partners was reported by 93%, but one-quarter of those did not always use a condom. Overall, 41% of the study population used condoms with regular partners.

## **Not Safe Enough: Sex with Regular and Casual Partners**

Among IDU with regular and casual opposite sex partners, condom use is low:

- ◆ Analysis of condom use among I-Track pilot survey participants indicates that reported condom use during penetrative and oral sex in the preceding six months was more infrequent with casual sex partners than with client sex partners, and more infrequent still with regular sex partners. This pattern of decreased condom use in more stable relationships was reported by both male and female IDU. Among males, 19.4% and 56.6% reported never using a condom during penetrative and oral sex respectively with their casual sex partners in the preceding six months. Among females, 28.4% and 34.0% reported never using a condom with casual sex partners during penetrative and oral sex respectively in the preceding six months. There were no marked differences in reported condom use between participating sites.<sup>3</sup>
- ◆ In the 1998 study of IDU in Winnipeg, 68.0% of women and 57.0% of men who had had regular partners in the previous year reported that they never used condoms. Of those who reported having had casual partners in this time period, approximately 30.0% of both men and women never used condoms.<sup>12</sup>
- ◆ Among IDU in the Regina seroprevalence study conducted in 2000, condom use with regular and casual partners was low. For example, 94% of male IDU and 92% of female IDU reported inconsistent or no condom use during vaginal sex with regular, opposite sex partners. Of those respondents who had casual partners, 58% of men and 71% of women reported inconsistent or no use of condoms with this type of partner.<sup>14</sup>
- ◆ In the VIDUS cohort study in Vancouver during 1996-2000, 18% of men and 20% of women reported the use of condoms

with regular sex partners in the previous six months; non-use of condoms with a regular sex partner was the most significant risk factor for seroconversion among women.<sup>7</sup>

## Male IDU and Same Sex Partners

The proportion of male IDU reporting sexual intercourse with same sex partners varies in different cities:

- ◆ In the I-Track pilot survey, among male IDU, 4.4% reported having had male sex partners in the preceding six months.<sup>3</sup>
- ◆ Among male IDU in the VIDUS study who reported having had sexual intercourse in the previous six months, 7.0% reported having had only same sex partners and 6.0% reported having had partners of both sexes in this time period.<sup>15</sup>
- ◆ In the SurvUDI study, 14.7% of repeat-visit male subjects reported same sex partners between 1995 and 2003.<sup>5</sup>
- ◆ In the 1998 Calgary NEP study, 7% of men and 12% of women IDU reported having had sex with the same sex partner in the six months preceding the study.<sup>6</sup>
- ◆ In the Omega cohort study of MSM in Montreal, 6% of the MSM reported injecting drugs, among whom 48% had borrowed used needles and 4% had exchanged sex for drugs.<sup>16</sup>

## Protective Behaviour Changes or Higher Risk Practices Following Positive HIV Test?

More research is needed to determine whether IDU continue to engage in high-risk behaviours or modify their behaviours after receiving a positive HIV antibody test:

- ◆ Among IDU in a Quebec cohort study conducted between 1996 and 1999, 73.1% of HIV-positive drug injectors had stopped lending needles compared with 56.0% of their HIV-negative counterparts

in the six months after their HIV serostatus result. However, 8.5% of HIV-positive IDU compared with 16.0% of their non-infected peers began lending needles to HIV-positive partners in this same period. In the same study, 62.2% of HIV-positive drug injectors had stopped borrowing needles compared with 58.6% of their HIV-negative counterparts in the six months following their HIV serostatus result. Of HIV-positive IDU, 16.7% compared with 19.5% of their non-infected peers began borrowing needles from HIV-positive partners in this same period.<sup>17</sup>

- ◆ The VIDUS study in Vancouver reported that 35.0% of subjects who were HIV-positive reported that they had borrowed needles before learning about their serostatus. In the months after their HIV positive test, only 21.0% of these subjects reported that they continued to borrow needles. Similarly, 37.0% of HIV-positive IDU reported needle lending before their positive HIV test, whereas only 21.0% of these subjects continued this practice after receiving their positive test results.<sup>18</sup>
- ◆ In a study of women in Montreal, the rate of condom use following a positive HIV test was low among IDU (19%) as compared with non-IDU of Haitian origin (30%) and non-IDU of Caucasian origin (62%).<sup>19</sup>

## Injecting Drug Use Is a Problem Among Street Youth and Inmates

Appropriate and accessible HIV prevention programs for drug injecting, street-involved youth and inmates are clearly needed:

- ◆ Results for the I-Track pilot survey showed that the mean age of initiation of injecting drug use was 21.4 years in the study population, and 30% reported beginning to inject at the age of 16 years or younger.<sup>3</sup>
- ◆ Results from the Montreal street youth study of those aged 14 to 25 years, from

1995 to 2000, show that 47.2% of the study participants had ever injected drugs. Injecting drug use was found to be the strongest indicator of HIV sero-conversion.<sup>20</sup>

- ◆ The New Montreal Street Youth Cohort study, a prospective cohort study of street youth aged 14 to 23 years conducted between July 2001 and August 2002, found that of the street youth who were IDU, 55.2% reported injecting with a previously used needle and 54.4% reported sharing of a cooker/spoon.<sup>21</sup>
- ◆ Among female inmates in a Quebec prison in 1994, 38.0% reported injecting drugs before they were incarcerated, and about half of these women had shared needles. Of those who reported drug injecting before going to prison, 11.0% admitted to injecting drugs during their incarceration, and most (80.0%) shared needles.<sup>22</sup>
- ◆ Among male inmates in this same study, 26.0% reported that they had injected drugs before being incarcerated, and about half of these had shared needles. Of those who admitted to injecting drugs outside prison, 2.0% reported injecting drug use during their incarceration, and most (92.0%) shared needles.<sup>22</sup>
- ◆ In the 2002 Student Drug Use Survey in New Brunswick, less than 1% of the grade 7, 9, 10 and 12 students surveyed had injected drugs in the year preceding the study period.<sup>23</sup>

## Comment

Although several ongoing regional studies in Canada collect risk behaviour data on IDU and a large number of one-time, cross-sectional surveys on risk-taking among IDU have been conducted, it is challenging, if not impossible, to compare levels of risk behaviours between data sets. In addition to disparities across study methodologies, different researchers have collected risk behaviour data using different questions or

differently worded questions, different variable or concept definitions, different time frames for reported behaviours and different response categories. It is therefore difficult to use available IDU risk behaviour information to identify trends or to help evaluate the effectiveness of prevention programs and policies at more than the regional or local level.

In addition, although the national HIV estimates for 2002 show a slight decline in the number of new infections attributed to injecting drug use in that year, the relative lack of behavioural trend data hinder the reliable interpretation of this finding. The establishment of the I-Track Survey will permit the tracking of injecting and sexual risk behaviours over time, will provide important trend data that could be used to inform prevention program design and would help evaluate program effectiveness. Such behavioural data could also be used to interpret changes in HIV prevalence and incidence among IDU and would serve as an early warning system for HIV spread in this population. The high levels of risky injecting and sexual behaviours reported by IDU in sentinel sites across Canada suggest that the potential for the transmission of HIV in these populations continues to be significant. Behavioural surveillance of key subgroups of IDU, namely street-involved youth and inmates, is also needed to formulate an appropriate response to the evolving HIV epidemic among IDU in Canada.

## References

1. Geduld J, Gatali M, Remis RS, Archibald CP. *Estimates of HIV prevalence and incidence in Canada, 2002*. *CCDR* 2003;29(23):197-206.
2. Health Canada. *HIV and AIDS in Canada: surveillance report to June 30, 2003*. Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Health Canada, 2003.

3. Health Canada. *I-Track: enhanced surveillance of risk behaviours among injecting drug users in Canada. Pilot survey report*. Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Health Canada, 2004.
4. Wood E, Tyndall, MW, Spittal PM et al. *Unsafe injection practices in a cohort of injection drug users in Vancouver: Could safer injection rooms help?* Can Med Assoc J 2001;164(4):405.
5. Parent R, Alary M, Morrissette C et al. and the SurvUDI working group. *Rapport SurvUDI 2003*.
6. Guenter CD, Fonseca K, Nielsen DM et al. *HIV prevalence remains low among Calgary's needle exchange program participants*. Can J Public Health 2000;91(2):129-32.
7. Spittal PM, Craib KJP, Wood E et al. *Risk factors for elevated HIV rates among female injection drug users in Vancouver*. Can Med Assoc J 2002; 166(7):894-9.
8. Koester S. *Following the blood: syringe re-use leads to blood-borne virus transmission among injection drug users*. J AIDS Hum Retrovirol 1998; 18:S139.
9. Greenfield L, Bigelow G, Brooner R. *HIV risk behaviour in drug users: increased blood "booting" during cocaine injection*. AIDS Educ Prev 1992; 4:95-107.
10. Needle R, Coyle S, Cesari H et al. *HIV risk behaviour associated with the injection process: multi-person use of drug injection equipment and paraphernalia in injection drug user networks*. Subst Use Misuse 1998; 33:2303-2423.
11. Bruneau J, Lamothe F, Soto J et al. *Sex-specific determinants of HIV infection among injection drug users in Montreal*. Can Med Assoc J 2001; 164:767-73.
12. Elliott L, Blanchard J, Dawood M et al. *The Winnipeg injection drug epidemiology (W.I.D.E.) study: a study of the epidemiology of injection drug use and HIV infection in Winnipeg, Manitoba*. Final Report submitted to the Division of HIV Epidemiology, Health Canada, 1999.
13. Laurie M L, Green K L. *Health risks and opportunities for harm reduction among injection drug-using clients of Saskatoon's needle exchange program*. Can J Public Health 2000;91(5):350-2.
14. Siushansian J, Hay K, Findlater R et al. *The Regina Seroprevalence Study: a profile of injection drug use in a Prairie city*. Report prepared for the Regina Health District, Division of HIV/AIDS Epidemiology and Surveillance, CIDPC, 2000.
15. Tyndall M. *Vancouver response: March 2001*. Presentation made at the Centre for Infectious Disease Prevention and Control, Consultation Meeting on MSM/IDU Data Issues, March 2001.
16. Dufour A, Alary M, Otis J et al. *Risk behaviours and HIV infection among men having sexual relations with men: baseline characteristics of participants in the Omega cohort study*. Can J Public Health 2000;91(5):345-9.
17. Brogly SB, Bruneau J, Lamothe F et al. *HIV positive notification and behaviour changes in Montreal injection drug users*. AIDS Educ Prev 2002; 14(1):17-28.
18. Coulter S, Tyndall M, Currie S et al. *Impact of a positive HIV test on subsequent behaviours among injection drug users*. Presented at the 9<sup>th</sup> Annual Canadian Conference on HIV/AIDS Research, Montreal, Quebec, April 2000.

19. Hankins C, Gendron S, Tran T et al. *Sexuality in Montreal women living with HIV*. AIDS CARE 1997;9(3):261-71.
20. Roy É, Haley N, Leclerc P et al. *HIV incidence among street youth in Canada*. AIDS 2003;17(7):1071-5.
21. Roy É, Haley N, Leclerc P et al. *HIV and HCV risk behaviours in the new Montreal street youth cohort*. Can J Inf Dis 2003;14(Suppl A):Abstract 216.
22. Dufour A, Alary M, Poulin C et al. *Prevalence and risk behaviours for HIV infection among inmates of a provincial prison in Quebec City*. AIDS 1996;10:1009-15.
23. Department of Health and Wellness, New Brunswick. *New Brunswick Student Drug Use Survey 2002 - highlights report*.

## Acknowledgements

National level HIV and AIDS surveillance is possible as a result of all provinces and territories participating in, and setting directions for, HIV and AIDS surveillance. CIDPC acknowledges the provincial/territorial HIV/AIDS coordinators, public health units, laboratories, health care providers, and reporting physicians for sharing non-nominal, confidential data for national surveillance.

### *For more information, please contact:*

**Surveillance and Risk Assessment Division  
Centre for Infectious Disease Prevention and Control  
Health Canada  
Tunney's Pasture  
Postal Locator 0602B  
Ottawa, ON K1A 0K9  
Tel: (613) 954-5169  
Fax: (613) 957-2842  
[www.hc-sc.gc.ca/pphb-dgsp/hast-vsmt/](http://www.hc-sc.gc.ca/pphb-dgsp/hast-vsmt/)**

Our mission is to help the people of Canada  
maintain and improve their health

*Health Canada*



# HIV/AIDS *EPI UPDATE*

Centre for Infectious Disease Prevention and Control

## Oral Sex and the Risk of HIV Transmission

### *At a Glance*

- ✦ **Unprotected oral sex has been associated with HIV infection in some studies.**
- ✦ **Poor oral health and the presence of other STIs may increase the risk of HIV transmission through oral sex.**
- ✦ **The actual risk of HIV transmission through oral sex is difficult to assess since research subjects may underreport sexual activities that are of higher risk.**
- ✦ **Oral sex, particularly unprotected receptive fellatio with ejaculation, should be considered as a potential risk behaviour for HIV transmission.**

### Introduction

The risk of HIV transmission through unprotected anal and vaginal intercourse is well known. Estimates of the probability of per-sex-act (receptive penile-anal intercourse with ejaculation) HIV transmission among homosexual men in the USA range from 0.005 to 0.03 during the asymptomatic phase of infection<sup>1</sup> to as high as 0.1-0.3 during primary HIV infection.<sup>2</sup> Analyses of data from North American and European studies of long-term heterosexual couples estimate the per-sex-act probability of HIV transmission through penile-vaginal intercourse to be approximately 0.001.<sup>3</sup> However, the independent risk of HIV transmission through orogenital contact has been more difficult to study and is not as well understood.

One study calculated the per-sex-act probability of HIV transmission in a cohort of men who have sex with men (MSM) and determined that for unprotected receptive anal intercourse, the probability was 0.82% per act, for unprotected insertive anal intercourse 0.06%, and for unprotected receptive oral intercourse with ejaculation 0.04%.<sup>4</sup> This remains the only study available that provides a probability for oral transmission, and further study is required to corroborate these estimates.

Another study attempted to calculate the population-attributable risk percentage (PAR%) for HIV prevalence associated with fellatio. PAR% refers to the incidence of a disease (in this case, HIV) in a population that can be attributed to a certain risk behaviour (in this case, fellatio). The study focused on MSM and found that the PAR% was 0.18% for MSM who had had one partner in the previous six months, 0.25% for two partners, and 0.31% for three partners.<sup>5</sup>

### *CIDPC Website:*

[www.hc-sc.gc.ca/pphb-dgsp/hasst-vsmt/](http://www.hc-sc.gc.ca/pphb-dgsp/hasst-vsmt/)

This report updates current information on oral sex and the risk of HIV transmission. Current recommendations on the use of condoms for oral intercourse are also reviewed.

### **Laboratory and Animal Studies: Evidence Links HIV Infection to Oral Intercourse in Humans**

- ◆ An animal study found that the minimal dose of simian immunodeficiency virus (SIV) (a virus closely related to HIV-1) required to achieve infection in adult rhesus monkeys through oral exposure was 6,000 times lower than was the minimal dose needed to achieve infection after rectal exposure. The researchers concluded that, as with oral exposure of rhesus monkeys to SIV, oral exposure of humans to HIV-1 likely carries the risk of infection.<sup>6</sup>
- ◆ In a laboratory study designed to explore the oral transmission of HIV by seminal fluid and colostrum, normal donor samples of human milk, colostrum, seminal fluid and blood were separately combined with samples of saliva and HIV-infected white blood cells. All samples, in normal physiologic volumes, prevented saliva from inactivating the HIV-infected blood cells, leading the researchers to conclude that successful oral transmission of HIV by seminal fluid, milk and colostrum may occur.<sup>7</sup>
- ◆ Another study took oral tissue samples from non-infected subjects and exposed them to three types of HIV. The researchers found that normal human oral keratinocytes (NHOKs), which are produced in the mouth, can become infected with HIV and transmit the virus to adjacent leukocytes. Though certain orally produced glycolipids can inhibit HIV replication and the infectivity noted was lower than in blood plasma, the results still demonstrate the risk of potential HIV oral transmission.<sup>8</sup>

### **Oral Sex between Homosexual Males: Not as Safe as once Perceived**

Several epidemiological studies have examined the risk of HIV infection through unprotected receptive oral intercourse (receptive fellatio):

- ◆ In a 1996-1999 study of MSM with a recent diagnosis of HIV infection, it was found that 7.8% of subjects (eight of 102) were probably infected through receptive oral sex.<sup>9</sup>
- ◆ In a 1986-1988 prospective study of HIV infection and AIDS among MSM in the Netherlands, four of 102 cases of seroconversion (3.9%) likely occurred as a result of receptive oral intercourse.<sup>10</sup>
- ◆ In a 1990-1992 study of gay men with newly diagnosed HIV infection, six of 37 patients (16.2%) who had been infected within a year before testing claimed receptive oral sex as the only possible route of their infection.<sup>11</sup>

Several studies have also explored the possibility of HIV transmission through unprotected insertive orogenital intercourse (insertive fellatio) or insertive oral-anal sex (insertive anilingus):

- ◆ In a prospective study of HIV infection among MSM in the Netherlands, five of 102 seroconverters (4.9%) may have been infected through insertive orogenital or oral-anal intercourse.<sup>10</sup>
- ◆ In an early cohort study of MSM, two of five cases of HIV seroconversion were attributed to insertive orogenital sex.<sup>12</sup>

Additional reports or studies, while not distinguishing the type of oral sex between MSM, further suggest the possibility of HIV transmission through oral-penile/oral-anal contact:

- ◆ In the UK, 13 cases of HIV transmission through orogenital contact had been

reported to the public health authorities up to December 1998. In two of these cases, the reporting physician was not convinced that orogenital contact was the only risk.<sup>13</sup>

- ◆ In a US study describing the clinical and epidemiological features of primary HIV infection, four of 46 patients reported having had only unprotected orogenital contact during the suspected sexual encounter that led to their seroconversion.<sup>14</sup>
- ◆ In a study of 741 MSM in the Netherlands, orogenital contact was identified as an independent risk for HIV acquisition, although this result was not statistically significant.<sup>15</sup>
- ◆ In a US study, homosexual males who were participating in a hepatitis B study were found to have a higher risk of HIV infection from both orogenital and oro-anal contact.<sup>16</sup>
- ◆ In the Omega cohort in Quebec, 10 out of 629 MSM participants (1.6%) seroconverted and listed only unprotected receptive oral intercourse as the possible route of their infection.<sup>17</sup>
- ◆ In Australia, researchers looking at MSM and risk behaviours found that five out of 75 recently seroconverted subjects (6.7%) in the study were likely infected by oral intercourse. The authors note that it is difficult to be certain of the actual mode of transmission. The subjects had varying risk profiles: for example, one had a penile piercing that could have caused transmission, another had gingivitis and dental treatment, and another had had protected anal intercourse.<sup>18</sup>

### **Prevalence of Unprotected Oral Sex among Homosexual Males**

- ◆ The Omega cohort study in Quebec examined the prevalence of unprotected oral sex among 400 MSM by the HIV serostatus of their partners. Researchers found rates for unprotected oral sex of

94% with a seronegative regular partner, 91% with a regular partner of unknown serostatus, and 88% with a seropositive regular partner. For casual partners the rates were 92% with unknown or seronegative partners and 73% with seropositive partners.<sup>19</sup>

- ◆ In the Polaris study in Ontario, researchers examining the difference between recent seroconverters and HIV-negative MSM reported that 97% of the sample of seroconverters ( $n = 62$ ) practised unprotected oral sex, as did 73% of HIV-negative MSM ( $n = 121$ ). Further, 55% of recent seroconverters and 27% of HIV-negative MSM reported exposure to ejaculate while engaging in unprotected oral sex.<sup>20</sup>

### **Oral Risk Behaviours among Heterosexuals**

- ◆ In a study of female street youth involved in prostitution in Montreal, researchers found that condom use was extremely low during oral sex. Only 5% of girls involved in prostitution and 4% of girls not involved in prostitution used condoms while performing fellatio.<sup>21</sup>

### **Female-to-Female Transmission of HIV through Oral Intercourse: Truth or Bias?**

To date, there have been several reports of HIV transmission through orogenital contact between lesbians (cunnilingus).<sup>22</sup> A number of researchers have suggested, however, that bisexual activity may be underreported by gay women, and therefore that not all the cases of female-to-female transmission of HIV infection are authentic.<sup>23</sup>

### **Possible Transmission of HIV Between Heterosexual Partners as a Result of Oral Intercourse**

- ◆ There are several reported cases in the literature of women who acquired HIV infection after performing oral sex on their



seropositive male partner (receptive fellatio).<sup>24</sup>

- ◆ Cases of infection in men following oral sex with their female partners have been reported, including one in which a man was apparently infected through fellatio involving a prostitute.<sup>25,26</sup>
- ◆ On the other hand, a study in Madrid of 135 serodiscordant couples reported over 19,000 instances of unprotected oral sex between spouses without one seroconversion, showing that this behaviour requires further investigation.<sup>27</sup>

### **Potential Co-Factors for HIV Transmission During Oral Sex**

Saliva that does not contain blood presents no potential for transmission, as research has shown that an enzyme in saliva inhibits HIV. In general, the mouth and throat are well defended against HIV: the oral mucosal lining contains few of the cells that are the most susceptible to HIV.<sup>28</sup> Other research notes that saliva contains several HIV inhibitors, such as peroxidases and thrombospondin-1, and that the hypotonicity of saliva disrupts the transmission of infected leukocytes (white blood cells).<sup>29</sup>

Case reports identify factors potentially associated with increased risk of HIV transmission through oral sex: oral trauma, sores, inflammation, concomitant sexually transmitted infections, ejaculation in the mouth, and systemic immune suppression.<sup>13</sup> For receptive fellatio, poor oral health and taking ejaculate in the mouth is a hazardous combination that increases the risk of HIV transmission.<sup>30</sup>

- ◆ In a 1996 cross-sectional study of crack cocaine smokers, oral lesions were associated with HIV infection among persons who reported receptive oral sex.<sup>31</sup>
- ◆ A 1993 study of female sex trade workers found that crack users who inconsistently used condoms when performing oral sex on their clients were more likely to be

infected with HIV than were those who consistently used condoms when performing fellatio.<sup>32</sup>

- ◆ Of the eight MSM in the Options Project in San Francisco in 2000 who may have acquired their HIV infection through receptive oral intercourse, three reported oral problems, including occasional bleeding gums.<sup>9</sup>

### **Oral Sex and “Safer Sex Counselling”: Existing Views and Recommendations**

- ◆ The Canadian AIDS Society (CAS) currently classifies insertive fellatio between men, or between women and men, as carrying a negligible risk of HIV transmission regardless of condom use. Receptive fellatio between men, or between men and women, is classified as carrying negligible risk if a condom is used and as low risk if a condom is not used (whether or not semen is taken in the mouth). The CAS currently cautions that the risk of transmission from receptive fellatio is increased if lesions or sores are present in the mouth.<sup>33</sup>
- ◆ With respect to insertive cunnilingus between men and women or between two women, the CAS regards this practice as carrying a negligible risk of HIV transmission if a barrier is used and as low risk if no barrier is used (regardless of menstrual status). Receptive cunnilingus between men and women or between two women is regarded as carrying a negligible HIV risk,<sup>33</sup>
- ◆ Both insertive and receptive anilingus, with or without a barrier, between partners of the same sex or opposite sex are viewed by the CAS as carrying a negligible risk of HIV transmission.<sup>33</sup>
- ◆ The CAS emphasizes that the risk of transmission of HIV (or other STIs) from any of these types of oral intercourse can be effectively reduced by the proper use of a latex barrier (condom or dental dam),

and thus advocates the avoidance of unprotected orogenital or oro-anal contact.<sup>33</sup>

## Conclusions

The risk of HIV transmission through oral sex is difficult to assess because HIV seroconverters may underreport other higher risk sexual practices. A literature review identified exposure to HIV through unprotected oral intercourse as an independent risk factor for HIV acquisition in only three (12.5%) of 24 epidemiological studies designed to examine risk of HIV from different sexual exposures.<sup>34</sup> It indicates that the importance of oral sex to HIV transmission is a complex result of the relative frequency of oral sex (among other activities), the infectivity of oral secretions and its modification by oral pathology, and the resistance to infection of inhibitory substances in saliva.<sup>34</sup> Also, the HIV incidence and prevalence in the community, the role of antiretroviral therapy and the extent to which personal prophylaxis is adopted will influence the contribution of oral sex to HIV transmission.<sup>34</sup>

While oral sex is a lower risk activity than unprotected anal or vaginal intercourse, repeated exposures may increase the risk. Although the risk of acquiring HIV through oral sex is low, the higher rates of practising oral sex indicate that it may contribute to significant numbers of HIV cases among MSM. Safer sex practices should consider oral sex, particularly unprotected receptive fellatio with ejaculation, as a potential risk behaviour for HIV transmission.

## References

1. DeGruttola V, Seage GR III, Mayer KH, Horsburgh CR. *Infectiousness of HIV between male homosexual partners*. J Clin Epidemiol 1989;42(9):849-56.
2. Jacquez JA, Koopman JS, Simon CP, Longini IM Jr. *Role of the primary infection in epidemics of HIV infection in gay cohorts*. J Acquir Immune Defic Syndr 1994;7(11):1169-84.
3. Mastro TD, de Vincenzi I. *Probabilities of sexual HIV-1 transmission*. AIDS 1996;10(Suppl A):S75-S82.
4. Vittinghoff E, Douglas J, Judson F et al. *Per-contact risk of human immunodeficiency virus transmission between male sexual partners*. Am J Epidemiol 1999;150(3):306-11.
5. Page-Shafer K, Shiboski CH, Osmond DH et al. *Risk of HIV infection attributable to oral sex among men who have sex with men and in the population of men who have sex with men*. AIDS 2002;16(17):2350-52.
6. Baba TW, Trichel AM, An L et al. *Infection and AIDS in adult macaques after non-traumatic oral exposure to cell-free SIV*. Science 1996;272(5267):1486-89.
7. Baron S, Poast J, Richardson J et al. *Oral transmission of human immunodeficiency virus by infected seminal fluid and milk: a novel mechanism*. J Infect Dis 2000;181(2):498-504.
8. Liu X, Zha J, Chen H et al. *Human immunodeficiency virus type 1 infection and replication in normal human oral keratinocytes*. J Virol 2003;77(6):3470-76.
9. Dillon B, Hecht FM, Swanson M et al. *Primary HIV infections associated with oral transmission*. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30th-February 2nd, 2000 (abstract 473).
10. Keet IP, Albrecht van Lent N, Sandfort TG et al. *Orogenital sex and the transmission of HIV among homosexual men*. AIDS 1992;6(2):223-26.

11. Grutzmeir S, Bratt G, Ramstedt G et al. *HIV transmission in gay men in Stockholm 1990-1992*. International Conference on AIDS, 1993 (abstract PO-CO2-2584).
12. Rozenbaum W, Gharakhanian S, Cardon B et al. *HIV transmission by oral sex*. *Lancet* 1988;1(8599):1395.
13. Robinson EK, Evans BG. *Oral sex and HIV transmissions*. *AIDS* 1999; 13(6):737-8.
14. Schacker T, Collier AC, Hughes J et al. *Clinical and epidemiologic features of primary HIV infection*. *Ann Intern Med* 1996;125(4):257-64.
15. Van Griensven GJP, Tielman RAP, Goudsmit J et al. *Risk factors and prevalence of HIV antibodies in homosexual men in the Netherlands*. *Am J Epidemiol* 1987;125(6):1048-57.
16. Darrow WW, Echenberg DF, Jaffe HW et al. *Risk factors for human immunodeficiency virus (HIV) infections in homosexual men*. *Am J Public Health* 1987;77(4):479-83.
17. Alary M, Remis RS, Otis J et al., the Omega Study Group. *Risk factors for HIV seroconversion among men having sex with men (MSM) in Montreal*. *Can J Infect Dis* 2002;13(Suppl A):46A.
18. Richters J, Grulich A, Ellard J et al. *HIV transmission among gay men through oral sex and other uncommon routes: case series of HIV seroconverters, Sydney*. *AIDS*. 2003;17(15):2269-71.
19. Remis RS, Dufour A, Alary M et al., the Omega Study Group. *Patterns of oral sex among men who have affective and sexual relations with other men (MASM) in Montreal, Quebec*. *Can J Infect Dis* 1998;9(Suppl A):31A (Abstract 210).
20. Calzavara L, Burchell AN, Remis RS et al. *Delayed application of condoms is a risk factor for human immunodeficiency virus infection among homosexual and bisexual men*. *Am J Epidemiol* 2003;157(3):210-7.
21. Weber AE, Boivin JF, Blais L et al. *HIV risk profile and prostitution among female street youths*. *J Urban Health* 2002;79(4):525-35.
22. Perry S, Jacobsberg L, Fogel K. *Orogenital transmission of human immunodeficiency virus*. *Ann Intern Med* 1989;111(11):951-52.
23. Edwards S, Carne C. *Oral sex and the transmission of viral STIs*. *Sex Transm Infect* 1998;74(1):6-10.
24. Puro V, Narciso P, Girardi E et al. *Male to female transmission of human immunodeficiency virus by orogenital sex*. *Eur J Clin Microbiol Infect Dis* 1991;10(1):47.
25. Spitzer PG, Weiner NJ. *Transmission of HIV infection from a woman to a man by oral sex*. *N Engl J Med* 1989; 320(4):251.
26. Quarto M, Germinario C, Troiano T et al. *HIV transmission by fellatio*. *Eur J Epidemiol* 1990;6(3):339-40.
27. Del Romero J, Marincovich B, Castilla J et al. *Evaluating the risk of HIV transmission through unprotected orogenital sex*. *AIDS* 2002;16(9): 1296-97.
28. Reucroft S, Swain J. *Saliva thwarts HIV*. *New Scientist* 1998;157(2117):23.
29. Baron S. *Oral transmission of HIV, a rarity: emerging hypotheses*. *J Dent Res* 2001;80(7):1602-4.

30. Saylor D. *Oral oversights*. Surviv News (Atlanta, Ga) Nov 10, 2001.
31. Faruque S, Edlin BR, McCoy CB et al. *Crack cocaine smoking and oral sores in three inner-city neighborhoods*. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13(1):87-92.
32. Wallace JI, Weiner AP. *Intravenous drug use, inconsistent use, and fellatio in relationship to crack smoking as risky behaviour for acquiring HIV among streetwalkers, New York City, April 1989-December 1993*. HIV Infected Women's Conference, February 22-24, 1995 (abstract S62).
33. Canadian AIDS Society. *HIV transmission: guidelines for assessing risk: a resource for educators, counsellors, and health care providers*. Ottawa: CAS, 1999.
34. Rothenberg RB, Scarlett M, Del Rio C et al. *Oral transmission of HIV*. AIDS 1998;12(16):2095-2105.

## Acknowledgements

National level HIV and AIDS surveillance is possible as a result of all provinces and territories participating in, and setting directions for, HIV and AIDS surveillance. CIDPC acknowledges the provincial/territorial HIV/AIDS coordinators, public health units, laboratories, health care providers, and reporting physicians for sharing non-nominal, confidential data for national surveillance.

### *For more information, please contact:*

**Surveillance and Risk Assessment Division  
Centre for Infectious Disease Prevention and Control  
Health Canada  
Tunney's Pasture  
Postal Locator 0602B  
Ottawa, ON K1A 0K9  
Tel: (613) 954-5169  
Fax: (613) 957-2842  
[www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/](http://www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/)**

Our mission is to help the people of Canada  
maintain and improve their health

*Health Canada*



# HIV/AIDS *EPI UPDATE*

Centre for Infectious Disease Prevention and Control

## HIV-1 Strain Surveillance in Canada

### *At a Glance*

- ◆ **The Canadian HIV Strain and Drug Resistance Program continues to monitor and assess HIV strains and the transmission of drug resistance in Canada.**
- ◆ **Although HIV-1 strain B continues to predominate, strains A, C, D, E, G and various circulating recombinants have been identified in Canada.**
- ◆ **The overall prevalence of non-B HIV-1 strains in Canada is 7.5%.**
- ◆ **Among HIV-1 strains from treatment-naïve individuals with newly diagnosed HIV infection in Canada, there are significantly higher proportions of non-B HIV-1 infections among females (compared with males), among persons reporting heterosexual contact as their primary exposure factor, and among persons of Black, Asian, or mixed ethnicities.**

### *CIDPC Website:*

[www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/](http://www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/)

### Introduction

Two types of HIV have been characterized in humans, HIV-1 and HIV-2. Both HIV-1 and HIV-2 can lead to AIDS. HIV-2 is less common than HIV-1 and is mainly found in West Africa. HIV-1 can be divided into three major groups: "M" (major), "O" (outlier) and "N" (new).<sup>1</sup> The vast majority of isolates cluster in the "M" group. Distinct lineages within group "M" have also been identified, and these lineages are called strains or subtypes. These include subtype designations A to E (subtype E is also referred to as CRF01\_AE, the circulating recombinant form, CRF A/E), F to H, J and K.<sup>2</sup> HIV-1 subtypes A and C are the most common, accounting for about one-half of HIV-1 infections worldwide. In Canada, the USA and Western Europe, HIV-1 subtype B predominates. However, because of travel and migration, non-B subtypes are increasingly being reported in these parts of the world.

This *Epi Update* describes why surveillance of HIV strains is important and provides a summary of the surveillance of HIV strains in Canada and the prevalence of divergent HIV strains in the USA and Western Europe.

### Why Conduct HIV Strain Surveillance?

The Canadian HIV Strain and Drug Resistance Surveillance Program (CHSDRSP) was initiated as an integrated group of projects aimed at enhancing the national surveillance of HIV. Through a collaborative approach between the provinces and Health Canada, laboratory samples (serum from individuals with newly diagnosed HIV) and corresponding epidemiological data are sent from the provincial health laboratories to Health Canada for HIV strain and drug resistance testing. The results are then shared with provincial and

other stakeholders. One of the central goals of this program is to conduct the systematic surveillance of HIV subtypes in Canada in order to attain the following four main objectives:

### 1. Improve HIV Diagnostics and Screening Strategies

The broad genetic diversity of HIV has implications for the ability of diagnostic tests to reliably detect circulating HIV strains.<sup>3,4</sup> The sentinel arm of the CHSDRSP, through the reference services of the National HIV Laboratories, addresses this goal by testing samples with unusual test results. Based on the knowledge of circulating HIV strains, modifications can be made to current tests to ensure that all HIV-positive persons are detected upon testing. This is also relevant for ensuring the safety of the blood supply, since the tests used for screening donated blood should be able to detect circulating HIV variants.

### 2. Inform Vaccine Development

It is important to know the distribution of the viral subtypes and intrasubtype variation to target vaccine development and testing, since the efficacy and effectiveness of vaccines may be subtype-specific.<sup>3,4</sup>

### 3. Assess HIV Transmission Patterns

Although genetic analyses have been used to assess the spread of HIV globally,<sup>4,5</sup> there is little consensus on whether differences in HIV subtype affect sexual and maternal transmission rates.<sup>6-9</sup> Some studies note differences in the biological properties of HIV-1 subtypes,<sup>10-12</sup> but this needs to be confirmed. Knowing the distribution of HIV variants in Canada, along with corresponding epidemiological factors, will help to assess the implications of any differences in transmissibility. The public health implications of such findings, including prevention and treatment strategies, are of special interest.

### 4. Assess HIV Pathogenesis and Progression of HIV-related Diseases

Although the rate of HIV-related disease progression is affected by many factors, including host factors, evidence suggests that the immunologic responses may be less suppressed by HIV-2 than by HIV-1;<sup>13,14</sup> this needs to be clarified. Whereas some studies suggest genetic subtypes play a role in disease progression, other studies suggest the reverse. Many of these studies are reviewed by Hu et al<sup>3</sup> and by Tatt et al.<sup>4</sup> This area needs further investigation.

## Distribution of HIV-1 Subtypes

### Canada

- ◆ Results from the CHSDRSP show that 7.5% of the sampled population ( $n = 1,673$ ) were infected with non-B subtypes (see Table 1 for subtype distribution).

**Table 1. Distribution of HIV-1 subtypes**

HIV-1 subtype	Frequency	Percentage
A	25	1.5
A/B	1	< 0.1
A/C	1	< 0.1
A/D	5	0.3
A/E*	9	0.5
A/G	3	0.2
B	1,547	92.5
B/C	1	< 0.1
B/D	1	< 0.1
C	73	4.4
D	6	0.4
G	1	< 0.1
Total	1,673	100

\*The recombinant A/E has also been referred to as subtype E.

- ◆ Preliminary results from the CHSDRSP suggest that a significant proportion of individuals infected with a non-B HIV-1

subtype are female, of African or Asian origin, and/or identify heterosexual sex as their primary risk factor.<sup>15</sup> These correlations are likely due to travel and migration from endemic areas where divergent HIV-1 subtypes predominate and where heterosexual sex is a major risk factor for HIV-1 infection.

- ◆ In 1995 HIV-1 subtype A was reported in an African-born male who moved to Canada in 1983.<sup>16</sup>
- ◆ The BC Centre for Excellence in HIV/AIDS has conducted genetic analyses of HIV linked to cohort studies and to the BC HIV drug treatment program. These studies suggest that non-B subtypes in BC represent 4.4% of HIV infections among individuals starting therapy.<sup>17</sup> HIV-1 subtypes A, C, D and CRF01\_AE were also identified.
- ◆ HIV-2 was detected in Canada as early as 1988.<sup>18</sup>

Existing studies on high-risk populations suggest that HIV-1 subtype B is the most common subtype found in the country.

- ◆ In 1998, serological samples from 31 HIV-positive persons of both genders, representing approximately 25% of known HIV positive persons in Newfoundland, were all of HIV-1 subtype B.<sup>19</sup>
- ◆ In 1999, all HIV-1 sequences analyzed from infected injection drug users ( $n = 17$ ) and men who have sex with men ( $n = 5$ ) residing in Montreal were of subtype B.<sup>20</sup>
- ◆ As of October 2003, 106 sequenced viruses of 107 participants in the Polaris HIV Seroconversion Study were found to be of subtype B. The one exception was a single subtype A/G recombinant.<sup>21</sup>

## United States

- ◆ As early as 1993, subtype D was reported in the United States.<sup>22</sup>
- ◆ Results from ongoing sentinel surveillance of strain and drug resistance by the Centers for Disease Control and Prevention have shown that 1.6% of persons newly diagnosed with HIV were infected with subtype A ( $n = 321$ ).<sup>23</sup>
- ◆ In another cohort study of 88 treatment-naive individuals presenting to a Boston hospital in 1999, nine (10%) were infected with non-B HIV-1 (subtypes A, C, E and the recombinant A/G). All these individuals were born outside the United States.<sup>24</sup>
- ◆ In a population-based study of people with HIV or AIDS, identified as at increased risk of group O infection on the basis of country of birth ( $n = 155$ ), two cases of group O infection and 27 cases of non-B, group M infection were identified. Both cases of group O infection were identified in individuals born in Africa.<sup>25</sup>
- ◆ A study of HIV-infected blood donors during 1997-2000 found 2.1% of non-B subtypes.<sup>26</sup>
- ◆ An investigation of a recently infected U.S. military cohort found a 5.4% prevalence of non-B subtypes, and these subtypes were associated with heterosexual activity (compared with homosexual/bisexual activity) and with overseas work.<sup>27</sup>

## Western Europe

- ◆ A rising prevalence of HIV-1 non-B subtypes has been reported in some Western European countries, and most of these infections could be attributed to countries where non-B HIV subtypes predominate. For example, a study of primary HIV infections in France in 1999-2000 found that 19% of subtypes were non-B.<sup>28</sup> A review of similar studies has been done by Thomson and Najera.<sup>29</sup>
- ◆ Group O HIV, which is most commonly found in West Africa, has been identified in Western Europe, including countries such as Norway,<sup>30</sup> Spain<sup>31</sup> and France.<sup>32</sup>
- ◆ Recombinant strains of HIV-1 have also been detected, in countries such as the UK,<sup>33</sup> Spain<sup>34</sup> and Greece.<sup>35</sup>

## Comment

The introduction of variant HIV strains into Canada will invariably challenge existing diagnostic tests and interpretation algorithms. Depending on the impact that strains have on vaccine effectiveness and efficacy, it may direct the course of future vaccine research and testing. Furthermore, depending on future findings related to strain-specific transmissibility, pathogenicity and treatment, HIV strain variation may play a role in changing the nature of the HIV epidemic in Canada. It is therefore important to implement the systematic collection and analysis of data related to strain surveillance across Canada.

## References

1. Simon F, Mauclore P, Roques P et al. *Identification of a new human immunodeficiency virus type distinct from group M and group O.* Nature 1996;4:1032-7.
2. Robertson DL, Anderson JP, Bradac JA et al. *HIV-1 nomenclature proposal.* Science 2000;288(5463):55-6.
3. Hu DJ, Buve A, Baggs J et al. *What role does HIV-1 subtype play in transmission and pathogenesis? An epidemiological perspective* AIDS 1999;13:873-81.
4. Tatt ID, Barlow KL, Nicoll A et al. *The public health significance of HIV-1 subtypes.* AIDS 2001;15 (Suppl 5): S59-S71.
5. Kuiken C, Thakallapalli R, Esklid A et al. *Genetic analysis reveals epidemiologic patterns in the spread of human immunodeficiency virus.* Am J Epidemiol 2000;152(9):814-22.
6. Kanki PJ, Travers KU, Mboup S et al. *Slower heterosexual spread of HIV-2 than HIV-1.* Lancet 1994;343:943-6.
7. Adjorlolo-Johnson G, De Cock KM, Ekpini et al. *Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast.* JAMA 1994;272(6):462-6.
8. Mastro TD, de Vincenzi I. *Probabilities of sexual HIV-1 transmission.* AIDS 1996;10(suppl A):S75-82.
9. Shaffer N, Roongpisuthipong A, Siriwasin W et al. *Maternal viral load and perinatal human immunodeficiency virus type 1 subtype E transmission, Thailand.* J Infect Dis 1999;179:590-9.
10. Kunanusont C, Foy HM, Kreiss JK et al. *HIV-1 subtypes and male-to-female transmission in Thailand.* Lancet 1995;345(8957):1078-83.
11. Renjifo B, Fawzi W, Mwakagile D et al. *Differences in perinatal transmission among human immunodeficiency virus type 1 genotypes.* J Hum Virol 2001;4(1):16-25.
12. Hu DJ, Vanichseni S, Mastro TD et al. *Viral load differences in early infection with two HIV-1 subtypes.* AIDS 2001;15(6):683-91.



13. Pepin J, Morgan G, Dunn D et al. *HIV-2 induced immunosuppression among asymptomatic West African prostitutes: evidence that HIV-2 is pathogenic, but less so than HIV-1.* AIDS 1991; 5:1165-72.
14. Whittle H, Morris J, Todd J et al. *HIV-2 infected patients survive longer than HIV-1 infected patients.* AIDS 1994; 6:803-7.
15. Health Canada. *HIV-1 strain and primary drug resistance in Canada. Surveillance report to June 30, 2002.* Division of HIV/AIDS Epidemiology and Surveillance, Centre for Infectious Disease Prevention and Control, Health Canada, 2002. URL: <http://www.hc-sc.gc.ca/pphb-dgsp/p/publicat/>.
16. Montpetit M. *HIV-1 subtype A in Canada.* AIDS Res Hum Retroviruses 1995;11(11):1421-2.
17. Alexander CS, Montessori V, Wynhoven B et al. *Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naïve individuals in British Columbia.* Antivir Ther 2002; 7:31-5.
18. Neumann PW, Lepine D, Woodside M et al. *HIV-2 infection detected in Canada.* Can Dis Wkly Rep 1988;14(28):125-6.
19. Montpetit ML, Ratnam S, Campbell C et al. *Molecular epidemiological analysis of human immunodeficiency virus type 1 in Newfoundland, Canada.* AIDS Res Hum Retroviruses 1998;14(13):1205-9.
20. Bernier L, Lamothe F, Bruneau J et al. *Eighth Annual Canadian Conference on AIDS, Vancouver BC, May 1-4 1999.* Can J Infect Dis 1999;10(suppl B):104A
21. Pilon R, for the POLARIS Seroconversion Study Group. *Field Surveillance Officer Workshop, CIDPC, Health Canada, November 5-7, 2003.*
22. Gao F, Yue L, Hill SC et al. *HIV-1 sequence subtype D in the United States.* AIDS Res Hum Retroviruses 1993;10:625-7.
23. Zaidi I, Weinstock H, Kalish ML et al. *Surveillance for HIV-1 subtypes in the United States, 1998-present.* Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Jan 31-Feb 3, 2000, # 215.
24. Hanna GJ, Balaguera H, Steger K et al. *Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, IL. Feb 5-8, 2001, #460.*
25. Sullivan PS, Do AN, Ellenberger D et al. *Human immunodeficiency virus (HIV) subtype surveillance of African-born persons at risk for group O and group N HIV infections in the United States.* J Infect Dis 2000;181(2):461-9.
26. Delwart EL, Orton S, Parekh B et al. *Two percent of HIV-positive U.S. blood donors are infected with non-subtype B strains.* AIDS Res Hum Retroviruses 2003;19:1065-70.
27. Brodine SK, Starkey MJ, Shaffer RA et al. *Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort.* AIDS 2003;17:2521-27.
28. Chaix ML, Descamps D, Harzic et al. *Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France.* AIDS 2003;17:2635-43.
29. Thomson MM, Najera R. *Travel and the introduction of human immunodeficiency virus type 1 non-B subtype genetic forms into Western countries.* Clin Infect Dis 2001;32(12):1732-7.

30. Jonassen T, Stene-Johansen K, Berg ES et al. *Sequence analysis of HIV-1 group O from Norwegian patients infected in the 1960s*. *Virology* 1997;231:43-7.
31. Soriano V, Gutierrez M, Garcia-Lerma G et al. *First case of HIV-1 group O infection in Spain*. *Vox Sang* 1996;71(1):66.
32. Couturier E, Damond F, Roques P et al. *HIV-1 diversity in France, 1996-1998*. *AIDS* 2000;14(3):289-96.
33. Barlow KL, Tatt ID, Cane PA et al. *Recombinant strains of HIV type 1 in the United Kingdom*. *AIDS Res Hum Retroviruses* 2001;17(5):467-74.
34. Holguin A, Rodes B, Soriano V. *Recombinant human immunodeficiency viruses type 1 circulating in Spain*. *AIDS Res Hum Retroviruses* 2000;16(5):505-11.
35. Paraskevis D, Magiorkinis M, Vandamme AM et al. *Re-analysis of human immunodeficiency virus type 1 isolates from Cyprus and Greece, initially designated 'subtype I' reveals a unique complex A/G/H/K mosaic pattern*. *J Gen Virol* 2001;82(Pt 3):575-80.

## Acknowledgements

National level HIV and AIDS surveillance is possible as a result of all provinces and territories participating in, and setting directions for, HIV and AIDS surveillance. CIDPC acknowledges the provincial/territorial HIV/AIDS coordinators, public health units, laboratories, health care providers, and reporting physicians for sharing non-nominal, confidential data for national surveillance.

### *For more information, please contact:*

**Surveillance and Risk Assessment Division  
Centre for Infectious Disease Prevention and Control  
Health Canada  
Tunney's Pasture  
Postal Locator 0602B  
Ottawa, ON K1A 0K9  
Tel: (613) 954-5169  
Fax: (613) 957-2842  
[www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/](http://www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/)**



# HIV/AIDS *EPI UPDATE* Centre for Infectious Disease Prevention and Control

## Primary HIV Anti-retroviral Drug Resistance in Canada

### *At a Glance*

- ✦ The Canadian HIV Strain and Drug Resistance Program (CHSDRSP) continues to monitor and assess HIV strains and the transmission of HIV drug resistance in Canada.
- ✦ Preliminary observations from the CHSDRSP of HIV drug resistance among treatment-naïve individuals with newly diagnosed HIV infection in Canada (i.e. primary drug resistance) are as follows:
  - The overall prevalence of primary drug resistance to at least one antiretroviral drug is 7%.
  - The overall prevalence of multi-drug resistance to two or more classes of antiretroviral drugs is 0.7%.
  - Primary drug resistance has been observed among both females and males, across different age groups, ethnicities, and exposure categories, in HIV-1 subtype A, B, and C infections, and among recent and older prevalent HIV infections.
- ✦ The prevalence of primary drug resistance is similar to what has been observed in other countries where highly active antiretroviral treatment (HAART) is widely used.

### *CIDPC Website:*

[www.hc-sc.gc.ca/pphb-dgsp/hast-vsmt/](http://www.hc-sc.gc.ca/pphb-dgsp/hast-vsmt/)

### Introduction

Drug resistance among individuals receiving treatment (secondary drug resistance) is well documented. Resistance observed in treatment-naïve individuals with newly diagnosed HIV infection, in whom resistance is presumably due to the transmission of a drug-resistant variant of HIV-1 (primary drug resistance), is less well understood. However, there is increasing evidence to suggest that transmission of drug-resistant strains of HIV is becoming more widespread in most countries where HAART is used. Drug resistance complicates the treatment of HIV, has important implications for HIV-related morbidity and mortality and may result in increased health care costs.

This *Epi Update* provides a summary of how drug resistance arises and how it is identified, and an overview of key studies on the prevalence of primary drug resistance in countries where HAART is commonly used.

### Why Conduct Primary Drug Resistance Surveillance?

Although HAART has led to a reduction in HIV-1 related morbidity and mortality in Canada and some other countries, there is a concern that its widespread use, the increased number of treatment failures and continuing risk behaviour may result in increased transmission of drug-resistant virus. The first case of primary drug resistance was reported in 1993 with the transmission of a zidovudine-resistant HIV-1 strain.<sup>1</sup> Since then, many reports of transmission of drug-resistant HIV strains have been published, and there is increasing evidence to suggest that the proportion of new HIV infections involving drug-resistant strains may be increasing in countries

where HAART is routinely used. (For an overview of these studies see Wainberg and Friedland<sup>2</sup> and Little.<sup>3</sup>)

What is less well understood is the prevalence of primary drug resistance and the variation of this prevalence over time, geographic area and population risk group. The CHSDRSP aims to address these questions, and the resulting information will help inform the development of any guidelines for initial therapeutic regimens and more effective HIV prevention strategies, including the prevention of vertical transmission.

## Evolution of Drug Resistance

Viral resistance develops largely as a result of changes (mutations) in the genetic material that codes for the HIV reverse transcriptase (RT) and protease enzymes. Both these enzymes are required for viral reproduction, and current antiretroviral drugs interact with them to impede their activity. Although new drugs are continually being developed, the most commonly used antiretroviral drugs that are approved for treatment of HIV infection fall into three classes: nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs). For a review of NRTI, NNRTI and PI resistance see Loveday,<sup>4</sup> Deeks<sup>5</sup> and Miller<sup>6</sup> respectively.

Most mutations are lethal or neutral and are not associated with conferring drug resistance. However, under conditions in which treatment does not completely inhibit viral replication, virus with drug-resistant mutations can develop and replicate, resulting in treatment failure. In general, it is theoretically possible for every single drug-resistant mutation to be generated daily.<sup>7</sup> For some drugs (e.g. NNRTIs), a single mutation is associated with a high level of drug resistance. Such a mutation is referred to as a "major" mutation. For other drugs (e.g. most protease inhibitors), a combination of mutations is often required to

confer resistance. Such mutations are known as "minor" mutations.

## Methods to Identify Drug Resistance

*Genotypic tests* identify mutations in the viral genetic material through commercially available probes for particular mutations or through sequencing viral genes of interest. By comparing the generated sequences with databases containing resistance-conferring mutation algorithms, the presence or absence of drug resistance can be identified.

*Phenotypic tests* determine the enzymatic activity of viral genes or assess viral growth in increasing concentrations of drugs. Resistance is usually defined when, compared with the wild type strain, four or more times the amount of drug is required to inhibit viral growth by 50%. This test is similar in concept to antibiotic resistance testing in bacterial culture.

*Note: Genotypic and phenotypic testing and interpretation for patient care are evolving fields that are extremely complex, requiring expert inputs.*

## Summary of Key Studies on the Prevalence of Primary Drug Resistance

It is difficult to make inter-study comparisons and arrive at firm conclusions because of differences in study design, including study populations, types of resistance testing used, and mutations studied and reported. However, the following observations can be made for Canada:

- ◆ Results from the CHSDRSP indicate that between 1998 and 2001, the overall prevalence of major mutations to at least one antiretroviral drug was between 4.5% and 10.5% (Table 1, final column). Pooling results from all years provides an estimate of 7% for overall prevalence of major mutations.

- ◆ A BC study in 1996-98 found an overall prevalence of 3.5%, and a Montreal study carried out between May 1996 and December 2001 found that the prevalence of major mutations to at least one antiretroviral drug was between 11.4% and 23.2% (Table 1, final column).
- ◆ Primary drug resistance to two or more classes of antiretroviral drugs (multi-drug resistance) has been observed in Canada with an overall prevalence of up to 9.9% (Table 1, column 7).

note that this table is NOT meant for inter-study comparisons: such interpretations are difficult to make because of differences in study design, including study populations, types of resistance testing used, and specific mutations analyzed and reported. The results suggest that the prevalence of major mutations associated with at least one antiretroviral drug is similar to that in Canada. Of note, mother-to-child transmission of zidovudine, nevirapine, or multi-drug resistant HIV-1 has been reported in the USA and in France.<sup>13,14</sup>

Table 2 shows the results of studies on primary drug resistance that were conducted in the USA and in Western Europe. Please

**Table 1. Summary of key studies on HIV-1 primary drug resistance in Canada**

Province*	Year of diagnosis	Risk exposures**	Sample size	RTIs† %	PIs‡ %	MDR¶ %	Total %
BC <sup>8</sup>	1996-1998	Mixed	423	1.9	1.9	0.2	3.5
QC <sup>9</sup>	1997-1999	IDU (26%) Sexual (69%)	81	20.0	6.0	9.9	-
QC <sup>10</sup>	May 1996-June 2000	Mixed	112	-	-	4.1	23.2
	July 2000-Dec 2001	Mixed	36	-	-	0	11.4
ON <sup>11</sup>	1997-1999	MSM	23	13.0	-	-	-
BC, AB, SK, MB, NS <sup>12</sup>	1997	Mixed	20	0	0	0	0
	1998	Mixed	51	9.8 (NRTI)	0	0	9.8
	1999	Mixed	270	4.8 (NRTI)	2.2	0.4	7.4
	2000	Mixed	314	2.2 (NRTI) 0.3 (NNRTI)	1.3	0.6	4.5
	2001	Mixed	181	5.0 (NRTI) 1.7 (NNRTI)	2.2	1.7	10.5

\*BC = British Columbia, QC = Quebec, ON = Ontario, AB = Alberta, SK = Saskatchewan, MB = Manitoba, NS = Nova Scotia.

\*\*Reported proportions may not add to 100% since risk exposure categories may not be mutually exclusive. IDU = injection drug use, MSM = men who have sex with men

†RTI = reverse transcriptase inhibitors, NRTI = nucleoside reverse transcriptase inhibitor, NNRTI = non-nucleoside reverse transcriptase inhibitor. Information on NRTI and NNRTI provided where available.

‡PI = protease inhibitors

¶MDR = multi-drug resistance

**Table 2. Summary of key studies on HIV-1 primary drug resistance in the United States and in western Europe**

Country	Year of diagnosis	Risk exposures*	Sample size	RTIs** %	PIs† %	MDR‡ %	Total§ %
United States <sup>15</sup>	1989-1998	MSM (80%)	141	0.7 (NNRTI)	1.4	1.4	2.1
United States <sup>16</sup>	1995-1999	MSM (94%)	80	12.5 (NRTI) 7.5 (NNRTI)	3.0	3.8	16.3
United States <sup>17</sup>	1997-2001	Mixed	1,082	6.4 (NRTI) 1.7 (NNRTI)	1.9	1.3	8.3
United States <sup>18</sup>	1998	Acute infection	182	8.8 (NRTI) 3.4 (NNRTI)	2.8	3.4	11.5
			238	3.4 (NRTI) 0.4 (NNRTI)	0	0	3.8
			240	8.3 (NRTI) 2.1 (NNRTI)	1.7	1.7	10.0
United States	1995-1998	MSM	245	6.9 (NRTI) 1.2 (NNRTI)	2.0	1.2	9.0
			377	8.5 (NRTI, n = 213) 1.7 (NNRTI, n = 176)	0.9 (n = 213)	3.8 (n = 213)	8.0
			48	15.9 (NRTI, n = 82) 7.3 (NNRTI, n = 82)	9.1 (n = 88)	10.2 (n = 88)	22.7
France <sup>20</sup>	1995-1998	Mixed	251	16.6	2.0	-	-
France <sup>21</sup>	1999-2000	Mixed	68	7.6 (NRTI) 4.0 (NNRTI)	5.2	4.8	-
Spain <sup>22</sup>	1996-1998	Mixed	31	16.2	6.0	4.4	-
Spain <sup>23</sup>	1997-1999	Mixed	21	16.1	9.7	0	25.8
Switzerland <sup>24</sup>	1999-2001	Mixed	21	0	4.8	0	4.8
			1996	5.6	3.0	-	8.6
			1997	6.9	7.7	-	14.6
			1998	6.8	2.0	-	8.8
Switzerland <sup>25</sup>	1999-2001	Mixed	200	3.1	1.9	-	5.0
			21	6.5 (NRTI) 0.5 (NNRTI)	1.0	1.5	10.0
United Kingdom <sup>26</sup>	1994-1996	Mixed	21	0	0	-	0
			22	13.6	0	0	13.6
			26	19.2	3.8	0	23.0
Europe <sup>27</sup>	1996-2002	Mixed	1,369	9.0	2.0	-	11.0

\*MSM = men who have sex with men

\*\*RTI = reverse transcriptase inhibitors, NRTI = nucleoside reverse transcriptase inhibitor, NNRTI = non-nucleoside reverse transcriptase inhibitor. Information on NRTI and NNRTI provided where available.

†PI = protease inhibitors

‡MDR = multi-drug resistance

§Total may include major and minor mutations associated with primary drug resistance.

## Comment

The prevalence of primary HIV drug resistance is widespread in most countries where HAART is used. Although the interpretation of results is difficult and evolving, persons infected with drug-resistant variants of HIV may be at increased risk of drug failure despite being therapy-naïve. Surveillance of primary drug resistance is needed not only to develop guidelines for initial therapy but also to better understand and prevent the transmission of resistant variants.

## References

1. Erice A, Mayers DL, Strike DG et al. *Primary infection with zidovudine-resistant human immuno-deficiency virus type 1*. N Engl J Med 1993; 328:163-5.
2. Wainberg MA, Friedland G. *Public health implications of antiretroviral therapy and HIV drug resistance*. JAMA 1998; 279(24):1977-83.
3. Little S. *Transmission and prevalence of HIV resistance among treatment-naïve subjects*. Antiviral Ther 2000;5:33-40.
4. Loveday C. *Nucleoside reverse transcriptase inhibitor resistance*. J Acquir Immune Defic Syndr 2001; 26:S10-S24.
5. Deeks SG. *Nonnucleoside reverse transcriptase inhibitor resistance*. J Acquir Immune Defic Syndr 2001; 26:S25-S33.
6. Miller V. *Resistance to protease inhibitors*. J Acquir Immune Defic Syndr 2001;26:S34-S50.
7. Hirsh MS, Conway B, D'Aquila RT et al. *Antiretroviral drug resistance testing in adults with HIV infection*. JAMA 1998;279(24):1984-91.
8. Brumme ZL, Chan KJ, Dong WW et al. *Prevalence and clinical implications of insertions in the HIV-1 p6Gag N-terminal region in drug-naïve individuals initiating antiretroviral therapy*. Antivir Ther 2003;8:91-6.
9. Salomon H, Wainberg MA, Brenner B et al. *Prevalence of HIV-1 viruses resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or intravenous drug use*. AIDS 2000; 14(2):F17-23.
10. Routy JP, Brenner B, Bruce S et al. *Link between the declines of drug-resistance prevalence in newly infected individuals and of the proportion of patients receiving treatment in Montreal*. XI International HIV Drug Resistance Workshop, Seville, Spain. July 2-5 2002. Antiviral Ther 2002;7(Suppl. 1): #179.
11. Cassol S, Calzavara L, Major C et al. *HIV-1 drug resistance in Ontario seroconverters*. Ninth Annual Canadian Conference on HIV/AIDS Research, Montreal, QC, April 27-30, 2000; #135P.
12. Jayaraman GC, Gleeson T, for the Canadian Strain and Drug Resistance Surveillance Program Team. *Preliminary analysis of the prevalence of primary drug resistance in Canada and associated trends (1999-2001)*. Can J Infect Dis 2003;14 (suppl A): p 44 A, abstract 210.
13. Johnson V, Petropoulos CJ, Woods CR et al. *Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant*. J Infect Dis 2001;183:1688-93.
14. Masquelier B, Chaix ML, Burgard, M et al. *Zidovudine genotypic resistance in HIV-1-infected newborns in the French perinatal cohort*. J Acquir Immune Defic Syndr 2001;27:99-104.

15. Little SJ, Daar ES, D'Aquila RT et al. *Reduced antiretroviral drug susceptibility among patients with primary HIV infection.* JAMA 1999;282:1142-49.
16. Boden D, Hurley A, Zhang L et al. *HIV-1 drug resistance in newly infected individuals.* JAMA 1999;282:1135-41.
17. Bennett DE, Zaidi IF, Heneine W et al. *Prevalence of mutations associated with antiretroviral drug resistance among men and women newly diagnosed with HIV in 10 US cities, 1997-2001* [Abstract]. Antivir Ther 2003;8:S133.
18. Bennett D, Zaidi I, Heneine W et al. *Prevalence of mutations associated with antiretroviral drug resistance among recently diagnosed persons with HIV 1998-2000.* Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, Feb 24-28 2002; #95.
19. Little S, Holte S, Routy JP et al. *Antiretroviral drug resistance among patients recently infected with HIV.* N Engl J Med 2002;347(6):385-94.
20. Tamalet C, Pasquier C, Yahi N et al. *Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV-1 infection.* J Med Virol 2000;61:181-6.
21. Chaix ML, Descamps D, Deveau C et al. *Antiretroviral resistance, molecular epidemiology and response to initial therapy among patients with HIV-1 primary infection in 1999-2000 in France.* XI International HIV Drug Resistance Workshop, Seville, Spain, July 2-5 2002. Antiviral Ther 2002;7(Suppl 1):#166.
22. Puig T, Perez-Olmeda M, Rubio A et al. *Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. The ERASE-2 Study Group.* AIDS 2000;14:727-32
23. De Mendoza C, del Romero J, Rodriguez C et al. *Decline in the rate of genotypic resistance to antiretroviral drugs in recent HIV seroconverters in Spain.* Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA Feb 24-28, 2002: 371M.
24. Yerly S, Vora S, Rizzardì P et al. *Acute HIV infection: impact on the spread of HIV and transmission of drug resistance.* AIDS 2001;15:2287-92.
25. Yerly S, Jost S, Telenti A et al. *Transmission of drug resistance: impact of primary and chronic HIV infection.* XI International HIV Drug Resistance Workshop, Seville, Spain. July 2-5 2002. Antiviral Ther 2002;7(Suppl 1):#183.
26. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. *Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom.* BMJ 2001;322:1087-88.
27. Wensing AMJ, van der Vijver DAMC, Asjo B et al. *Prevalence of transmitted drug resistance in Europe is largely influenced by the presence of non-B sequences: analysis of 1400 patients from 16 countries: the CATCH-Study* [Abstract]. Antivir Ther 2003;8:S131.



## Acknowledgements

National level HIV and AIDS surveillance is possible as a result of all provinces and territories participating in, and setting directions for, HIV and AIDS surveillance. CIDPC acknowledges the provincial/territorial HIV/AIDS coordinators, public health units, laboratories, health care providers, and reporting physicians for sharing non-nominal, confidential data for national surveillance.

***For more information, please contact:***

**Surveillance and Risk Assessment Division  
Centre for Infectious Disease Prevention and Control  
Health Canada  
Tunney's Pasture  
Postal Locator 0602B  
Ottawa, ON K1A 0K9  
Tel: (613) 954-5169  
Fax: (613) 957-2842  
[www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/](http://www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/)**



# HIV/AIDS *EPI UPDATE* Centre for Infectious Disease Prevention and Control

## Nonoxynol-9 and the Risk of HIV Transmission

### *At a Glance*

- ◆ **Nonoxynol-9 should not be promoted as a means of HIV prevention.**
- ◆ **Recent data indicate that nonoxynol-9 does not reduce the risk of HIV transmission and in some circumstances may increase the risk.**
- ◆ **There is an urgent need for the development of an effective and safe anti-HIV microbicide.**

### **Introduction**

The purpose of this *Epi Update* is to summarize recent data on the effectiveness of nonoxynol-9 (N-9) as a microbicide, with particular reference to its effect on HIV transmission. While the effectiveness of N-9 as a spermicide is well known, its usefulness as a microbicide has been questioned, and in fact recent data indicate that it may actually increase the risk of HIV transmission. This *Epi Update* examines the implications of these data in the context of HIV prevention efforts.

### **Background**

Microbicides are chemical substances that kill viruses and bacteria and thus have the potential to reduce the transmission of HIV and other sexually transmitted pathogens when applied vaginally or rectally before sexual intercourse. The development of an effective microbicide is an important research objective, since it would not only improve the effectiveness of condoms in preventing disease transmission but, more importantly, it would also offer an alternative for women to protect themselves from infection without having to obtain the cooperation of their male sexual partner (to wear a male condom). Such an alternative would be especially welcome since the vast majority of global HIV transmissions occur through heterosexual activity.

### ***CIDPC Website:***

[www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/](http://www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/)

An ideal microbicidal product would be effective against multiple sexually transmitted infections (STIs) including HIV, safe to use several times daily, fast acting, acceptable to users, affordable, colorless, odorless, easy to store and to use, easy to obtain, and available in a variety of preparations, including with or without a contraceptive component. None of the

compounds currently in development meets these ideal standards, and experts say it is unlikely that any one product will meet them all. The immediate priority is to develop a microbicide product that would provide protection against HIV.<sup>1</sup>

N-9 is one of the best studied microbicides for the prevention of HIV and other STIs. N-9 was initially developed as a spermicide – a chemical that kills sperm and therefore prevents pregnancy. These chemicals are used in contraceptive spermicidal products and as complementary components in the lubricant for barrier methods of contraception, such as the male condom. Studies have demonstrated that when spermicides are used alone, they are 75% to 85% effective in preventing pregnancy.<sup>2,3</sup> In addition, N-9 has been identified as a compound that can kill viruses and bacteria, and so has been proposed as a candidate microbicide for HIV prevention. Laboratory studies have shown that N-9 kills or stops the growth of the HIV virus as well as the pathogens of other STIs such as genital herpes, gonorrhoea, syphilis, trichomoniasis and chlamydia.<sup>4</sup>

A number of products containing N-9 are licensed for use as contraceptives in Canada. These products are available without a prescription and come in a variety of forms, including creams, films, foams, gels and condoms with spermicidal lubricant. Examples of products include VCF foam, Delfen foam, Advantage 24 contraceptive gel, KY Plus Jelly spermicidal lubricant, Protectaid contraceptive sponge and many brands of condoms labelled as containing spermicide. However, in Canada, there are currently no products with N-9 that are licensed or indicated for use as microbicides (Mueller T, (former) Therapeutic Products Programme, Health Canada: personal communication, September 8, 2000) ; condoms both with and without N-9 make disease prevention claims based on the efficacy of the condom as a mechanical barrier.

## Evidence Regarding Nonoxynol-9 and HIV Transmission

The frequent use of N-9 can induce lesions and ulcerations to genital mucosa, thereby increasing the probability of transmission of infectious agents.<sup>5</sup> Studies have also indicated that these adverse effects of N-9 are dose related, supporting the notion that it has a potentially narrow margin of safety.<sup>6</sup>

While laboratory studies have clearly indicated that N-9 could be an effective barrier to HIV, clinical trials in humans have produced mixed results. Several observational studies have indicated that N-9 may reduce the risk of HIV transmission, but the study design did not permit definitive conclusions.<sup>7-10</sup> A meta-analysis investigation that combined data from several studies concluded that N-9 may have a protective effect against both gonorrhoea and chlamydia<sup>11</sup>, but a recent randomized controlled trial found that N-9 gel did not protect against urogenital gonococcal or chlamydial infection.<sup>12</sup> As well, a recent report from the World Health Organization (WHO) concluded that spermicides containing N-9 do not protect against gonorrhoea and chlamydia.<sup>13</sup> A recently published cohort study found no evidence of N-9 protection against HIV,<sup>14</sup> as was also the case in two controlled trials on this subject. One trial found no significant protection but a higher incidence of genital ulcers in the N-9 group compared with the control group,<sup>15</sup> and another trial found increased HIV infections in the N-9 group compared with the control group, though this difference was not statistically significant.<sup>16</sup> The most significant recent data are from a study of COL-1492, a vaginal gel containing N-9, conducted between 1996 and 2000 among sex trade workers in four countries: Benin, Cote D'Ivoire, South Africa and Thailand. The results showed that this gel had an adverse effect on vaginal integrity when used frequently, thus increasing women's susceptibility to HIV-1 infection. At low frequency use, nonoxynol-9 had no effect,

either positive or negative, on HIV-1 infection.<sup>17</sup>

The association between N-9 and genital lesions was also seen in a study of monogamous, low risk women who had a much lower frequency of sexual intercourse than the sex workers in the UNAIDS study. In this second study, women applied a vaginal N-9 gel or a placebo gel twice daily. The N-9 group had significantly more vaginal itching, burning and mucosal lesions.<sup>18</sup> While it is difficult to extrapolate the findings of these two studies to the general population in terms of sexual frequency, dosage and mode of N-9 use (including the occasional use of an N-9 lubricated condom), the theoretical benefits of N-9 use in such situations would have to be weighed against the demonstrated potential for harmful side effects.

## Recommendations

Taken together, the recent evidence is convincing that frequent use of N-9 does not reduce the risk of infection by HIV and may in fact increase the risk by causing disruptions and lesions in the genital mucosal lining. There are currently few data available to address the question of whether these results also apply to situations in which the dosage and/or frequency of N-9 use is lower. The WHO has stated that N-9 clearly does not prevent HIV infection and may even favour infection if used frequently.<sup>13</sup> It has recommended that N-9 should not be used to prevent STIs (including HIV) or for contraception in females who have frequent intercourse or have a high risk of HIV infection, and that N-9 not be used rectally.<sup>19</sup>

The United States Food and Drug Administration has proposed new warning labels for over-the-counter contraceptives that contain this spermicide.<sup>20</sup> The warning will state that these contraceptives do not protect against infection from HIV or other STIs. The proposed label warnings would also tell consumers that the use of the contraceptives can increase vaginal irritation, which may raise the risk of

contracting HIV and other STIs. A number of condom manufacturers, including SSL International, Johnson & Johnson and Mayer, have voluntarily decided to stop producing condoms with N-9.<sup>21</sup>

Health Canada has never recommended N-9 on its own as an effective means of HIV prevention. Current assessment of the data indicates the following:

- ◆ N-9 should not be promoted as an effective means of HIV prevention. In particular, individuals who cannot use a condom for HIV prevention should not be counseled to use N-9 as an alternative.
- ◆ For the prevention of STIs, including HIV, a condom lubricated with N-9 is better than no condom at all. The protection provided by the mechanical barrier of the condom would appear to outweigh the potential risk of the N-9, at least for low frequency of use and dosage.
- ◆ If N-9 is used as an aid to contraception, its benefit should be carefully considered in light of the increased risk of genital lesions and the resulting potential for an increased risk of HIV transmission.

Similar recommendations have been released from the Centers for Disease Control and Prevention in the USA.<sup>22,23</sup>

## Future Directions

These disappointing data on the ineffectiveness of N-9 as a microbicide serve to further reinforce the importance and urgency of research on the development of other possible compounds as microbicides. Other classes of compounds that show promise include topical non-nucleoside reverse transcriptase inhibitors (such as efavirenz), inhibitors of viral attachment (such as cellulose sulphate) and natural products (such as buffer gels). Recently, an experimental gel has been developed that appears to be a safe, effective contraceptive, according to animal studies. The compound known as mandelic acid condensation

polymer, or SAMMA, blocked HIV and two strains of herpes simplex virus in laboratory testing.<sup>24</sup> In addition, there have been promising developments from a study of sulfated K5 *Escherichia coli* polysaccharide derivatives. These derivatives appeared to prevent infection as well as suppress HIV-1 viral replication, suggesting that their action may be specific to initial phases of viral attachment and cellular entry.<sup>25</sup>

There is an urgent need to develop a microbicide that can substantially reduce the transmission of sexually transmitted infections, including HIV, and that can be used by women. For individuals who are unable to access condoms or negotiate condom use, particularly women, the identification of safe and effective alternatives in HIV prevention is a public health priority.

## References

1. *Microbicides. Update: issue update. The Henry J. Kaiser Family Foundation. May 2001.*
2. Trussell J, Hatcher RA, Cates W Jr et al. *Contraceptive failure in the United States: an update.* Stud Fam Plann 1990;21(1):51-4.
3. Steiner MJ, Hertz-Picciotto I, Schulz KF et al. *Measuring true contraceptive efficacy. A randomized approach – condom vs. spermicide vs. no method.* Contraception 1998;58(6):375-8.
4. U.S. National Library of Medicine. *Spermicides (vaginal).* MEDLINE plus Health Information. Micromedex Inc. Revised July 28, 1993.
5. Gagne N, Cormier H, Omar RF et al. *Protective effect of a thermoreversible gel against the toxicity of nonoxynol-9.* Sex Transm Dis 1999;26:N.3 177-83.
6. Rustomjee R, Abdool Karim Q, Abdool Karim SS et al. *Phase I trial of nonoxynol-9 film among sex workers in South Africa.* AIDS 1999;13(12): 1511-5.
7. Wittkowski KM, Dietz K. *The protective effect of condoms and nonoxynol-9 against HIV infection.* National Conference Women and HIV, May 4-7, 1997 (Abstract no. P1.68).
8. Wittkowski KM, Susser E, Dietz K. *Nonoxynol-9 in preventing heterosexual transmission of HIV- using multivariate methods in re-analysing previous and planning future studies.* 12th International AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland (Abstract no. 33142).
9. Wittkowski KM, Susser E, Dietz K. *The protective effect of condoms and Nonoxynol-9 against HIV infection.* Am J Pub Health 1998;88(4):590-6.
10. *Comment.* Am J Public Health 1999; 89(1):198-10.
11. Cook RL, Rosenberg MJ. *Do spermicides containing N-9 prevent sexually transmitted infections? A meta-analysis.* Sex Transm Dis 1998;25(3):144-50.
12. Roddy R E, Zekeng L, Ryan KA et al. *Effect of nonoxynol-9 gel on urogenital gonorrhoea and chlamydial infection: a randomized controlled trial.* JAMA 2002;287:1117-22.
13. World Health Organization (WHO). *Nonoxynol-9 ineffective in preventing HIV infection.* 28 June, 2002. Press Release WHO/55. URL: <<http://www.who.int/en/pr-2002-55.html>>.

14. Hira SK, Feldblum PJ, Kamanga J et al. *Condom and nonoxynol-9 use and the incidence of HIV infection in sero-discordant couples in Zambia*. *Int J STD AIDS* 1997;8(4):243-50.
15. Roddy RE, Zekeng L, Ryan KA et al. *A controlled trial of nonoxynol-9 film to reduce male-to-female transmission of sexually transmitted diseases*. *N Engl J Med* 1998;339(8):504-10.
16. Kreiss J, Ngugi E, Holmes K et al. *Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes*. *JAMA* 1992;268(4):477-82.
17. Van Damme L, Ramjee G, Alary M et al. *Effectiveness of COL-1492, a non-oxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial*. *Lancet* 2002;360(9338):971-7. Erratum in *Lancet* 2002;360(9348):1892.
18. Hoffman T, Taha TE, Martinson F et al. *Adverse health event occurring during an N-9 Gel pilot study: Malawi*. 13<sup>th</sup> International AIDS Conference, July 9-14, 2000, Durban, South Africa (Abstract no. TuPpC1171).
19. World Health Organization (WHO). *Declaration on dual protection: male and female condoms and spermicides*. *AIDS Summary*, No. 9 (Sept. 2003):3. URL: <[http://www.ippfwhr.org/publications/serial\\_article\\_e.asp?serialissuesid=140&articleid=299](http://www.ippfwhr.org/publications/serial_article_e.asp?serialissuesid=140&articleid=299)> (accessed January 20<sup>th</sup> 2004).
20. Centers for Disease Control and Prevention. *FDA proposes new warning for over-the-counter contraceptive drugs containing nonoxynol 9*. Associated Press (01.16.03). [PreventionNews@cdcnpin.org](mailto:PreventionNews@cdcnpin.org). CDC HIV/STD/TB Prevention News Update 01/17/03.
21. *The body: an AIDS and HIV information resource*. HIV/AIDS Newsroom, January 21, 2004. URL: <[http://www.thebody.com/kaiser/2004/jan21\\_04/nonoxynol\\_9.html](http://www.thebody.com/kaiser/2004/jan21_04/nonoxynol_9.html)> (accessed Jan. 30, 2004).
22. Centers for Disease Control and Prevention. *Dear Colleague Letter*, August 4, 2000.
23. Centers for Disease Control and Prevention. *CDC statement on study results of product containing nonoxynol-9*. *MMWR* 2000;49(31):717.
24. Reuters Health. *Vaginal contraceptive/HIV fighter seems promising* (12.05.02).
25. Vicenzi E, Gatti A, Ghezzi S et al. *Broad spectrum inhibition of HIV-1 infection by sulfated K5 Escherichia coli polysaccharide derivatives*. *AIDS* 2003;17(2):177-81.

## Acknowledgements

National level HIV and AIDS surveillance is possible as a result of all provinces and territories participating in, and setting directions for, HIV and AIDS surveillance. CIDPC acknowledges the provincial/territorial HIV/AIDS coordinators, public health units, laboratories, health care providers, and reporting physicians for sharing non-nominal, confidential data for national surveillance.

***For more information, please contact:***

**Surveillance and Risk Assessment Division  
Centre for Infectious Disease Prevention and Control  
Health Canada  
Tunney's Pasture  
Postal Locator 0602B  
Ottawa, ON K1A 0K9  
Tel: (613) 954-5169  
Fax: (613) 957-2842  
[www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/](http://www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/)**

Our mission is to help the people of Canada  
maintain and improve their health

*Health Canada*



# HIV/AIDS *EPI UPDATES*

**Centre for Infectious Disease Prevention and Control**

## Glossary

A *Guide to HIV/AIDS Epidemiological and Surveillance Terms* is available. The guide contains over 65 terms and over 20 frequently asked questions, and is accessible at <http://www.hc-sc.gc.ca/pphb-dgspsp/publicat/haest-tesvs/index.html>. Hard copies may be obtained through the Surveillance and Risk Assessment Division, whose address is listed under the "Information to Readers of HIV/AIDS Epi Updates" section. A selected number of acronyms and terms that may be useful when reading *HIV/AIDS Epi Updates* are listed below.

### ACRONYMS

<b>AIDS</b>	↔ Acquired immunodeficiency syndrome
<b>HIV</b>	↔ Human immunodeficiency virus
<b>IDU</b>	↔ Injecting drug users
<b>MSM</b>	↔ Men who have sex with men
<b>NEP</b>	↔ Needle exchange program
<b>WHO</b>	↔ World Health Organization

### TERMS

#### Cohort Study

The purpose of a cohort study is to investigate the development of new occurrences of a disease or to investigate how responses to treatment are related to specific factors. These factors can be recorded at the beginning of the study and/or during the course of the study.

A cohort study starts with a group of people who will be participants in the study. This group of people is called a cohort.

The cohort is followed for a specified period, which can be weeks, months, years or decades. Follow-up data are collected at regularly defined periods either through the use of questionnaires, personal interviews, laboratory testing, medical examinations, or a combination of these methods.

A cohort study is sometimes referred to as a prospective or longitudinal study.

#### Co-Infection

Having two infections at the same time. For example, a person infected with both HIV and hepatitis C (HCV), or HIV and tuberculosis (TB), has a co-infection. With co-infections the progression of either disease can potentially be accelerated as a result of infection with the other disease.

#### Exposure Category

In HIV and AIDS surveillance, exposure category refers to the most likely way a person became infected with the HIV virus, that is, the most likely route through which HIV was transmitted to that person.

#### Incidence

Incidence is the number of *new* events of a specific disease during a specified period of time in a specified population. HIV incidence is the number of *new* HIV infections occurring in a specified period of time in a specified population.



## **Methodology**

The methodology section of a report or research study describes how the study was conducted (the methods) and the principles used by study investigators. These methods include how participants were recruited and how the data were collected, organized and analyzed.

## **Notifiable Disease**

A disease that is considered to be of such importance to public health that its occurrence is required to be reported to public health authorities.

## **Perinatal Transmission**

The transmission of HIV from an HIV-infected mother to her child either *in utero*, during childbirth, or through breastfeeding.

## **Person Years**

Person years describes the length of time of experience or exposure of a group of people who have been observed for varying periods of time. It is the sum total of the length of time each person has been exposed, observed or at risk. You will sometimes see person years reported as PY or py. Person years is often used as the denominator in expressing incidence rate.

## **Population at Risk**

The population at risk represents those persons at risk of contracting a disease.

## **Prevalence**

Prevalence is the total number of people with a specific disease or health condition living in a defined population at a particular time. HIV prevalence among Canadians is the total number of people living with HIV infection (including those with AIDS) in Canada at a particular time.

## **Rate**

A rate is an expression of the frequency with which an event occurs in a defined population in a specified period of time. In HIV/AIDS research, a rate can be the

proportion of a population with a particular "event", such as HIV infection, occurring during a specified time period.

## **Risk Factor**

Is an aspect of someone's behaviour or lifestyle, a characteristic that a person was born with, or an event that he or she has been exposed to that is known to be associated with a health-related condition. A *behavioural* risk factor describes a specific behaviour that carries a proven risk of a particular outcome. In HIV/AIDS research, you will often see the term "HIV-related risk behaviour" to describe a behaviour that, when practised, carries a proven risk of HIV infection.

## **Self-Reported Data**

In research studies, self-reported data is a term applied to information that is directly reported by the study participants.

## **Sentinel Surveillance**

Is a type of surveillance activity in which specific facilities, such as offices of certain health care providers, hospitals or clinics across a geographic region, are designated to collect data about a disease, such as HIV infection. These data are reported to a central database for analysis and interpretation.

## **Seroconversion**

The root "sero" means the serum of the watery portion of blood. In HIV/AIDS research, seroconversion refers to the development of detectable antibodies to HIV in the blood as a result of HIV infection. A person who goes from being HIV-negative to HIV-positive is said to have seroconverted or is a seroconverter.

## **Seroprevalence**

The terms refers to the prevalence or prevalence rate of a disease determined by testing blood rather than saliva, urine or sputum.

## **Surveillance**

Is the ongoing collection, analysis and interpretation of data about a disease such as HIV or about a health condition. The objective of surveillance is to assess the health status of populations, detect changes in disease trends or changes in how the disease is distributed, define priorities, assist in the prevention and control of the disease, and monitor and evaluate related treatment and prevention programs.